Document:

EX-10.4

 Exhibit 10.4 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED
WITH THE COMMISSION. 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

BY AND BETWEEN 
 PFIZER
INC. 
 AND 

CELLECTIS SA 
 JUNE 17,
2014 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
			
	 1.
	 	 DEFINITIONS
	  	 	1	  
			
	 2.
	 	 RESEARCH PROGRAM
	  	 	13	  
				
		 	 2.1
	 	 Selection of Pfizer Targets
	  	 	13	  
				
		 	 2.2
	 	 Selection of Cellectis Program Targets
	  	 	14	  
				
		 	 2.3
	 	 Selection of Other Cellectis Targets
	  	 	14	  
				
		 	 2.4
	 	 Target Selection Process
	  	 	14	  
				
		 	 2.5
	 	 Scope and Conduct of the Research Program
	  	 	15	  
				
		 	 2.6
	 	 Research Plans
	  	 	15	  
				
		 	 2.7
	 	 Governance of the Research Program
	  	 	16	  
				
		 	 2.8
	 	 Alliance Managers
	  	 	18	  
				
		 	 2.9
	 	 Conformance with Law
	  	 	18	  
				
		 	 2.10
	 	 Cellectis Personnel Matters
	  	 	18	  
				
		 	 2.11
	 	 Non-Solicit
	  	 	18	  
				
		 	 2.12
	 	 Debarment Certification
	  	 	19	  
				
		 	 2.13
	 	 Subcontractors
	  	 	19	  
				
		 	 2.14
	 	 Inspections
	  	 	20	  
				
		 	 2.15
	 	 Records
	  	 	20	  
			
	 3.
	 	 PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS
	  	 	20	  
				
		 	 3.1
	 	 General
	  	 	20	  
				
		 	 3.2
	 	 Diligence
	  	 	20	  
				
		 	 3.3
	 	 Remedies for Breach of Cellectis Diligence Obligations
	  	 	22	  
				
		 	 3.4
	 	 Regulatory Approvals
	  	 	22	  
				
		 	 3.5
	 	 Control of Commercialization Activities
	  	 	23	  
				
		 	 3.6
	 	 Manufacturing
	  	 	23	  
				
		 	 3.7
	 	 Pfizer Progress Reporting
	  	 	23	  
				
		 	 3.8
	 	 Cellectis Progress Reporting
	  	 	23	  
				
		 	 3.9
	 	 Right of First Refusal
	  	 	23	  
				
		 	 3.10
	 	 Right of Negotiation
	  	 	24	  
			
	 4.
	 	 LICENSES AND RELATED GRANTS OF RIGHTS
	  	 	24	  
				
		 	 4.1
	 	 Grants to Pfizer
	  	 	24	  

  
 i 

 TABLE OF CONTENTS 

(continued) 

									
	 	 	 	 	 	  	Page	 
				
		 	 4.2
	 	 Grants to Cellectis
	  	 	26	  
				
		 	 4.3
	 	 Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information
	  	 	27	  
				
		 	 4.4
	 	 Retained Rights
	  	 	27	  
				
		 	 4.5
	 	 Other Pfizer Programs
	  	 	27	  
				
		 	 4.6
	 	 No Implied Rights
	  	 	28	  
			
	 5.
	 	 PAYMENTS TO CELLECTIS
	  	 	28	  
				
		 	 5.1
	 	 Upfront Fee
	  	 	28	  
				
		 	 5.2
	 	 Research Support Funding
	  	 	28	  
				
		 	 5.3
	 	 Milestones
	  	 	29	  
				
		 	 5.4
	 	 Royalties
	  	 	31	  
				
		 	 5.5
	 	 Diagnostic and Prognostic Products
	  	 	32	  
				
		 	 5.6
	 	 Reports and Payments
	  	 	33	  
				
		 	 5.7
	 	 Maintenance of Records; Audits
	  	 	34	  
				
		 	 5.8
	 	 No Guarantee of Success
	  	 	35	  
			
	 6.
	 	 INTELLECTUAL PROPERTY
	  	 	36	  
				
		 	 6.1
	 	 Inventions
	  	 	36	  
				
		 	 6.2
	 	 Patent Rights
	  	 	37	  
				
		 	 6.3
	 	 Interference, Opposition, Revocation and Declaratory Judgment Actions
	  	 	42	  
				
		 	 6.4
	 	 Infringement of Third Party Patent Rights
	  	 	43	  
			
	 7.
	 	 CONFIDENTIALITY
	  	 	43	  
				
		 	 7.1
	 	 Confidentiality
	  	 	43	  
				
		 	 7.2
	 	 Authorized Disclosure
	  	 	43	  
				
		 	 7.3
	 	 Public Announcements; Publications
	  	 	45	  
				
		 	 7.4
	 	 Obligations in Connection with Change of Control
	  	 	46	  
			
	 8.
	 	 REPRESENTATIONS AND WARRANTIES
	  	 	46	  
				
		 	 8.1
	 	 Mutual Representations and Warranties
	  	 	46	  
				
		 	 8.2
	 	 Representations and Warranties of Cellectis
	  	 	47	  
				
		 	 8.3
	 	 Representations and Warranties of Pfizer
	  	 	48	  
				
		 	 8.4
	 	 Cellectis Covenants
	  	 	48	  
				
		 	 8.5
	 	 Mutual Covenants
	  	 	48	  

  
 ii 

 TABLE OF CONTENTS 

(continued) 

									
	 	 	 	 	 	  	Page	 
				
		 	 8.6
	 	 Representation by Legal Counsel
	  	 	49	  
				
		 	 8.7
	 	 Disclaimer
	  	 	50	  
			
	 9.
	 	 GOVERNMENT APPROVALS; TERM AND TERMINATION
	  	 	50	  
				
		 	 9.1
	 	 Government Approvals
	  	 	50	  
				
		 	 9.2
	 	 Term
	  	 	50	  
				
		 	 9.3
	 	 Termination by Pfizer for Failure of Cellectis to Obtain Shareholder Approval
	  	 	50	  
				
		 	 9.4
	 	 Termination by Either Party for Cause
	  	 	50	  
				
		 	 9.5
	 	 Termination by Pfizer for Convenience
	  	 	51	  
				
		 	 9.6
	 	 Termination on Insolvency of Cellectis
	  	 	51	  
				
		 	 9.7
	 	 Effects of Termination
	  	 	51	  
				
		 	 9.8
	 	 Disposition of Inventories of Products
	  	 	54	  
				
		 	 9.9
	 	 Survival of Certain Obligations
	  	 	54	  
				
		 	 9.10
	 	 Right to Termination of Research Project(s) or Research Program by Pfizer upon Change of Control of Cellectis
	  	 	55	  
				
		 	 9.11
	 	 Bankruptcy
	  	 	55	  
			
	 10.
	 	 LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE
	  	 	56	  
				
		 	 10.1
	 	 No Consequential Damages
	  	 	56	  
				
		 	 10.2
	 	 Indemnification by Pfizer
	  	 	56	  
				
		 	 10.3
	 	 Indemnification by Cellectis
	  	 	56	  
				
		 	 10.4
	 	 Procedure
	  	 	56	  
				
		 	 10.5
	 	 Insurance
	  	 	58	  
			
	 11.
	 	 MISCELLANEOUS
	  	 	58	  
				
		 	 11.1
	 	 Other Cellectis Targets
	  	 	58	  
				
		 	 11.2
	 	 Assignment
	  	 	58	  
				
		 	 11.3
	 	 Further Actions
	  	 	59	  
				
		 	 11.4
	 	 Force Majeure
	  	 	59	  
				
		 	 11.5
	 	 Notices
	  	 	59	  
				
		 	 11.6
	 	 Amendment
	  	 	60	  
				
		 	 11.7
	 	 Waiver
	  	 	60	  
				
		 	 11.8
	 	 Severability
	  	 	60	  
				
		 	 11.9
	 	 Descriptive Headings
	  	 	60	  

  
 iii 

 TABLE OF CONTENTS 

(continued) 

									
	 	 	 	 	 	  	Page	 
				
		 	 11.10
	 	 Dispute Resolution
	  	 	60	  
				
		 	 11.11
	 	 Election of Resolution Process
	  	 	61	  
				
		 	 11.12
	 	 Arbitration Process
	  	 	61	  
				
		 	 11.13
	 	 Governing Law
	  	 	63	  
				
		 	 11.14
	 	 Consent to Jurisdiction
	  	 	63	  
				
		 	 11.15
	 	 Entire Agreement
	  	 	63	  
				
		 	 11.16
	 	 Independent Contractors
	  	 	63	  
				
		 	 11.17
	 	 Pfizer Anti-Bribery and Anti-Corruption Practices
	  	 	64	  
				
		 	 11.18
	 	 Counterparts
	  	 	64	  
				
		 	 11.19
	 	 No Third Party Rights or Obligations
	  	 	64	  

  
 iv 

 EXHIBITS 
 Exhibit
1: Pfizer anti-bribery and anti-corruption principles 
 SCHEDULES 

Schedule 1.52: Expected Subcontractors 
 Schedule 2.6.1: Research
Plan 
 Schedule 8.2.1: In-Licensed Patent Right comprised in the Cellectis Technology 

Schedule 8.2.3: Cellectis Patent Rights 
 Schedule 8.2.4:
[Exception to Representation and Warranties of Cellectis 8.2.4] 
 Schedule 8.2.8: [Exception to Representation and Warranties of Cellectis 8.2.8] 

Schedule 8.2.9: [Exception to Representation and Warranties of Cellectis 8.2.9] 

Schedule 8.2.10 Disclosed Third Party Agreement 

  
 v 

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (the “Agreement”) is entered into as of June 17, 2014 (the
“Effective Date”), by and among Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States
(“Pfizer”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Pfizer and Cellectis may each
be referred to herein individually as a “Party” and collectively as the “Parties.” 
 WHEREAS,
Pfizer is engaged in the research, development and commercialization of pharmaceutical and health care products and has developed and owns proprietary rights to certain technology related to protein engineering and target validation; 

WHEREAS, Cellectis has developed and controls proprietary rights to certain technology relating to adoptive immunotherapy CAR T-cell and
genome engineering technologies; and 
 WHEREAS, Pfizer and Cellectis desire to collaborate to discover and research novel CAR-Ts active
against certain designated targets and to provide for Pfizer to further research, develop, manufacture and commercialize such CAR-Ts and products containing such CAR-Ts, as provided for herein. 

NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	DEFINITIONS. 

 When used in this Agreement, the following capitalized terms will have the
meanings set forth in this Article 1. Any terms defined elsewhere in this Agreement will be given equal weight and importance as though set forth in Article 1. 

1.1. “Additional Third Party Licenses” is defined in Section 5.4.2(b). 

1.2. “Affiliate” means, with respect to any Person, any other Person that controls, is controlled by or is under common
control with such Person. A Person will be regarded as in control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term “Affiliate” will not include subsidiaries or other entities in which a Party or its Affiliates owns a
majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or otherwise, until such time as such restrictions are no longer in
effect. 
 1.3. “Agreement” is defined in the introduction to this Agreement. 

  
 1 

 1.4. “Agreement CAR-T” means any CAR-T utilizing the Cellectis Technology
that is identified, created or developed Targeting a Pfizer Target. 
 1.5. “Alliance Manager” is defined in
Section 2.8. 
 1.6. “Annual Net Sales” means, with respect to any Pfizer Licensed Product in a Pfizer Year
during the applicable Royalty Term for such Pfizer Licensed Product, the aggregate Net Sales by Pfizer, its Affiliates and its Sublicensees from the sale of such Pfizer Licensed Product in the Territory during such Pfizer Year. 

1.7. “Applicable Law” means the laws, statutes, rules, regulations, guidelines, or other requirements that may be in
effect from time to time and apply to a Party’s activities to be performed under this Agreement, including any such laws, statutes, rules, regulations, guidelines, or other requirements of the FDA or the EMA. 

1.8. “Applicable Pfizer Technology” means any (a) Know-How Controlled by Pfizer or its Affiliates that was
invented, discovered or developed during the Term and in connection with Pfizer’s or its Affiliates’ activities under the Agreement and (b) Patent Rights Controlled by Pfizer or its Affiliates as of the date of Termination, to the
extent that such Patent Right claims any Know-How described in clause (a) above, to the extent that such Know-How and Patent Rights are necessary for the further development, manufacture and commercialization of Continuation Products

 1.9. [***] 
 1.10.
“Binding Obligation” means, with respect to a Party (a) any oral or written agreement or arrangement that binds or affects such Party’s operations or property, including any assignment, license agreement, loan agreement,
guaranty, or financing agreement; (b) the provisions of such Party’s charter, bylaws or other organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such
Party or by which any of such Party’s operations or property are bound. 
 1.11. “Biosimilar Biologic
Product” is defined in Section 5.4.2(a). 
 1.12. “Biosimilar Notice” means a copy of any application
submitted by a Third Party to the FDA under 42 U.S.C. § 262(k) of the PHS Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biological product, which application
identifies a Pfizer Licensed Product as the reference product with respect to such product, and other information that describes the process or processes used to manufacture the biological product. 

1.13. “BLA” means a Biologics License Application filed with the FDA in the United States with respect to a Licensed
Product, as defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et. seq. 
 1.14. “Business
Day” means a day other than a Saturday, a Sunday or a day that is a national holiday in the United States. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 2 

 1.15. “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.16. “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and
ending on December 31. 
 1.17. “CAR” means a chimeric antigen receptor expressed from an experimentally
validated Cellectis viral construct with specific molecular architecture and signaling domain sequences. 
 1.18.
“CAR-T” means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Cellectis Technology. 

1.19. [***] 
 1.20. [***] 

1.21. “Cellectis CAR-T Developed IP” means Developed IP directed to the manufacture, composition or use of CAR-Ts
Targeting a Cellectis Program Target. 
 1.22. “Cellectis Diligence Obligation” is defined in Section
3.2.4. 
 1.23. “Cellectis Improvement” [***] 

1.24. “Cellectis Indemnified Party” is defined in Section 10.2. 

1.25. “Cellectis Insolvency Event” means the occurrence of any of the following: (a) a case is commenced by or
against Cellectis under applicable bankruptcy, insolvency or similar laws, (b) Cellectis files for or is subject to the institution of bankruptcy, reorganization, liquidation, receivership or similar proceedings, (c) Cellectis assigns all
or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for Cellectis’ business, (e) a substantial portion of Cellectis’ business is subject to attachment or similar process,
(f) Cellectis suspends or threatens to suspend making payments with respect to all or any class of its debts or (g) anything analogous to any of the events described in the foregoing clauses (a) through (f) occurs under the laws
of any applicable jurisdiction. 
 1.26. “Cellectis Know-How” means any Know-How comprised in the Cellectis
Technology that is introduced into the Research Program by Cellectis pursuant to the applicable Research Plan. 
 1.27.
“Cellectis Non-Compete Period” is defined in Section 2.1.4. 
 1.28. “Cellectis Patent Right”
means any Patent Right comprised in the Cellectis Technology. The Cellectis Patent Rights existing as of the Effective Date include those set forth on Schedule 8.2.3 attached hereto. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 3 

 1.29. “Cellectis Product” means any product incorporating a CAR-T
Targeting a Cellectis Program Target which would infringe a Valid Claim of any Licensed Pfizer Intellectual Property in the absence of the Licenses from Pfizer pursuant to Section 4.2 or that is claimed or covered by, or was made using or
otherwise incorporates, any Pfizer Intellectual Property or Developed IP. 
 1.30. “Cellectis Program Target”
means [***], plus any additional Cellectis Program Targets added to the Agreement pursuant to Section 2.2. 
 1.31.
“Cellectis Technology” [***] 
 1.32. “Cellectis Third Party Agreement” means any agreement
between Cellectis and any Third Party under which Cellectis obtains rights in or to any Cellectis Licensed Intellectual Property. 

1.33. “Change of Control” means, with respect to a Party, (a) a merger, reorganization or consolidation of such
Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty (50%) of the combined voting power of the surviving entity immediately after such merger,
reorganization or consolidation, (b) a Third Party becoming the beneficial owner of fifty (50%) or more of the combined voting power of the outstanding securities of such Party or (c) the sale or other transfer to a Third Party of all
or substantially all of such Party’s business or assets to which this Agreement relates. 
 1.34. “Change
Order” is defined in Section 2.6.3. 
 1.35. “Combination Product” means a Pfizer Licensed Product
containing an Agreement CAR-T and one or more other therapeutically active ingredients. 
 1.36.
“Commercialization” or “Commercialize” means activities directed to marketing, promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold a Pfizer Licensed Product.
Commercialization will not include any activities related to Manufacturing or Development. 
 1.37. “Commercially
Reasonable Efforts” means [***] 
 1.38. “Confidential Information” of a Party means all Know-How or
other information, including proprietary information and materials (whether or not patentable) regarding such Party’s technology, products, business or objectives, that is communicated in any way or form by the Disclosing Party to the Receiving
Party, either prior to or after the Effective Date of this Agreement (including any information disclosed pursuant to the Confidentiality Agreement), and whether or not such Know-How or other information is identified as confidential at the time of
disclosure. The terms and conditions of this Agreement will be deemed to be the Confidential Information of each Party. Cellectis Improvements will be deemed to be the Confidential Information of Cellectis. Pfizer Improvements will be deemed to be
the Confidential Information of Pfizer. Developed IP will be deemed to be the Confidential Information of each Party, except that CAR-T Developed IP, upon assignment thereof to Pfizer pursuant to Section 6.1.1(d), will be deemed to be the
Confidential Information solely of Pfizer. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 4 

 1.39. “Confidentiality Agreement” means that certain Confidentiality
Agreement between the Parties dated March 31, 2014. 
 1.40. “Continuation Product” is defined in Section
9.7.4(c). 
 1.41. “Control” or “Controlled” means, with respect to any (a) item of
information, including Know-How, or (b) intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this Agreement) by a Party of the ability to grant to the other Party access to or a license
under such item or right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party. 

1.42. “Develop” or “Development” means to discover, research or otherwise develop a product, including
conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology, pharmacology and other similar efforts, test method development and stability testing, manufacturing process
development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and post-approval studies), development of diagnostic assays in connection
with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing, pricing or reimbursement approval. 

1.43. “Developed IP” [***] 

1.44. “Development Milestone” is defined in Section 5.3.1. 

1.45. “Development Milestone Payment” is defined in Section 5.3.1. 

1.46. “Diligence Issue” is defined in Section 3.2.5. 

1.47. “Disclosed Third Party Agreement” is defined in Section 8.2.10(a). 

1.48. “Disclosing Party” is defined in Section 7.1. 

1.49. “Effective Date” is defined in the introduction to this Agreement. 

1.50. [***] 
 1.51.
“EMA” means the European Medicines Agency, or any successor agency thereto. 
 1.52. “Expected
Subcontractors” means the subcontractor or contractors listed in Schedule 1.52, that Cellectis is using, or intends to use, as of the Effective Date, to engage for the performance any Research Plan Services or Research Program
activities. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 5 

 1.53. “FD&C Act” means the United States Federal Food, Drug, and
Cosmetic Act (21 U.S.C. § 301 et seq.), as amended, and the rules and regulations promulgated thereunder. 
 1.54.
“FDA” means the United States Food and Drug Administration or any successor agency thereto. 
 1.55.
“Field” means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. 
 1.56.
“First Commercial Sale” means, with respect to any Pfizer Licensed Product and any country of the world, the first sale of such Pfizer Licensed Product under this Agreement by Pfizer, its Affiliates or its Sublicensees to a Third
Party in such country, after such Pfizer Licensed Product has been granted Regulatory Approval by the competent Regulatory Authorities in such country. 

1.57. [***] 
 1.58.
“FTE” means a full time equivalent scientific person (with B.S., M.S. or Ph.D. level or equivalent degrees, including laboratory technicians with exams recognized according to European standards) year, consisting of a minimum of a
total of [***] of scientific work directly related to and in support of the Research Program by an employee of Cellectis or any of its Affiliates. 

1.59. “FTE Rate” means [***] per FTE. 

1.60. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.61. “Generic Competition” is defined in Section 5.4.2(a). 

1.62. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national,
state, county, city or other political subdivision. 
 1.63. “IND” means an Investigational New Drug
Application, as defined in the FD&C Act, that is required to be filed with the FDA before beginning clinical testing of a Pfizer Licensed Product or Cellectis Product, as applicable, in human subjects, or an equivalent foreign filing.

 1.64. “Indemnified Party” is defined in Section 10.4.1.  

1.65. “Indemnifying Party” is defined in Section 10.4.1. 

1.66. “Joint Developed IP” is defined in Section 6.1.1(c). 

1.67. “Joint Patent Right” is defined in Section 6.2.1(d). 

1.68. “Joint Research Committee” or “JRC” is defined in Section 2.7.1. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 6 

 1.69. “Know-How” means any proprietary invention, discovery, data,
information, process, method, technique, material, technology, result or other know-how, whether or not patentable. 
 1.70.
“Law” means any law, statute, rule, regulation, order, judgment or ordinance of any Governmental Authority. 

1.71. “Liability” is defined in Section 10.2.  

1.72. “License” is defined in Section 4.1.1. 

1.73. “Licensed Cellectis Intellectual Property” means any and all intellectual property (including Patent Rights and
Know-How) Controlled by Cellectis, including the Cellectis Technology, the Cellectis Improvements and Cellectis’ interest in the Developed IP, for Pfizer to make, have made, use, have used, sell, have sold, offer for sale, have offered for
sale, import, have imported and otherwise exploit and Commercialize Pfizer Licensed Products. 
 1.74. “Licensed Pfizer
Intellectual Property” means any and all Pfizer Technology, Pfizer Improvement, and Pfizer’s interest in the Developed IP, for Cellectis to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale,
import, have imported and otherwise exploit and Commercialize Cellectis Products. 
 1.75. “Litigation
Conditions” is defined in Section 10.4.2. 
 1.76. “MAA” means an application with the EMA seeking
Regulatory Approval of a Licensed Product in Europe using the EMA’s centralized procedure. 
 1.77. “Major EU
Market Country” means any of [***]. 
 1.78. “Major Market Country” means any Major EU Market Country
[***]. 
 1.79. “Manufacturing” or “Manufacture” means activities directed to making,
producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. 

1.80. “Marginal Royalty Rates” is defined in Section 5.4. 

1.81. [***] 
 1.82.
“Misuse” means any use of Cellectis Confidential Information or Know-How by Pfizer in violation of Pfizer’s non-use obligations pursuant to this Agreement or outside the scope of the licenses granted hereunder. For the
avoidance of doubt, “Misuse” will not include Pfizer’s disclosure of Cellectis Confidential Information to any Third Party in violation of Section 7. 

1.83. “Necessary” is defined in Section 5.4.2(b). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 7 

 1.84. “Net Sales” means, [***]  

1.85. “Non-Disclosing Party” is defined in Section 7.3.2.  

1.86. “Notice of Dispute” is defined in Section 11.10.1. 

1.87. “Other Cellectis Target” means [***], plus any additional Other Cellectis Targets added to the Agreement pursuant
to Section 2.3. 
 1.88. “Party” and “Parties” is defined in the introduction to this
Agreement. 
 1.89. “Patent Rights” means any and all (a) patents, (b) pending patent applications,
including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by
existing or future extension or restoration mechanisms, including patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) any other form of government-issued right
substantially similar to any of the foregoing and (f) all United States and foreign counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such Party pursuant to the provisions of this
Agreement. 
 1.90. “Person” means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or
department or agency of a government. 
 1.91. “Pfizer” is defined in the introduction to this Agreement.

 1.92. “Pfizer CAR-T Developed IP” [***] 

1.93. “Pfizer Diligence Obligation” is defined in Section 3.2.4. 

1.94. “Pfizer Improvements” [***] 

1.95. “Pfizer Indemnified Party” is defined in Section 10.3. 

1.96. “Pfizer Know-How” means any Know-How comprised in the Pfizer Technology. 

1.97. “Pfizer Licensed Product” means any product containing an Agreement CAR-T that is claimed or covered by, or was
made using or otherwise incorporates, any Licensed Cellectis Intellectual Property. 
 1.98. “Pfizer Patent
Right” means any Patent Right comprised in the Pfizer Technology. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 8 

 1.99. “Pfizer Proprietary Materials” means any and all biological
(including any Antibodies) and other materials Controlled by Pfizer and provided by Pfizer to Cellectis under this Agreement. 

1.100. “Pfizer Quarter” means each of the four thirteen week periods (a) with respect to the United States,
commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. 

1.101. “Pfizer Target” means [***], plus any additional Pfizer Targets added to the Agreement pursuant to Section
2.1. 
 1.102. “Pfizer Technology” means [***] 

1.103. “Pfizer Year” means the 12 month fiscal periods observed by Pfizer (a) commencing on January 1 with
respect to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States 

1.104. “Phase I Clinical Trial” means a study of a Pfizer Licensed Product in human subjects or patients with the
endpoint of determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. § 312.21(a), or its successor regulation, or
the equivalent regulation in any other country. A so-called Phase I/II Clinical Trial will be deemed to be a Phase I Clinical Trial unless such study, when completed, allows Pfizer to proceed directly to a Phase III Clinical Trial. 

1.105. “Phase II Clinical Trial” means a study of a Pfizer Licensed Product in human patients to determine the safe and
effective dose range in a proposed therapeutic indication as and to the extent defined for the United Sates in 21 C.F.R. § 312.21(b), or its successor regulation, or the equivalent regulation in any other country. 

1.106. “Phase III Clinical Trial” means a study of a Pfizer Licensed Product in human patients with a defined dose or a
set of defined doses of a Pfizer Licensed Product designed to (a) ascertain efficacy and safety of such Pfizer Licensed Product for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the
Pfizer Licensed Product in the dosage range to be prescribed; and (c) support preparing and submitting applications for Regulatory Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the
United States in 21 C.F.R.§ 312.21(c), or its successor regulation, or the equivalent regulation in any other country. 

1.107. “PHS Act” means the United States Public Health Service Act, as amended, and the rules and regulations
promulgated thereunder. 
 1.108. “Price Approval” means, in any country where a Governmental Authority
authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing
approval or determination (as the case may be) 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 9 

 1.109. “Receiving Party” is defined in Section 7.1. 

1.110. “Regulatory Approval” means all technical, medical and scientific licenses, registrations, authorizations and
approvals (including approvals of BLAs, MAAs, supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling approvals) of any Regulatory Authority, necessary for the use, Development, Manufacture
and Commercialization of a pharmaceutical product in a regulatory jurisdiction. For the sake of clarity, Regulatory Approval will not be achieved for a Pfizer Licensed Product in a country until all applicable Price Approvals have also been obtained
by Pfizer, its Affiliates, sublicensees or distributors, where applicable, for such Pfizer Licensed Product in such country. 

1.111. “Regulatory Approval Application” means any application submitted to an appropriate Regulatory Authority seeking
any Regulatory Approval. 
 1.112. “Regulatory Authority” means, with respect to any national, supra-national,
regional, state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. 

1.113. “Representative” is defined in Section 7.2.1. 

1.114. “Research Plan” is defined in Section 2.6.1. 

1.115. “Research Plan Services” is defined in Section 2.6.2. 

1.116. “Research Program” is defined in Section 2.5. 

1.117. “Research Project” is defined in Section 2.6.1. 

1.118. “Research Term” means four (4) years from the Effective Date. 

1.119. “Royalty Term” means, on a Pfizer Licensed Product-by-Pfizer Licensed Product and country-by-country basis, the period
of time from the First Commercial Sale of such Pfizer Licensed Product in such country until the later of (i) the expiration of the last Valid Claim that would, but for the license to or ownership by Pfizer hereunder, be infringed by the sale
of such Pfizer Licensed Product in such country; (ii) the loss of regulatory exclusivity for the Pfizer Licensed Product in such country or (iii) the tenth (10th) anniversary of the date of the First Commercial Sale of such Pfizer
Licensed Product in such country, but in no event later than the twentieth (20th) anniversary of the date of the First Commercial Sale in any country. 

1.120. “Sales Milestone” is defined in Section 5.3.2. 

1.121. “Sales Milestone Payment” is defined in Section 5.3.2. 

  
 10 

 1.122. “Sales Threshold” is defined in Section 5.3.2. 

1.123. “SEC” means the United States Securities and Exchange Commission. 

1.124. “Servier Agreement” means that certain Research, Product Development, Option, License and Commercialization
Agreement by and between Servier and Cellectis dated February 17, 2014. 
 1.125. “Servier Targets” means
[***], and the five other targets set forth in the Servier Agreement. 
 1.126. “Subcontractors” is defined in
Section 2.13. 
 1.127. “Sublicensee” means any Person to whom Pfizer grants or has granted, directly or
indirectly, a sublicense of rights licensed by Cellectis to Pfizer under this Agreement, in accordance with the provisions of this Agreement. 

1.128. “[***] Patent Rights” means the Patent Rights set forth on Schedule 8.23 under the headings: CELLECTIS Patent
Portfolio on [***], In-licensed Patent applications from [***], In-Licensed patent applications from [***], In-Licensed Patent applications from [***] and In-Licensed from [***]. The value attributed to the [***] Patent Rights corresponds to [***]
of the total value of the Cellectis Technology. 
 1.129. “Target” means (a) a specific biological
molecule that is identified by a GenBank accession number or similar information, or by its amino acid or nucleic acid sequence, and (b) any biological molecule substantially similar in amino acid or nucleic acid sequence that has substantially
the same biological function as a molecule disclosed in clause (a), including any naturally occurring mutant or allelic variant of a molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and
post-transcriptional isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have
a biological function substantially similar to that of any biological molecules disclosed in clause (a) or clause (b). 

1.130. “Target Designation Date” means, with respect to the original Cellectis Program Target, Other Cellectis Targets
and Pfizer Targets, the Effective Date, and with respect to additional Pfizer Targets, Cellectis Program Targets and Other Cellectis Target designated pursuant to Section 2.4, such date as provided in Section 2.4. 

1.131. “Targeting” means, when used to describe the relationship between a molecule and a Target, that the molecule
(a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part through binding to such Target (or such portion thereof). 

1.132. “Term” is defined in Section 9.2. 

1.133. “Terminated Pfizer Licensed Product” is defined in Section 9.7.2(b). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 11 

 1.134. “Terminated Target” is defined in Section 9.7.2. 

1.135. “Territory” means the entire world. 

1.136. “Third Party” means any Person other than Pfizer, Cellectis or their respective Affiliates. 

1.137. “Third Party Claim” is defined in Section 10.4.1. 

1.138. “Trademark” means any trademark, trade dress, design, logo, slogan, house mark or name used in connection with
the Commercialization of any Pfizer Licensed Product by Pfizer or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the foregoing. 

1.139. “Useful” is defined in Section 5.4.2(b). 

1.140. “Valid Claim” means, with respect to a particular country, a claim of an issued and unexpired patent right
included within the Licensed Intellectual Property or Developed IP that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental authority of competent jurisdiction, which decision is
unappealed or unappealable within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. A Pfizer Licensed Product is
“Covered” by a Valid Claim if its referenced activity by Pfizer or its Sublicensees would, but for the licenses granted by Cellectis under this Agreement, infringe such Valid Claim. 

1.141. [***] 
 1.142.
Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and
vice versa), (b) the words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same
meaning and effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and
assigns, (f) the words “herein”, “hereof’ and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all
references herein to sections or exhibits will be construed to refer to sections or exhibits of this Agreement, and references to this Agreement include all exhibits hereto, (h) the word “notice” means notice in writing (whether or
not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,”
“consent” or “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 12 

 
excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current
amendments thereto or any replacement or successor law, rule or regulation thereof, (k) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), and (1) the term “or” will be interpreted in the inclusive
sense commonly associated with the term “and/or.” 
  

	2.	RESEARCH PROGRAM. 

 2.1 Selection of Pfizer Targets. 

2.1.1. Pfizer Targets. Pfizer hereby designates [***] as the initial Pfizer Targets for the first six Pfizer Research
Projects. 
 2.1.2. Additional Pfizer Target Right. Pfizer will have the right following each anniversary of the
Effective Date during the Research Term to add up to three additional Pfizer Targets under this Agreement, subject to availability of such Target, as set forth in Section 2.4 below. 

2.1.3. Exclusivity of Pfizer Targets. Subject to Sections 3.2.6 and 4.5, during the Term of this Agreement, for each Pfizer
Target, except as set forth in a Research Plan, neither Cellectis nor any of its Affiliates will (a) grant, or seek to grant, any right under any Cellectis Technology, Cellectis Improvements, Pfizer Improvements licensed to Cellectis pursuant
to Section 4.2.3 or Developed IP to any Third Party with respect to such Pfizer Target or (b) use any Cellectis Technology, Cellectis Improvements, Pfizer Improvements licensed to Cellectis pursuant to Section 4.2.3 or Developed IP to
Develop (itself or through or with a Third Party) or Commercialize CAR-Ts Targeting such Pfizer Target. 
 2.1.4. CAR-T
Exclusivity. Except to the extent required of Cellectis pursuant to the Servier Agreement, until the earlier of (i) completion or termination of the Research Term or (ii) the filing by Cellectis of an IND for a Cellectis Program Target
or Other Cellectis Target (together the “Cellectis Non-Compete Period”), neither Cellectis nor any of its Affiliates will grant, or seek to grant, any right under any Cellectis Technology, Cellectis Improvements, Pfizer Improvements
licensed to Cellectis pursuant to Section 4.2.3 or Developed IP to any Third Party to Develop or Commercialize CAR-Ts in the Field, other than academic institutions solely for internal academic non-profit research, non-commercial research
collaborations, and subcontractors of Cellectis and its Affiliates. For clarity, in the event that Cellectis files an IND for a product for a Cellectis Program Target or Other Cellectis Target the Cellectis Non-Compete Period will terminate at such
time for such Cellectis Program Target or Other Cellectis Target, but will remain in effect for all other Targets, including the remaining Cellectis Program Target or Other Cellectis Target, pursuant to terms of this Section 2.1.4. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 13 

 2.2 Selection of Cellectis Program Targets. 

2.2.1. Cellectis Program Targets. Cellectis hereby designates [***] as the initial Cellectis Program Target for the first
Cellectis Research Project. 
 2.2.2. Additional Cellectis Program Target Right. Cellectis will have the right following
each anniversary of the Effective Date during the Research Term to add an additional Cellectis Program Target under this Agreement, subject to availability of such Target, as set forth in Section 2.4 below. 

2.2.3. Exclusivity of Cellectis Program Targets. During the Research Term, until the earlier of (i) completion or
termination of the Research Term or (ii) the filing by Cellectis of an IND for a Cellectis Program Target (together the “Cellectis Program Target Non-Compete Period”), neither Pfizer nor any of its Affiliates will
(a) grant, or seek to grant, any right under any Pfizer Technology, Pfizer Improvements, Cellectis Improvements licensed to Pfizer pursuant to Section 4.1.2 or Developed IP Controlled by Pfizer to any Third Party with respect to such
Cellectis Program Target in the Field or (b) use any Pfizer Technology, Pfizer Improvements, Cellectis Improvements licensed to Pfizer pursuant to Section 4.1.2 or Developed IP Controlled by Pfizer to Develop (itself or through or with a
Third Party) or Commercialize T-cells expressing a chimeric antigen receptor construct Targeting such Cellectis Program Target in the Field. For clarity, in the event that Cellectis files an IND for a product for a Cellectis Program Target or enters
into an agreement with a Third Party related to such Cellectis Program Target, other than academic institutions solely for internal academic non-profit research, non-commercial research collaborations, or subcontractors for a Cellectis Program
Target then the Cellectis Program Target Non-Compete Period will terminate at such time for such Cellectis Program Target, but will remain in effect for all other Cellectis Program Targets, pursuant to terms of this Section 2.2.3. 

2.3 Selection of Other Cellectis Targets. 

2.3.1. Other Cellectis Targets. Cellectis hereby designates [***] as the initial Other Cellectis Targets. 

2.3.2. Additional Other Cellectis Target Right. Cellectis will have the right following each anniversary of the Effective Date
during the Research Term to add up to two additional Other Cellectis Targets under this Agreement, subject to availability of such Target, as set forth in Section 2.4 below. 

2.4 Target Selection Process. On or within 10 days of each anniversary of the Effective Date during the Research Term (including
the 3rd anniversary of the Effective Date), Pfizer and Cellectis will meet, either in person or by phone, to designate additional Targets as either Pfizer Targets, Cellectis Program Targets, or Other Cellectis Targets 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 14 

 
(each such date a “Target Designation Date”). The order of designation will be, subject to the limitations set forth in Sections 2.2.2 and 2.3.2: (i) Pfizer designates a
Pfizer Target, (ii) Cellectis designates a Cellectis Target (either a Cellectis Program Target or an Other Cellectis Target) (iii) Pfizer designates a Pfizer Target, (iv) Cellectis designates a Cellectis Target (either a Cellectis
Program Target or an Other Cellectis Target), (v) Pfizer designates a Pfizer Target and (vi) Cellectis designates a Cellectis Target (either a Cellectis Program Target or an Other Cellectis Target). The Parties hereby acknowledge and agree
that neither Party will be able to designate a Target as a Pfizer Target, Cellectis Program Target or Other Cellectis Target, as applicable, if such Target has previously been designated a Pfizer Target, Cellectis Program Target, Other Cellectis
Target, or Servier Target. Following the 3rd anniversary of the Effective Date, Cellectis will have the right, but not the obligation, to nominate any additional Targets as Other Cellectis
Targets. 
 2.5 Scope and Conduct of the Research Program. Under the terms and conditions set forth herein, Cellectis
and Pfizer will collaborate to conduct discovery and pre-clinical Development activities to generate and validate Agreement CAR-Ts to the Pfizer Targets and Cellectis Program Targets (the “Research Program”). The Research Program
will be conducted in accordance with the Research Plan for each Research Project (as more fully provided in Section 2.6 below), and each Party will use its Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all
of its obligations under each Research Plan in accordance with the timelines and budgets set forth in the applicable Research Plan. In addition, each Party will conduct its activities under the Research Plan(s) in accordance with Applicable Law.

 2.6 Research Plans. 

2.6.1. Adoption of Research Plans. The Parties will adopt a research plan (the “Research Plan”) for the Pfizer
Targets and Cellectis Program Target’s a “Research Project” will mean the work to be performed pursuant to such a Research Plan. The initial Research Plan for [***] is attached as Schedule 2.6.1. The Research Plan for any other
Pfizer Target or Cellectis Program Target will be prepared by the JRC and adopted within [***] of the Target Designation Date for such Pfizer Target or Cellectis Program Target by the JRC. Each Research Plan will reference this Agreement and will be
subject to all of the provisions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent any provisions of a Research Plan conflict or are inconsistent with the provisions of this Agreement, the
provisions of this Agreement will control. Unless otherwise expressly stated in a Research Plan, the provisions of each Research Plan will be independent of and will not affect the provisions of any other Research Plan. If the Parties are unable to
agree on a Research Plan within the specified time period, the JRC may specify the Research Plan, and all disputes regarding the preparation or modification of any Research Plan (including the approval of any Change Order) will be resolved by the
JRC pursuant to the procedures set forth in Section 2.7.5. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 15 

 2.6.2. Responsibilities. Each Research Plan will set forth the services and the
obligations and responsibilities assigned to each Party under the corresponding Research Project (collectively the “Research Plan Services”), and will include the following minimum terms: 

(a) [***] 
 (b) [***]. 

(c) Payment obligations of each Party. 

2.6.3. Changes in Research Plans. A Research Plan may be amended by a written amendment (a “Change Order”) to
such Research Plan. Proposed Change Orders will be prepared in writing by the JRC and will be subject to review and written approval by each of the Parties. Each Change Order will set forth the agreed changes to the applicable task, protocol,
specifications, responsibility, budget, timeline or other matter. As used in this Agreement, a Research Plan will be deemed to include any Change Orders with respect thereto. Each Change Order will reference this Agreement and the Research Plan it
relates to and will be subject to the provisions of this Agreement. To the extent any provisions of a Change Order conflict or are inconsistent with the provisions of this Agreement, the provisions of this Agreement will control. All Change Orders
will be incorporated herein by reference and form a part hereof. 
 2.7 Governance of the Research Program. 

2.7.1. Formation of the Joint Research Committee. Cellectis and Pfizer will establish a “Joint Research
Committee” (or “JRC”) to oversee and coordinate the activities of the Parties under this Agreement in regard to the Research Program. The JRC will also serve as a forum to facilitate communications between the Parties
regarding the Research Program. The JRC will be comprised of three (3) representatives from each Party as appointed by such Party, with such representatives possessing appropriate expertise and seniority to carry out the Research Projects. The
JRC may change its size from time to time by mutual consent of its members. A Party may replace one or more of its representatives from time to time upon written notice to the other Party. Each Party, respectively, will designate its initial members
of the JRC within thirty (30) days after the Effective Date. The JRC will exist until expiration of the Research Term, unless the Parties otherwise agree in writing. 

Co-Chairpersons and Secretary of the Joint Research Committee. Each Party will designate a co-chairperson of the JRC and a secretary of
the JRC will be designated in accordance with Section 2.8 below. A Party may change the designation of its co-chairperson from time to time upon written notice to the other Party. The co-chairpersons will be responsible for scheduling meetings
of the JRC, preparing agendas for meetings and sending to all JRC members notices of all regular meetings and agendas for such meetings at least five (5) Business 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 16 

 
Days before such meetings. The co-chairpersons will solicit input from both Parties regarding matters to be included on the agenda, and any matter either Party desires to have included on the
agenda will be included for discussion. Nothing herein will be construed to prohibit the JRC from discussing or acting on matters not included on the applicable agenda. The secretary will record the minutes of the meeting, circulate copies of
meeting minutes to the Parties and each JRC member promptly following the meeting for review, comment and approval by the JRC members and finalize approved meeting minutes. The co-chairpersons will be members of the JRC but the secretary need not be
a member of the JRC. 
 2.7.2. Meetings. The JRC will meet at least once each Calendar Quarter until it has been terminated in
accordance with Section 2.7.1 at dates and times mutually agreed by the JRC, unless otherwise mutually agreed by the Parties. The initial meeting of the JRC will be held within thirty (30) days after the Effective Date. Either Party may
call a special meeting of the JRC on fifteen (15) days written notice to the other Party’s members of the JRC (or upon such shorter notice as exigent circumstances may require). Such written notice will include an agenda for the special
meeting. In-person meetings, including special meetings, of the JRC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the JRC. Meetings of the JRC may be held telephonically or by video conference;
provided, however, that at least [***] will be held in-person. Meetings of the JRC will be effective only if at least one (1) representative of each Party is in attendance or participating in the meeting. Members of the JRC will have the right
to participate in and vote at meetings held by telephone or video conference. In addition, the JRC may act on any matter or issue without a meeting if it is documented in a written consent signed by each member of the JRC. 

2.7.3. Responsibilities of the Joint Research Committee. The JRC will be responsible for (a) planning and supervising research and
development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b) receiving and reviewing all data and other information obtained by either Party in connection with the
Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c) documenting and approving initiation and completion of each Research Project; (d) evaluating FTE requirements for the
performance of the Research Plans; and (e) such other functions as expressly specified hereunder or as agreed by the Parties. 
 2.7.4.
Decisions. The JRC members will use good faith efforts to reach agreement on any and all matters properly brought before them related to the Research Program. In the event that, despite such good faith efforts, agreement on a particular
matter cannot be reached by the JRC within ten days after the JRC first meets to consider such matter, or such later date as may be mutually acceptable to the parties (each such matter, a “Disputed Matter”), then either party may
refer that Disputed Matter for resolution by their respective senior 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 17 

 
executives, and such senior executives would promptly initiate discussions in good faith to resolve such Disputed Matter. If the senior executives are unable to resolve the Disputed Matter within
thirty (30) days of it being referred to them, then Cellectis will have the final decision making authority with respect to all Disputed Matters related to Cellectis Program Targets and Pfizer will have final decision making authority with
respect to all other Disputed Matters; provided that neither Party will have the authority to obligate the other Party to perform Research Plan Services that are substantially greater than the those set forth in the Research Plan attached hereto as
Schedule 2.6.1. 
 2.8 Alliance Managers. In addition to the foregoing governance provisions, each of the Parties will appoint
a single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to facilitate the relationship between the Parties as established by this Agreement. The Alliance
Managers will attend meetings of the JRC and support the respective co-chairpersons of such committee in the discharge of their responsibilities. Unless otherwise determined by the JRC, Pfizer’s Alliance Manager will serve as secretary at each
meeting of the JRC. Alliance Managers will be non-voting participants in such committee meetings. A Party may replace its Alliance Manager from time to time upon written notice to the other Party. 

2.9 Conformance with Law. Each Party will perform and discharge its obligations under this Agreement and the Research Program in
conformance with (a) professional standards and practices, (b) this Agreement and the Research Plan(s) and (c) all Applicable Laws. Without limiting the generality of the foregoing, each Party will retain all records relating to its
performance of this Agreement and the Research Plan(s) for the time periods required by Applicable Laws. 
 2.10 Cellectis
Personnel Matters. Cellectis acknowledges and agrees that it is solely responsible for the compensation of the personnel assigned to the Research Plan Services, and as employer will be responsible for withholding all national, state, local or
other applicable taxes and similar items. Cellectis also will be responsible for all other employer related obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law
affecting the gross wages of each employee. Cellectis personnel assigned to the Research Plan Services are not nor will they be deemed to be employees of Pfizer. 

2.11 Non-Solicit. 

2.11.1. Cellectis Employees. Pfizer hereby undertakes, on behalf of itself and its Affiliates, that prior to any Change of Control of
Cellectis and during the period of time from the Effective Date until [***], neither Rinat nor Pfizer’s oncology research unit (or the immumo-oncology or oncology research unit of a Third Party acquired by Pfizer) nor any person acting on their
behalf will, without the prior written consent of Cellectis, directly or indirectly, encourage to quit, or attempt to encourage to quit any director or officer, executive or scientific research employee (project leader level or higher) of any of
Cellectis and its Affiliates with 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 18 

 
whom Pfizer had contact during the Research Term, provided however, that Pfizer may engage in general solicitations such as through a search firm, newspaper or other media advertisement. In the
event that Pfizer is alleged to have breached this Section 2.11.1 and Cellectis provides written notification to Pfizer of its objection to such alleged breach within 2 months of such alleged breach, the Parties will use reasonable efforts to
resolve to resolve such alleged breach. In no event will a breach of this Section 2.11.1 be deemed a material breach of this Agreement for the purposes of Section 9.4 below. 

2.11.2. Pfizer Employees. Cellectis hereby undertakes, on behalf of itself and its Affiliates, that prior to any Change of Control of
Pfizer and during the period of time from the Effective Date [***], neither Cellectis nor any of its Affiliates nor any person acting on their behalf will, without the prior written consent of Pfizer, directly or indirectly, encourage to quit, or
attempt to encourage to quit any director or officer, executive or scientific research employee (director level or higher) of any of Pfizer and its Affiliates with whom Cellectis had contact during the Research Term, provided however, that Cellectis
may engage in general solicitations such as through a search firm, newspaper or other media advertisement. In the event that Cellectis is alleged to have breached this Section 2.11.2 and Pfizer provides written notification to Cellectis of its
objection to such alleged breach within 2 months of such alleged breach, the Parties will use reasonable efforts to resolve such alleged breach. In no event will a breach of this Section 2.11.2 be deemed a material breach of this Agreement for
the purposes of Section 9.4 below. 
 2.12 Debarment Certification. Neither Party nor any Person employed or retained to
perform services by either Party has been debarred under Section 306(a) or (b) of the FD&C Act or any comparable provision of foreign law and no debarred Person will in the future be employed or retained to perform services by either
Party in connection with any work to be performed for or on behalf of the other Party. If, at any time after execution of this Agreement, either Party becomes aware that such Party or any Person employed or retained to perform services by such Party
in connection with any work performed for or on behalf of such Party is, or is in the process of being, debarred, such Party will so notify the other Party immediately. 

2.13 Subcontractors. Except for Expected Subcontractors that are hereby accepted by Pfizer, Cellectis may not engage any
contractor, or subcontractor (a “Subcontractor”) to perform any Research Plan Services or Research Program activities without Pfizer’s prior written consent, provided that such decision will be determined and communicated in a
timely manner and any consent will not be unreasonably withheld. Cellectis will be responsible for the management of all permitted Subcontractors. The engagement by Cellectis of any Subcontractor in compliance with this Section 2.13 will not
relieve Cellectis of its obligations under this Agreement or any applicable Research Plan. Any agreement between Cellectis and a permitted Subcontractor pertaining to the Research Plan Services will be consistent with the provisions of this
Agreement. Furthermore, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any Subcontractor to perform any obligations hereunder, Cellectis will cause such Subcontractor to agree in writing to be bound by terms
providing for Pfizer rights no less favorable to Pfizer than the rights granted to Pfizer in this Agreement. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 19 

 2.14 Inspections. Each Party’s authorized representative(s), and Regulatory
Authorities to the extent required by law and applicable to the scope of the Research Plan Services performed, may, during regular business hours and, to the extent legally possible, at times arranged in advance with the other Party, audit, inspect
and copy all data, records and work products, and audit and inspect all facilities, relating to the Research Plan Services and such other Party’s performance under this Agreement and the applicable Research Plan(s) (including all data, records,
work products and facilities of subcontractors). 
 2.15 Records. Each Party will prepare, maintain and retain complete
and accurate written records, accounts, notes, reports and data of the Research Plan Services and its performance under this Agreement and the Research Plan(s), in a form and of quality reasonably acceptable to both Parties. All such information
will be treated as Confidential Information of Pfizer for the purpose of this Agreement. 
  

	3.	PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. 

3.1 General. Except as expressly set forth in Article 2, Pfizer will have sole authority over and control of the Development,
Manufacture and Commercialization of Pfizer Licensed Products Targeting such Pfizer Target. 
 3.2 Diligence.

 3.2.1. Pfizer Development Diligence. Pfizer will use Commercially Reasonable Efforts to Develop [***] for [***] during the
Term. For avoidance of doubt, any actions taken by Pfizer’s Affiliates or Sublicensees under this Agreement will be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.1. Additionally,
during the Research Term, Pfizer, or its Affiliates or Sublicensees will: 
 (a) Initiate Development for [***] within [***] from the Target
Designation Date [***]; 
 (b) Develop [***] during the Research Term; provided that if there are [***] designated [***], such Development
will apply to the remaining [***]; and 
 (c) Not stop Development for [***] for [***] during the Research Term. For clarity, if Pfizer stops
Development of a [***] for [***], but re-initiates Development activities prior to [***], Pfizer will be deemed to have satisfied its obligation with respect to this Section 3.2.1(c). 

3.2.2. Cellectis Development Diligence. Cellectis will use Commercially Reasonable Efforts to Develop at least one Cellectis Product for
each Cellectis Program Target during the Research Term. For avoidance of doubt, any actions 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 20 

 
taken by Cellectis’ Affiliates or Sublicensees under this Agreement will be treated as actions taken by Cellectis in regard to satisfaction of the requirements of this Section 3.2.2.
Additionally, Cellectis or its Affiliates or Sublicensees will, during the Research Term,: 
 (a) Initiate Development for [***] within [***]
from the Target Designation Date for [***]; and 
 (b) Not stop Development for [***] for [***] during the Research Term. For clarity, if
Cellectis stops Development of a Cellectis Program Target for [***], but re-initiates Development activities prior to [***], Cellectis will be deemed to have satisfied its obligation with respect to this Section 3.2.2(b). 

3.2.3. Commercial Diligence. Pfizer will use Commercially Reasonable Efforts to Commercialize [***] where Pfizer has received Regulatory
Approval for [***] in such country. Pfizer will have no other diligence obligations with respect to the Commercialization of Pfizer Licensed Products under this Agreement. For avoidance of doubt, any actions taken by Pfizer’s Affiliates or
Sublicensees under this Agreement will be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.2. 

3.2.4. Exceptions to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary, each Party will be relieved
from and will have no obligation to undertake any efforts with respect to any diligence obligation under each of the Pfizer Targets or Cellectis Program Targets, as applicable, pursuant to Section 3.2.1 or Section 3.2.3 (each, a
“Pfizer Diligence Obligation”) or Section 3.2.2 (a “Cellectis Diligence Obligation”) in the event that: 

(a) Pfizer or Cellectis receives or generates any safety, tolerability or other data reasonably indicating or signaling, as measured by
Pfizer’s safety and efficacy evaluation criteria and methodology, that such Pfizer Licensed Product has or would have an unacceptable risk-benefit profile or is otherwise not reasonably suitable for initiation or continuation of clinical trials
in humans; 
 (b) Pfizer or Cellectis receive any notice, information or correspondence from any applicable Regulatory Authority, or any
applicable Regulatory Authority takes any action, that reasonably indicates that such Pfizer Licensed Product is unlikely to receive Regulatory Approval; or 

(c) the Pfizer Diligence Obligation breach or Cellectis Diligence Obligation breach, as applicable, related to such Pfizer Target or Cellectis
Program Target, as applicable, is caused by the negligence, recklessness or intentional acts of the other Party. 
 3.2.5. Assertion of
Diligence Obligation Claims. If a Party is, becomes, or reasonably should be aware of facts that might form a reasonable basis that the Other Party has failed to meet any Pfizer Diligence Obligation or Cellectis Diligence Obligation, as
applicable, then Cellectis or Pfizer, as applicable, will 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 21 

 
promptly notify Pfizer or Cellectis, as applicable, in writing of such potential alleged performance failure (each such potential alleged performance failure, a “Diligence
Issue”). Promptly upon Pfizer’s or Cellectis’, as applicable, receipt of any notice of a Diligence Issue pursuant to this Section 3.2.4, the Pfizer Alliance Manager and Cellectis Alliance Manager will meet to discuss the
specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [***] receipt of such a notice, (a) the Parties have not reached consensus regarding whether Pfizer has failed to satisfy
the Pfizer Diligence Obligations or Cellectis has failed to satisfy the Cellectis Diligence Obligations and (b) the Parties’ respective Alliance Managers have not agreed upon an appropriate corrective course of action for such Diligence
Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.10. If Cellectis or Pfizer, as applicable, fails to notify Pfizer or Cellectis, as applicable, of a Diligence
Issue pursuant to this Section 3.2.5 [***] the date that Cellectis or Pfizer, as applicable, first discovers or reasonably should have discovered such Diligence Issue, then Pfizer or Cellectis, as applicable, will be deemed to have satisfied
its Pfizer Diligence Obligations or Cellectis Diligence Obligations, as applicable, with respect to such Diligence Issue. 
 3.2.6.
Remedies for Breach of Pfizer Diligence Obligations. If Pfizer materially breaches any Pfizer Diligence Obligation and fails to remedy such breach within [***] of Pfizer’s receipt of notice of such breach from Cellectis, then, with
respect to Pfizer Targets [***], the applicable Pfizer Target, [***] will cease to be a Pfizer Target and will become a Cellectis Program Target and with respect to any Pfizer Targets other than [***], the applicable Pfizer Target(s) will no longer
be subject to the exclusivity provisions set forth in Section 2.1.3 above. 
 3.3 Remedies for Breach of Cellectis Diligence
Obligations. If Cellectis materially breaches any Cellectis Diligence Obligation and fails to remedy such breach within [***] of Cellectis’ receipt of notice of such breach from Pfizer, then the Pfizer Non-Compete Period with respect to
such Cellectis Program Target(s) as set forth in Sections 2.2.3 will terminate. 
 3.4 Regulatory Approvals. Pfizer or
its designated Affiliate(s) will file, in its own name, all Regulatory Approval applications for Pfizer Licensed Products Targeting such Pfizer Target where Pfizer, in its sole discretion, determines it is commercially advantageous to do so. Pfizer,
or its designated Affiliate(s), will have the sole responsibility for, and sole authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval Application or any Regulatory Approval for a Pfizer Licensed
Product once granted. Except to the extent necessary to fulfill its obligations under Section 3.2.1, neither Pfizer nor any of its Affiliates will have any obligation to seek Regulatory Approval for any Pfizer Licensed Product. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 22 

 3.5 Control of Commercialization Activities. 

3.5.1. General. Pfizer will have sole and exclusive control over all matters relating to the Commercialization of Pfizer Licensed
Products Targeting such Pfizer Target; and 
 3.5.2. Trademarks. Pfizer will select and own all Trademarks used in connection with the
Commercialization of any such Pfizer Licensed Products, including all goodwill associated therewith. Neither Cellectis nor its Affiliates will use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any
Trademarks used by or on behalf of Pfizer, its Affiliates or Sublicensees in connection with any Pfizer Licensed Product. Nothing in this Section 3.5.2 will be construed to prevent Cellectis from granting Pfizer any license or right in and to
any trademark, trade dress, design, logo, slogan, house mark or name Controlled by Cellectis. 
 3.6 Manufacturing. Pfizer will have
the exclusive right (subject to Sections 3.2.5 and 4.5) to Manufacture Pfizer Licensed Products Targeting such Pfizer Target itself or through one or more Affiliates or Third Parties selected by Pfizer. Pfizer will have no diligence obligations with
respect to the Manufacture of Pfizer Licensed Products except to the extent necessary to fulfill the Pfizer Diligence Obligations. Pfizer will be responsible for 100% of the associated costs for the manufacturing of Pfizer Licensed Products. 

3.7 Pfizer Progress Reporting. Commencing upon the Effective Date and until delivery of the first royalty report pursuant to
Section 5.6.2, Pfizer will provide Cellectis with annual written reports on Pfizer’s activities to Develop and Commercialize Pfizer Licensed Products Targeting such Pfizer Target. Any information or written report provided by Pfizer to
Cellectis pursuant to this Section 3 will be deemed to be Pfizer’s Confidential Information subject to the provisions of Article 7. 

3.8 Cellectis Progress Reporting. Commencing upon the Effective Date and until the end of the Pfizer Non-Compete Period, Cellectis will
provide Pfizer with annual written reports on Cellectis’ activities to Develop and Commercialize products or compounds to a Cellectis Program Target. Any information or written report provided by Cellectis to Pfizer pursuant to this
Section 3.8 will be deemed to be Cellectis’ Confidential Information subject to the provisions of Article 7. 
 3.9 Right of
First Refusal. 
 In the event that Cellectis proposes to enter into any Third Party agreement related to the Development or
Commercialization of any CAR Targeting a Cellectis Program Target (each a “Cellectis Target Product”) in the Field, Cellectis will first provide Pfizer with written notice of such proposal, including all material terms and
conditions thereof (each a “Cellectis Target Product Notice”). For [***] following receipt of the Cellectis Target Product Notice, Pfizer will have the option to purchase or license from Cellectis the Cellectis Target Product upon
the terms and conditions set forth in the Cellectis Target Product Notice. In the event Pfizer elects to purchase or license the Cellectis Target Product from Cellectis, Pfizer will give written notice of its election to Cellectis

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 23 

 
within such [***] and the Parties will negotiate a mutually agreeable agreement for the purchase or license of the Cellectis Target Product within [***]; provided that the timeline for completing
the agreement is not delayed by the actions or inactions of Cellectis. If Pfizer does not elect to purchase or license the Cellectis Target Product, Cellectis may, within [***] following the expiration of the option right granted to Pfizer, transfer
or license the Cellectis Target Product to the proposed transferee or any other transferee, provided that this transfer will not be on terms and conditions more favorable to the transferee than those contained in the Cellectis Target Product Notice.
In the event that Cellectis does not enter into the Third Party agreement to which the Cellectis Target Product Notice relates, this Section 3.9 will continue to apply with respect to the Cellectis Product Target. This Section 3.9 will be
applicable to any potential Third Party agreement that Cellectis proposes entering into during the Term related to the Development or Commercialization of any CAR Targeting a Cellectis Program Target in the Field. 

3.10 Right of Negotiation. In the event that Cellectis proposes to enter into any Third Party agreement related to the Development or
Commercialization of any product Targeting an Other Cellectis Target, Cellectis will provide Pfizer with written notice of such intent and will negotiate in good faith with Pfizer regarding Pfizer’s purchase or license of such product Targeting
an Other Cellectis Target. 
  

	4.	LICENSES AND RELATED GRANTS OF RIGHTS. 

 4.1 Grants to Pfizer. 

4.1.1. Exclusive License. Subject to the terms and conditions of this Agreement, on a Pfizer Target-by-Pfizer Target basis and effective
on the Target Designation Date for such Pfizer Target, Cellectis hereby grants to Pfizer and its Affiliates an exclusive (even as to Cellectis, except to the extent necessary for Cellectis to perform its obligations under the Research Program)
license under the Licensed Cellectis Intellectual Property (excluding [***] Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize
Pfizer Licensed Products in the Field in the Territory, with the right to sublicense as provided in Section 4.1.4 (the “License”). 

4.1.2. [***] Patent Rights. 

(a) Subject to the terms and conditions of this Agreement on a Pfizer Target-by-Pfizer Target basis and effective on the Target Designation
Date for such Pfizer Target, Cellectis hereby grants to Pfizer and its Affiliates the right to use the [***] engineered by Cellectis pursuant to this Agreement to Develop Pfizer Licensed Products until the filing of an IND for each Pfizer Licensed
Product, in the Field. 
 (b) Exclusive License. Subject to the terms and conditions of this Agreement, on a Pfizer Target-by-Pfizer
Target basis and effective upon the filing of an IND 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 24 

 
for each individual Pfizer Licensed Product developed under 4.1.2(a), Cellectis hereby grants to Pfizer and its Affiliates an exclusive (even as to Cellectis) license under the [***] Patent
Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Pfizer Licensed Product in the Field in the Territory, with the right to
sublicense as provided in Section 4.1.3. For the sake of clarity, the license granted to Pfizer by Cellectis herein does not give Pfizer the right to [***]. 

4.1.3. License to Cellectis Improvements. Subject to the terms and conditions of this Agreement, Cellectis hereby grants to Pfizer and
its Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Cellectis Improvements that were solely or jointly invented by the employees, agents or independent contractors of Pfizer or its
Affiliates to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes. 

4.1.4. Right to Sublicense. Pfizer will have the right to grant sublicenses to its Affiliates and Third Parties of any and all licenses
granted to Pfizer under this Agreement by Cellectis, provided that (a) Pfizer will be jointly and severally responsible with its Sublicensees to Cellectis for failure by its Sublicensees to comply with the terms and conditions of this
Agreement; (b) each sublicense will include obligations on the Sublicensee that are consistent with the terms of this Agreement,; and (c) Pfizer will remain responsible for the payment to Cellectis of all Milestone Payments and royalties
payable with respect to the activities and Net Sales of any Sublicensee. 
 4.1.5. Direct License to Affiliates. Pfizer may at any
time request and authorize Cellectis to grant licenses directly to Affiliates of Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, Cellectis will enter into and sign a
separate direct license agreement with such designated Affiliate of Pfizer. All such direct license agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and
regulations in the country in which the direct license will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the
terms of this Agreement as set forth on the Effective Date. In countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements will not become binding between the
parties thereto until such approval or registration is granted, which approval or registration will be obtained by Pfizer. All costs of making such direct license agreement(s), including Cellectis’ reasonable attorneys’ fees, under this
Section 4.1.4 will be borne by Pfizer. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 25 

 4.1.6. Right of Reference. Cellectis hereby grants to Pfizer a “Right of
Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by Cellectis or its Affiliates (a) that relates to the Licensed Cellectis Intellectual Property, the Agreement CAR-Ts, the Pfizer Licensed Products or
preclinical studies with respect to the Pfizer Licensed Products and (b) that Pfizer reasonably believes may be necessary or useful to the Development, Manufacturing or Commercialization of any Agreement CAR-T or any Pfizer Licensed Product
pursuant to this Agreement, and Cellectis will provide a signed statement to the foregoing effect, if so requested by Pfizer in accordance with 21 C.F.R. § 314.50(g)(3). 

4.1.7. Technology Transfer Assistance to Pfizer. Cellectis will provide reasonable assistance, at no additional cost to Pfizer, to
affect the timely and orderly transfer to Pfizer of the Know-How included in the Licensed Cellectis Intellectual Property necessary for Pfizer’s use in performing its responsibilities under the Research Plans, and for the Development,
Manufacturing and Commercialization of Pfizer Licensed Products pursuant to the License. 
 4.2 Grants to Cellectis. 

4.2.1. Research License. Subject to the terms and conditions of this Agreement and during the Research Term with respect to each Pfizer
Target, Pfizer hereby grants to Cellectis a non-exclusive, worldwide, royalty-free license, with no right to grant sublicenses, under the Pfizer Technology to perform the activities assigned to Cellectis under the applicable Research Plan. 

4.2.2. Non-Exclusive License. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to Cellectis and its
Affiliates a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under the Licensed Pfizer Intellectual Property Controlled by Pfizer solely to make, have made, use, have used, sell, have sold, offer for sale, have offered for
sale, import, have imported and otherwise exploit and Commercialize Cellectis Products Targeting Cellectis Program Targets. Cellectis will have the right to grant sublicenses of the foregoing license to Third Party collaborators following the
Cellectis Non-Compete Period only if Cellectis has entered into a written agreement with such Third Party collaborator (i) obtaining a covenant not to sue or (ii) granting Pfizer a non-exclusive, worldwide, royalty-free, perpetual and
irrevocable license under improvements to the Cellectis Technology developed in the framework of the collaboration between Cellectis and such Third Party that are Controlled by such Third Party. 

4.2.3. License to Pfizer Improvements. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to Cellectis and its
Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Pfizer Improvements that were solely or jointly invented by the employees, agents or independent contractors of Cellectis or its
Affiliates to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes. 

  
 26 

 4.2.4. Technology Transfer Assistance to Cellectis. Pfizer will provide reasonable
assistance, at no additional cost to Cellectis, to affect the timely and orderly transfer to Cellectis of the Know-How included in the Pfizer Technology, Pfizer Improvements, Developed IP solely owned by Pfizer, and CAR-T Developed IP (if
applicable) necessary for Cellectis’ use in performing its responsibilities under the Research Plans, and for the Development, Manufacturing and Commercialization of Cellectis Products Targeting Cellectis Programs Targets pursuant to the
License under Sections 4.2.1 and 4.2.2 above. 
 4.3 Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential
Information. Without limiting any other license granted to either Party under this Agreement and subject to the terms of Section 7: 

4.3.1. Cellectis hereby grants to Pfizer and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable, royalty-free, fully
paid-up, worldwide license to use any and all Cellectis Know-How included in the Licensed Cellectis Intellectual Property and Cellectis Confidential Information disclosed to Pfizer during the Term of this Agreement solely for internal research
purposes. 
 4.3.2. Pfizer hereby grants to Cellectis and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable,
royalty-free, fully paid-up, worldwide license to use any and all Pfizer Know-How and Pfizer Confidential Information (other than any information regarding the identity of or Pfizer’s reasons for selecting any Pfizer Target or Additional Pfizer
Target, which will only be disclosed by Cellectis to its Representatives as necessary to comply with the terms of this Agreement) disclosed to Cellectis during the Term of this Agreement solely for internal research purposes. 

4.3.3. Notwithstanding the foregoing, neither Pfizer nor Cellectis will have any right under this Section 4.3 to make or use any physical
material supplied by the other Party for use in the Research Program other than for use in the Research Program. 
 4.4 Retained
Rights. For the avoidance of doubt, except as expressly provided in regard to the licenses contained in this Article 4 or in the provisions of Section 6.1.1, each Party will retain ownership of all of its Pfizer Technology or Cellectis
Technology, as applicable. 
 4.5 Other Pfizer Programs. Cellectis understands and acknowledges that Pfizer may have present or future
initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or that may compete with a product, program, technology or
process covered by this Agreement. Cellectis acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, 

  
 27 

 
covenant or inference that Pfizer will not itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to Develop,
Manufacture or Commercialize products, programs, technologies or processes that are similar to or that may compete with any product, program, technology or process covered by this Agreement. Notwithstanding the foregoing, if Pfizer or its
Affiliates, other than pursuant to this Agreement, themselves Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize T-cells expressing
a chimeric antigen receptor construct other than a CAR-T, with respect to a particular Pfizer Target in the Field, then any exclusive licenses granted to Pfizer under this Agreement with respect to a Pfizer Licensed Product Targeting such Pfizer
Target will be automatically converted into non-exclusive licenses, and Cellectis’ exclusivity obligation under Sections 2.1.3 and 2.1.4 will not apply with respect to such Pfizer Target. 

4.6 No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed, by estoppel, implication or
otherwise, to have granted the other Party any license or other right with respect to any intellectual property of such Party. 
  

	5.	PAYMENTS TO CELLECTIS. 

 5.1 Upfront Fee. Within [***] the Effective Date [***],
unless this Agreement is terminated by Pfizer pursuant to Section 9.3 below, Pfizer will pay to Cellectis, concurrent with the purchase by Pfizer of the Cellectis securities pursuant to the Subscription Agreement, the non-creditable,
non-refundable amount of Eighty Million Dollars ($80,000,000). 
 5.2 Research Support Funding. 

5.2.1. Research Program Payments. Each Party will pay the other Party for the costs and expenses as set forth in each Research Plan,
provided that Pfizer will bear the costs associated with Research Plan Services performed by Cellectis related to Pfizer Targets, as set forth in the Research Plan, at the FTE Rate. During the Research Term, Pfizer will provide [***] Pfizer FTEs
[***] for Research Plan Services related to Cellectis Program Targets utilizing Pfizer infrastructure and technology as set forth in the Research Plan. Subject to the foregoing, the JRC shall determine the specific number of FTEs that shall perform
Research Plan Services for Cellectis from time to time. Notwithstanding the foregoing, Pfizer shall only be obligated to reimburse Cellectis for the number of FTEs actually incurred and reported pursuant to Section 5.2.3 in the performance of
its Research Plan Services. 
 5.2.2. Other Expenses. Except as expressly set forth in Section 5.2.1, each Party will be solely
responsible for all costs and expenses it incurs in performing its obligations under the Research Program. Pfizer will be funding capital equipment required at Pfizer sites and Cellectis will be funding capital equipment required at Cellectis sites.
Pfizer will be funding capital equipment required at Cellectis sites 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 28 

 
that will at a later time be transferred to Pfizer and Cellectis will be funding capital equipment required at Pfizer sites that will at a later time transferred to Cellectis. 

5.2.3. Reports and Reimbursement Payments. Within thirty (30) days after the end of each Calendar Quarter of the Research Term,
Cellectis will provide Pfizer with a quarterly report containing a detailed account of activities performed together with an invoice for amounts payable under Section 5.2.1, with respect to such Calendar Quarter. Each report must be accompanied
by a certificate executed by a duly appointed officer of Cellectis confirming the actual total number of FTE hours supplied by Cellectis during such Calendar Quarter and the identity of, and number of FTE hours performed by, each individual
performing Research Plan Services during such Calendar Quarter. Payment shall be due within [***] after Pfizer receives such an invoice from Cellectis. 

5.2.4. Audit Rights. During the Research Term and for a period of [***], Cellectis shall keep and maintain accurate and complete records
showing the time devoted and activities performed by each FTE in performing Cellectis’ obligations under the Research Program. Upon [***] prior written notice from Pfizer, Cellectis shall permit an independent certified public accounting firm
of nationally recognized standing selected by Pfizer and reasonably acceptable to Cellectis to examine, at Pfizer’s sole expense, the relevant books and records of Cellectis as may be reasonably necessary to verify the accuracy of the invoices
submitted to Pfizer under Section 5.2.3 for the number of FTEs applied to the performance of Cellectis’ obligations under the Research Program. An examination by Pfizer under this Section 5.2.4 shall occur not more than [***] and
shall be limited to the pertinent books and records for [***] before the date of the request. Such examination shall be conducted during Cellectis’ normal business hours at Cellectis’ facility(ies) where such books and records are normally
kept. Cellectis may require the accounting firm to sign a reasonable and customary non-disclosure agreement. The accounting firm shall provide both Cellectis and Pfizer a written report disclosing whether the invoices submitted by Cellectis are
correct or incorrect and the specific details concerning any discrepancies. If the accounting firm determines the number of FTEs actually utilized by Cellectis was less than the number funded by Pfizer during the period covered by the audit,
Cellectis shall, at Pfizer’s sole discretion, either (a) refund the excess payments to Pfizer within [***] of its receipt of the auditor’s report so concluding or (b) immediately offset all such excess payments against any
outstanding or future amounts payable by Pfizer to Cellectis under this Agreement until Pfizer has received full credit for all such overpayments. Additionally, if the amount to be refunded exceeds [***] of the amount that was properly payable,
Cellectis shall reimburse Pfizer for the cost of the audit. 
 5.3 Milestones 

5.3.1. Development Milestones. Pfizer will pay to Cellectis the amount set forth below within [***] of receipt of Cellectis’
invoice following the first occurrence 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 29 

 
of each event (each, a “Development Milestone”) described below for each Pfizer Licensed Product for each Pfizer Target (each such amount, a “Development Milestone
Payment”) to be payable only once with respect to each Pfizer Licensed Product Targeting a Pfizer Target. For the avoidance of doubt, if any Development Milestone Payment is paid for an Agreement CAR-T or Pfizer Licensed Product Targeting a
Pfizer Target and the Development or Commercialization of such Agreement CAR-T or Pfizer Licensed Product is terminated and such Agreement CAR-T or Pfizer Licensed Product is replaced with another Agreement CAR-T or Pfizer Licensed Product Targeting
the same Pfizer Target, such Development Milestone Payment will not be owed by Pfizer if such Agreement CAR-T or Pfizer Licensed Product later achieves the same Development Milestone. 

 

					
	 Development Milestone
	  	Development
Milestone Payments	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 If any Development Milestone described above occurs before a previous Development Milestone occurs, then any
Development Milestone that has not yet been paid for achievement of any previous Development Milestone shall become due upon the achievement of the subsequent Development Milestone and payable together with the payment due upon achievement of such
subsequent Development Milestone. For clarity, the achievement of a Development Milestone related to [***] will not result in the payment of any other Development Milestone related to [***]. 

5.3.2. Sales Milestones. Pfizer will pay to Cellectis the following one-time payments (each, a “Sales Milestone
Payment”) within [***] of the last day of the Pfizer Year when aggregate Annual Net Sales of a Pfizer Licensed Product in a Pfizer Year first reach the respective threshold (a “Sales Threshold”) indicated below (each, a
“Sales Milestone”); provided that such Sales Threshold with respect to a Pfizer Licensed Product must be reached within [***] following the First Commercial Sale of such Pfizer Licensed Product in the Territory. 

 

					
	 Total Annual Net Sales
	  	Sales Milestone
Payments	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 30 

 5.4 Royalties. With respect to each Pfizer Licensed Product and subject to the provisions
of Section 5.4.2, Pfizer will pay Cellectis royalties in the amount of the applicable rates (“Marginal Royalty Rates”) set forth below of Annual Net Sales of any Pfizer Licensed Product Targeting such Pfizer Target during the
Royalty Term: 
  

					
	 Annual Net Sales
	  	Marginal Royalty
Rates (% of the
Annual Net Sales)	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 5.4.1. Marginal Royalty Rate Application. Each Marginal Royalty Rate set forth in the table above will
apply only to that portion of the Annual Net Sales of a given Pfizer Licensed Product in the Territory during a given Pfizer Year that falls within the indicated range. 

5.4.2. Royalty Adjustments. The following adjustments will be made, on a Pfizer Licensed Product-by-Pfizer Licensed Product and
country-by-country basis, to the royalties payable pursuant to this Section 5.4: 
 (a) Generic Competition. Royalties payable
following establishment of Generic Competition with respect to the sale by a Third Party of a product that is a Biosimilar Biologic Product to such Pfizer Licensed Product in such country will be payable at [***] of the otherwise applicable rate
prior to application of this Section 5.4.2(a). “Generic Competition” means, with respect to a given Calendar Year with respect to a Pfizer Licensed Product in any country, that during such Calendar Year, one (1) or more
Third Parties have received Regulatory Approval to sell in such country a Biosimilar Biologic Product, such Biosimilar Biologic Product(s) will be commercially available in such country and such Biosimilar Biologic Product(s) will have, in the
aggregate. A product will be a “Biosimilar Biologic Product” with respect to a Pfizer Licensed Product if such product (1) has been licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of
the Public Health Service Act (42 U.S.C. 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation, (2) has been licensed as a similar biological medicinal product by EMA pursuant to Directive 2001/83/EC, as may be
amended, or any subsequent or superseding law, statute or regulation, or (3) has otherwise achieved analogous Regulatory Approval from another applicable Regulatory Authority. 

(b) Third Party Patents. If, after the Effective Date, it is Necessary or Useful for Pfizer to license one or more Patent Rights from
one or more Third Parties in order to Develop, Manufacture, Commercialize or use any Pfizer Licensed Product, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its sole discretion, negotiate and obtain a license
under such Patent 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 31 

 
Right(s) (each such Third Party license referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to Cellectis under this Agreement with respect
to Net Sales of any Pfizer Licensed Product by Pfizer, its Affiliates or Sublicensees will be reduced by [***] of the amounts payable to Third Parties pursuant to any Additional Third Party Licenses, such reduction to continue until all such amounts
have been expended, provided that in no event will the total royalty payable to Cellectis for any Pfizer Licensed Product be less than [***] and in no event will the royalty payable to Cellectis for any Pfizer Licensed Product be reduced below [***]
(in each case, other than in the case of Cellectis’ breach of any representation, warranty or covenant hereunder). For purposes of this Section 5.4.2(b), (i) “Necessary” means that, without a license to use the Third
Party’s Patent Right, the Development, Manufacture, Commercialization or use of any Pfizer Licensed Product in the form such Pfizer Licensed Product exists at the time that the Additional Third Party License is executed would, in Pfizer’s
opinion, infringe such Third Party’s Patent Right and (ii) “Useful” means that Pfizer has determined in its discretion that use of such Third Party’s Patent Right would enhance the commercial potential of such Pfizer
Licensed Product. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.4.2(b) will not apply with respect to royalties payable by Pfizer to any Third Party under any agreement in existence as of the Effective Date.
Neither Party will intentionally negotiate with a Third Party an exclusive license that excludes sublicense rights to the other Party, in the event such Third Party rights are necessary, as determined by the negotiating Party, to Develop and
Commercialize Licensed Pfizer Products and Cellectis Products in connection with the Research Program in the Field. 
 (c) Cellectis Third
Party Agreements. Cellectis will be solely responsible for all obligations, including royalty obligations, that are due and owing or may become due and owing with respect to any Cellectis Third Party Agreements that are in effect as of the
Effective Date or that Cellectis or any of its Affiliates enters into during the Term of this Agreement. 
 5.4.3. Fully Paid-Up, Royalty
Free License. After expiration of the Royalty Term for any Pfizer Licensed Product in a country in the Territory, no further royalties will be payable in respect of sales of such Pfizer Licensed Product in such country and thereafter the License
with respect to such Pfizer Licensed Product in such country will be a fully paid-up, perpetual, exclusive, irrevocable, royalty-free license. 

5.5 Diagnostic and Prognostic Products. In no event will any milestone, net sales or royalty payments become due or owing pursuant to
Sections 5.3 or 5.4 above with respect to any Pfizer Licensed Product Developed or Commercialized for diagnostic or prognostic purposes. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 32 

 5.6 Reports and Payments. 

5.6.1. Cumulative Royalties. The obligation to pay royalties under Section 5.4 will be imposed only once with respect to a single
unit of a Pfizer Licensed Product regardless of how many Valid Claims in Patent Rights included within the Licensed Cellectis Intellectual Property would, but for this Agreement, be infringed by the use or sale of such Pfizer Licensed Product in the
country in which such Pfizer Licensed Product is used or sold. 
 5.6.2. Royalty Statements and Payments. Within [***] after the end
of each Pfizer Quarter, Pfizer will deliver to Cellectis a report setting forth for such Pfizer Quarter the following information, on a Pfizer Licensed Product-by-Pfizer Licensed Product basis: (a) the Net Sales of each Pfizer Licensed Product,
(b) the basis for any adjustments to the royalty payable for the sale of each Pfizer Licensed Product and (c) the royalty due hereunder for the sale of each Pfizer Licensed Product. No such reports will be due for any Pfizer Licensed
Product before the First Commercial Sale of such Pfizer Licensed Product in the Territory. The total royalty due for the sale of Pfizer Licensed Products during such Pfizer Quarter will be remitted at the time such report is delivered to Cellectis.

 5.6.3. Taxes and Withholding. It is understood and agreed between the Parties that any payments made under this Agreement are
exclusive of any value added or similar tax (“VAT”), which will be added thereon as applicable. Where VAT is properly added to a payment made under this Agreement, the party making the payment will pay the amount of VAT only on
receipt of a valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT is chargeable. In addition, in the event any of the payments made by Pfizer pursuant to this Agreement become subject to withholding
taxes under the Laws of any jurisdiction, Pfizer will deduct and withhold the amount of such taxes for the account of Cellectis, to the extent required by Law, such amounts payable to Cellectis will be reduced by the amount of taxes deducted and
withheld, and Pfizer will pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Cellectis an official tax certificate or other evidence of such tax obligations together with proof of payment
from the relevant Governmental Authority of all amounts deducted and withheld sufficient to enable Cellectis to claim such payment of taxes. Any such withholding taxes required under applicable Law to be paid or withheld will be an expense of, and
borne solely by, Cellectis. Pfizer will provide Cellectis with reasonable assistance to enable Cellectis to recover such taxes as permitted by Law. 

5.6.4. Currency. All amounts payable and calculations hereunder will be in United States dollars. As applicable, Net Sales and any
royalty deductions will be converted into United States dollars in accordance with Pfizer’s customary and usual conversion procedures, consistently applied. 

5.6.5. Method of Payment. Except as permitted pursuant to Section 5.6.4, each payment hereunder will be made by electronic transfer
in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 33 

 
mechanism, or any other means of electronic funds transfer, at Pfizer’s election, to such bank account as the Cellectis will designate in writing to Pfizer at least forty-five (45) days
before the payment is due. 
 5.6.6. Additional Provisions Relating to Payments. Cellectis acknowledges and agrees that nothing in
this Agreement (including any schedules and exhibits hereto) will be construed as representing an estimate or projection of either (a) the number of Pfizer Licensed Products that will or may be successfully Developed or Commercialized or
(b) anticipated sales or the actual value of any Pfizer Licensed Product. PFIZER MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED,
THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT(S), PROVIDED THAT THE FOREGOING WILL NOT LIMIT PFIZER’S OBLIGATIONS UNDER THIS AGREEMENT. 

5.7 Maintenance of Records; Audits. 

5.7.1. Record Keeping. Pfizer will keep, and cause its Affiliates and Sublicensees to keep, accurate books of account and records in
connection with the sale of Pfizer Licensed Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Pfizer will maintain, and cause its Affiliates and Sublicensees
to maintain, such records for a period of at least [***] after the end of the Calendar Year in which they were generated. 
 5.7.2.
Audits. Upon thirty (30) days prior written notice from Cellectis, Pfizer will permit an independent certified public accounting firm of internationally recognized standing selected by Cellectis and reasonably acceptable to Pfizer to
examine, at Cellectis’ sole expense, the relevant books and records of Pfizer during the period covered by such examination, as may be reasonably necessary to verify the accuracy of the reports submitted by Pfizer in accordance with
Section 5.6 and the payment of royalties hereunder. An examination by Cellectis under this Section 5.7.2 will occur not more than [***] and will be limited to the pertinent books and records for any Calendar Year ending not more than [***]
before the date of the request. The accounting firm will be provided access to such books and records at Pfizer’s or its Affiliates’ facilities where such books and records are kept and such examination will be conducted during
Pfizer’s normal business hours. Pfizer may require the accounting firm to sign a reasonable and customary non-disclosure agreement before providing the accounting firm access to Pfizer’s facilities or records. Upon completion of the audit,
the accounting firm will provide both Pfizer and Cellectis a written report disclosing whether the reports submitted by Pfizer are correct or incorrect, whether the royalties paid are correct or incorrect and, in each case, the specific details
concerning any discrepancies. No other information will be provided to Cellectis. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 34 

 5.7.3. Underpayments/Overpayments. If such accounting firm concludes that additional
royalties were due to Cellectis, Pfizer will pay to Cellectis the additional royalties within thirty (30) days of the date Pfizer receives such accountant’s written report so concluding. If such underpayment exceeds [***] of the royalties
that were to be paid to Cellectis, Pfizer also will reimburse Cellectis for all reasonable charges of such accountants for conducting the audit. If such accounting firm concludes that Pfizer overpaid royalties to Cellectis, Cellectis will repay such
amount to Pfizer in full within thirty (30) days of the receipt of such accountant’s report, or, at Pfizer’s option, Pfizer will be entitled to offset all such overpayments against any outstanding or future amounts payable to
Cellectis hereunder until Pfizer has received full credit for such overpayments. 
 5.7.4. Confidentiality. All financial information
of Pfizer which is subject to review under this Section 5.7 will be deemed to be Pfizer’s Confidential Information subject to the provisions of Article 7 hereof, and Cellectis will not disclose such Confidential Information to any Third
Party or use such Confidential Information for any purpose other than verifying payments to be made by Pfizer to Cellectis hereunder. 

5.7.5. Costs. Cellectis shall pay the full cost of the audit unless the discrepancy is to the Cellectis’ detriment and is greater
than [***] of all amounts due in such calendar year, in which cases Pfizer shall pay the reasonable cost charged by such accountant for such inspection. 

5.8 No Guarantee of Success. Pfizer and Cellectis acknowledge and agree that payments to Cellectis pursuant to Section 5.2,
Section 5.3 and Section 5.4: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if a Pfizer Licensed Product is successfully Developed or Commercialized, as applicable; (b) are
solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of a Pfizer Licensed Product between Pfizer (who will receive all Pfizer Licensed Product sales revenues) and Cellectis; (c) are not
intended to be used and will not be used as a measure of damages if this Agreement is terminated for any reason, including pursuant to Pfizer’s right to terminate at for convenience, before any such success is achieved and such amounts become
due; and (d) will only be triggered, and will only be relevant as provided, in accordance with the terms and conditions of such provisions. Pfizer and Cellectis further acknowledge and agree that nothing in this Agreement will be construed as
representing any estimate or projection of (i) the successful Development or Commercialization of any Pfizer Licensed Product under this Agreement, (ii) the number of Pfizer Licensed Products that will or may be successfully Developed or
Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Pfizer Licensed Products that may be successfully Developed or Commercialized under this Agreement or (iv) the damages, if any, that may be payable if
this Agreement is terminated for any reason. Pfizer makes no representation, warranty or covenant, either express or implied, that (A) it will successfully Develop, Manufacture, Commercialize or continue to Develop, Manufacture or Commercialize
any Pfizer Licensed Product in any country, (B) if Commercialized, that any Pfizer Licensed Product will achieve any particular sales level, whether in any individual country or 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 35 

 
cumulatively throughout the Territory or (C) Pfizer will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Pfizer Licensed Product in
any country, or in the Territory in general, other than is expressly required under Section 3.2. 
  

	6.	INTELLECTUAL PROPERTY. 

 6.1 Inventions. 

6.1.1. Ownership. All determinations of inventorship under this Agreement will be made in accordance with the laws of the United States.

 (a) Pfizer Improvements. Pfizer will own [***]. 

(b) Cellectis Improvements. Cellectis will own [***]. 

(c) Developed IP. Except as provided in Section 6.1.1(d), [***]. 

(d) Assignment of Pfizer CAR-T Developed IP. [***]. 

(e) Assignment of Cellectis CAR-T Developed IP. [***]. 

(f) Implementation. Each Party will assign, and does hereby assign, to the other Party such Patent Rights, Know-How or other
intellectual property rights as necessary to achieve ownership as provided in this Section 6.1.1. Each assigning Party will execute and deliver all documents and instruments reasonably requested by the other Party to evidence or record such
assignment or to file for, perfect or enforce the assigned rights. Each assigning Party will make its relevant employees, agents and independent contractors (and their assignments and signatures on such documents and instruments) reasonably
available to the other Party for assistance in accordance with this Section 6.1.1 at no charge. 
 6.1.2. Disclosure. Each Party
will promptly (and in no event less than [***] before filing any initial Patent Right disclosing such intellectual property) disclose to the other Party any Developed IP, Cellectis Improvement and Pfizer Improvement, including all invention
disclosures or other similar documents submitted to such Party by its, or its Affiliates’, employees, agents or independent contractors describing such Developed IP, Cellectis Improvement or Pfizer Improvement, and the proposed inventorship of
any new Patent Rights intended to be filed. The other Party will promptly raise any issue regarding inventorship. Any inventorship issue raised more than [***] after notice of the filing of an initial Patent Rights and the content thereof, or the
subsequent filing of new patent claims in a Patent Right directed to substantially different inventions, will not affect ownership of the Patent Right as determined in accordance with the initial inventorship determination 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 36 

 6.2 Patent Rights. 

6.2.1. Filing, Prosecution and Maintenance of Patent Rights. 

Cooperation. Without limiting any other rights and obligations of the Parties under this Agreement, the Parties will cooperate with
respect to the timing, scope and filing of patent applications and patent claims relating to any Cellectis Improvements, Pfizer Improvements and Developed IP to preserve and enhance the patent protection for Agreement CAR-Ts, including the
manufacture and use thereof. If the ownership rights in any Patent Rights included in Cellectis Improvements or Developed IP are substantially impeding or would substantially impede Pfizer’s prosecution of CAR-T Developed IP assigned to Pfizer
pursuant to Section 6.1.1(d), or Cellectis’s prosecution of Cellectis CAR-T Developed IP assigned to Cellectis pursuant 6.1.1(e), the Parties will negotiate in good faith an amendment of the ownership of such Patent Rights included in
Cellectis Improvements or Developed IP while preserving for each Party substantially the same rights, including all Milestone Payments and royalty payments, as are afforded in this Agreement. 

(a) Pfizer Patent Rights. Pfizer, at its own expense, will have the sole right, but not the obligation, to prepare, file, prosecute and
maintain, throughout the world, any Patent Rights that it solely owns, including Pfizer Patent Rights and Patent Rights comprised in the Pfizer Improvements and CAR-T Developed IP (to the extent assigned to Pfizer pursuant to Section 6.1.1(d)).
Pfizer will keep Cellectis informed regarding the status of any Patent Right comprised in any such CAR-T Developed IP at Cellectis’ reasonable request. To the extent Pfizer wishes not to file, prosecute or maintain any such Patent Right, Pfizer
will provide Cellectis with thirty (30) days prior written notice to such effect, in which event Cellectis may elect to continue filing, prosecution or maintenance of such Patent Right, and Pfizer, upon Cellectis’ written request received
within such thirty (30) day period, will execute such documents and perform such acts, at Cellectis’ expense, as may be reasonably necessary to permit Cellectis to file, prosecute and maintain such Patent Right. Any such Patent Right that
is prosecuted or maintained by Cellectis pursuant to this Section 6.2.1(c)(i) will continue to be owned by Pfizer, and (ii) subject to the Parties’ other rights and obligations under this Agreement, may be licensed by Pfizer to one or
more Third Parties. 
 (b) Cellectis Patent Rights. Cellectis, at its own expense, will have the sole right, but not the obligation,
to prepare, file, prosecute and maintain, throughout the world, any Patent Rights included in Licensed Intellectual Property that it solely owns or has in-licensed from Third Parties, including Cellectis Patent Rights and Patent Rights comprised in
the Cellectis Improvements. Cellectis will not disclose any Pfizer Confidential Information in any Patent Rights that it files, or in connection with the prosecution of any such Patent Rights, without Pfizer’s prior written consent. Cellectis
will notify Pfizer promptly upon filing or otherwise 

  
 37 

 
obtaining rights in any Patent Right after the Effective Date that covers or may cover the Development, Manufacture, Commercialization or use of any Pfizer Licensed Product. In the absence of
such prompt notification, any such Patent Rights will be excluded from the Valid Claim definition. Cellectis will keep Pfizer informed regarding each Patent Right included in the Licensed Intellectual Property that Cellectis or any Third Party
licensor is prosecuting and will consider in good faith any recommendations made by Pfizer in regard to the filing, prosecution or maintenance of any such Patent Right. To the extent Cellectis wishes not to file, prosecute or maintain any such
Patent Right (other than any such Patent Right owned or co-owned by a Third Party licensor), Cellectis will provide Pfizer with thirty (30) days prior written notice to such effect, in which event Pfizer may elect to continue filing,
prosecution or maintenance of such Patent Right, and Cellectis, upon Pfizer’s written request received within such thirty (30) day period, will execute such documents and perform such acts, at Pfizer’s expense, as may be reasonably
necessary to permit Pfizer to file, prosecute and maintain, at its own discretion, such Patent Right. Any such Patent Rights that are prosecuted or maintained by Pfizer pursuant to this Section 6.2.1(c) will continue to be owned by Cellectis,
and will be excluded from the Valid Claim definition; and, in addition to the exclusive licenses granted to Pfizer under Section 4, Cellectis will and does hereby grant to Pfizer (subject to any existing Third Party rights) a non-exclusive,
sublicensable, perpetual, irrevocable, royalty-free, fully paid-up, worldwide license to practice and exploit such Patent Rights for any and all purposes. Cellectis will not decline to pay for or participate in the filing, prosecution or maintenance
of any Patent Right under any Cellectis Third Party Agreement that is included in the Licensed Intellectual Property without Pfizer’s prior written consent. 

(c) Joint Patent Rights. In the event the Parties conceive or generate any Joint Developed IP, other than any Joint Developed IP that
constitutes CAR-T Developed IP and is assigned to Pfizer pursuant to Section 6.1.1(c), or Cellectis CAR-T Developed IP and is assigned to Cellectis pursuant to Section 6.1.1(d), the Parties will promptly meet to discuss and determine,
based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Patent Right covering or claiming any such Joint Developed IP (a “Joint Patent Right”) Pfizer will have the first right to file on and
control prosecution of any Patent Right covering or claiming any Joint Developed IP used in the development, manufacture, composition or use of any CAR-T Targeting such Pfizer Target in accordance with Section 6.2.1(b). For avoidance of doubt,
“prosecution” as used in this Section 6.2.1 includes oppositions, nullity or revocation actions, post-grant reviews and other patent office proceedings involving the referenced Patent Rights. 

(d) Liability. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right included in the Licensed Intellectual
Property or Developed IP (including CAR-T Developed IP) or otherwise exercising its rights under this Section 6.2.1, such Party, and its Affiliates, employees, agents or representatives, will not be liable to the other Party in respect of any
act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. 

  
 38 

 (e) Extensions. The decision to file for a patent term extension and particulars thereof
(including which patent(s) to extend) will be made with the goal of obtaining the optimal patent term and scope of protection for Pfizer Licensed Products. Pfizer will have the sole right but not the obligation to apply for and obtain any patent
term extension or related extension of rights, including supplementary protection certificates and similar rights, for any patent relating to a Pfizer Licensed Product (including the choice of which patent(s) to extend), provided that it will
consult with Cellectis before applying for or obtaining any such extensions or rights for any patents included in the Licensed Cellectis Intellectual Property. The Parties will provide reasonable assistance to each other in connection with obtaining
any such extensions for any patent included in the Licensed Cellectis Intellectual Property. To the extent reasonably and legally required in order to obtain any such extension in a particular country, each Party will make available to the other a
copy of the necessary documentation to enable such other Party to use the same for the purpose of obtaining the extension in such country. 

(f) Joint Research Agreement. This Agreement will be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3)
entered into for the purpose of researching, identifying and Developing Agreement CAR-Ts and Pfizer Licensed Products. 
 (g)
Recording. If a Party deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then
the Parties will agree on a proposed evidence of such recording and the Parties will comply with the terms of Section 7.2.3 in respect of such filing. Each Party will execute and deliver to the other Party any documents necessary or desirable
to complete such registration or recordation in accordance with the terms of Section 7.2.3. 
 6.2.2. Enforcement of Patent Rights.

 (a) Notice. If either Pfizer or Cellectis becomes aware of any infringement that may affect competition of either Party within the
Field, anywhere in the world, of any issued Patent Right within the Licensed Intellectual Property or Developed IP, such Party will promptly notify the other Party in writing to that effect. 

(b) Infringement of Certain Patent Rights. 

(i) Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, if any infringement of a Patent Right included in
the Licensed Intellectual Property by a Third Party arises from the Development, Manufacture or 

  
 39 

 
Commercialization of a product that does, or may, compete with a Pfizer Licensed Product Targeting such Pfizer Target, Pfizer will have the first right, but not the obligation, to take action to
obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Patent Right within six (6) months from the date of notice and to join Cellectis as a party plaintiff in each of the following circumstances:
(x) where the Pfizer Licensed Product with which the Third Party’s infringement will compete has been [***] or is the subject of [***] and no Cellectis Product or CAR-T product of another Cellectis licensee has begun or completed [***], or
(y) where such Patent Right is directed exclusively to a Pfizer Target or a Pfizer Licensed Product Targeting such Pfizer Target; in all other circumstances, Pfizer may, with prior written consent of Cellectis (not to be unreasonably withheld),
have the right to take action against such Third Party infringer. 
 (ii) Pfizer will bear all the expenses of any suit brought by it
claiming infringement of any such Patent Right. Cellectis will cooperate with Pfizer in any such suit and will have the right to consult with Pfizer and to participate in and be represented by independent counsel in such litigation at its own
expense. Pfizer will incur no liability to Cellectis as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Patent Right invalid or unenforceable, and Pfizer will not, without
Cellectis’ prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Cellectis or admits the invalidity or unenforceability of any such Patent Right. 

(iii) If Pfizer has not obtained a discontinuance of infringement by, or filed suit against, any such Third Party infringer within the six
(6) month period set forth in subsection (i) above, then Cellectis will have the right, but not the obligation, to bring suit against such Third Party infringer, at Cellectis’ sole expense; provided, however, that Cellectis will only
have the foregoing right if Pfizer would not be required (by Applicable Law or otherwise) to join such suit as a party and such suit would not involve a Patent Right covering a then-existing Agreement CAR-T or Pfizer Licensed Product. Pfizer will
have no obligation to cooperate with Cellectis in any such litigation, provided that Pfizer may, at its sole discretion, elect to consult with Cellectis and to participate in and be represented by independent counsel in such litigation at its own
expense. Cellectis will incur no liability to Pfizer as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Cellectis Patent Right or Joint Patent Right invalid or unenforceable;
and Cellectis will not, 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 40 

 
without Pfizer’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Pfizer or admits the invalidity
or unenforceability of any such Patent Right. 
 The enforcing Party will keep the other Party reasonably informed of all material
developments in connection with any such suit. Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, any recoveries obtained by either Party as a result of any proceeding against such a Third Party infringer will be
allocated as follows: 
 (A) Such recovery will first be used to reimburse each Party for all out-of-pocket litigation costs in connection
with such litigation paid by that Party; and 
 (B) With respect to any remaining portion of such recovery, if Pfizer was the enforcing
Party, Cellectis will receive an amount equal to the royalty that would be payable, pursuant to Section 5.4, on an amount of Net Sales of the relevant Pfizer Licensed Product(s) in the country(ies) where such infringement occurred equal to such
remaining portion of such recovery, and Pfizer will receive any remaining portion of such recovery; or 
 (C) With respect to any remaining
portion of such recovery, if Cellectis was the enforcing Party, Cellectis will receive any remaining portion of such recovery, except to the extent such recovery was calculated based on lost sales of Pfizer, in which case the allocation of such
remaining portion will be made as provided in Section 6.2.2(b)(iv)(B). 
 (c) Other Infringement of Joint Patent Rights. With
respect to any notice of a Third Party infringer of any Joint Patent Right other than in the case of a Joint Patent Right subject to Section 6.2.2(b), the Parties will meet as soon as reasonably practicable to discuss such infringement and
determine an appropriate course of action and the Parties’ respective rights and responsibilities with respect to any enforcement thereof. 

6.2.3. Biosimilar Notices. 

(a) Upon Pfizer’s request any time after completion of the first Phase II Clinical Trial for any Pfizer Licensed Product, Cellectis will
use reasonable efforts to assist and cooperate with Pfizer in establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and preparing submissions responsive to any Biosimilar Notices
received by Pfizer; provided that Pfizer will make the final decisions with respect to such strategy and any such responses. 

  
 41 

 (b) Biosimilar Notices. Pfizer will comply with the applicable provisions of 42 U.S.C. §
262(1) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in the United States, or any similar statutory or regulatory requirement in any non-U.S.
country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received by Pfizer from any Third Party regarding any Pfizer Licensed Product that is being Commercialized in the applicable jurisdiction, and the exchange
of information between any Third Party and Pfizer pursuant to such requirements; provided that, prior to any submission of information by Pfizer to a Third Party, Cellectis will have the right to review the patent information included in such
proposed submission, solely with respect to Patent Rights Controlled by Cellectis, and to make suggestions as to any changes to such patent information that Cellectis reasonably believes to be necessary; provided further that Pfizer will determine
the final content of any such submission. In the case of a Pfizer Licensed Product approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United States, any similar law), to the extent permitted
by Applicable Law, Pfizer, as the sponsor of the application for the Pfizer Licensed Product, will be the “reference product sponsor” under the PHS Act. Pfizer will give written notice to Cellectis of receipt of a Biosimilar Notice
received by Pfizer with respect to a Pfizer Licensed Product, and Pfizer will consult with Cellectis with respect to the selection of the Patent Rights to be submitted pursuant to 42 U.S.C. § 262(1) (or any similar law in any country of the
Territory outside the United States); provided that Pfizer will have final say on such selection of Patent Rights. Cellectis agrees to be bound by the confidentiality provisions of 42 U.S.C. § 262(1)(1)(B)(iii). In order to establish standing
in connection with any action brought by Pfizer under this Section 6.2.3, Cellectis, upon Pfizer’s request, will reasonably cooperate with Pfizer in any such action, including timely commencing or joining in any action brought by Pfizer
under this Section 6.2.3 solely to the extent any Patent Rights Controlled by Cellectis are involved in any such action, and the Parties rights and responsibilities regarding any action will be determined in accordance with
Section 6.2.2(b). 
 6.3 Interference, Opposition, Revocation and Declaratory Judgment Actions. If the Parties mutually determine
that, based upon the review of a Third Party’s patent or patent application or other intellectual property rights, it may be desirable in connection with any Agreement CAR-T or Pfizer Licensed Product to provoke or institute an interference,
opposition, revocation, post-grant review or other patent office proceedings or declaratory judgment action with respect thereto, then the Parties will consult with one another and will [***] in connection with such an action. Unless otherwise
mutually determined by the Parties, if (i) such impasse exists during the Research Term then Cellectis will control such action and will select counsel for such action and (ii) such impasse exists following the Research Term then Pfizer
will control such action and will select counsel for such action. The rights and obligations of the Parties under Section 6.4 are expressly subject to this Section 6.3. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 42 

 6.4 Infringement of Third Party Patent Rights. If the Development, Manufacture or
Commercialization of any Pfizer Licensed Product is alleged by a Third Party to infringe a Third Party’s patent or other intellectual property rights, the Party becoming aware of such allegation will promptly notify the other Party. The Party
that is alleged to infringe the Third Party’s patent or intellectual property rights will have the right to take such action as it deems appropriate in response to such allegation, and will be solely responsible for all damages, costs and
expenses in connection therewith, subject to Section 10.1. 
  

	7.	CONFIDENTIALITY 

 7.1 Confidentiality. Except to the extent expressly authorized
by this Agreement, the Parties agree that, during the Term and [***], each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will:
(a) keep the Disclosing Party’s Confidential Information confidential; (b) not disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing
Party’s Confidential Information for any purpose, provided, however, that a Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information (i) was already known by the
Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by the Disclosing Party; (ii) was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the Receiving Party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its
obligations under this Agreement; (iv) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving
Party; or (v) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information of the Disclosing Party. 

7.2 Authorized Disclosure. 

7.2.1. Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1, the Receiving Party may
disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s, its Affiliates’ and its Sublicensees’ officers, directors, employees, consultants, contractors, licensors and agents (collectively,
“Representatives”) who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement
and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Article 7. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 43 

 7.2.2. Disclosure to Third Parties. 

(a) Notwithstanding the foregoing provisions of Section 7.1, the Parties may disclose Confidential Information belonging to the other
Party: 
 (i) to Governmental Authorities (A) to the extent reasonably necessary to obtain or maintain INDs or Regulatory Approvals for
any Agreement CAR-T or Pfizer Licensed Product Targeting such Pfizer Target, or any Cellectis Target or Cellectis Product Targeting such Cellectis Target, within the Territory, and (B) in order to respond to inquiries, requests, investigations,
orders or subpoenas relating to this Agreement; 
 (ii) to outside consultants, contractors, advisory boards, managed care organizations,
and non-clinical and clinical investigators, in each case to the extent reasonably necessary for the performance of this Agreement and under reasonable obligations of confidentiality; 

(iii) to the extent reasonably necessary, in connection with filing or prosecuting Patent Rights or Trademark rights as permitted by this
Agreement; 
 (iv) to the extent reasonably necessary, in connection with prosecuting or defending litigation as permitted by this
Agreement; 
 (v) subject to Section 7.3.2, in connection with or included in scientific presentations and publications relating to
Agreement CAR-Ts or Pfizer Licensed Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to clincialtrials.gov or PhRMA websites; and 

(vi) to the extent necessary in order to enforce its rights under this Agreement and as permitted in the Agreement. 

(b) In the event a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to
Section 7.2.2(a)(i)(B), the Disclosing Party will to the extent possible give reasonable advance written notice of such disclosure to the other Party and take all reasonable measures to ensure confidential treatment of such information. 

7.2.3. SEC Filings and Other Disclosures. Notwithstanding any provision of this Agreement to the contrary, either Party may disclose the
terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or
any equivalent governmental agency in any country in the Territory. Notwithstanding 

  
 44 

 
the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties will consult with one another on the terms of this Agreement to be
redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.2.3, such Party will, at its own expense, seek such confidential treatment of confidential
portions of this Agreement and such other terms, as may be reasonably requested by the other Party. 
 7.3 Public Announcements;
Publications. 
 7.3.1. Announcements. Except as may be expressly permitted under Section 7.2.3, neither Party will make any
public announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement will prevent (a) either Party from making any public disclosure relating to this Agreement if
the contents of such public disclosure have previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; (b) Pfizer from making any scientific publication or public announcement with respect
to any Pfizer Licensed Product Targeting such Pfizer Target under this Agreement; provided, however, that, except as permitted under Section 7.2, Pfizer will not disclose any of Cellectis’ Confidential Information in any such publication
or announcement without obtaining Cellectis’ prior written consent to do so and (c) Cellectis from making any scientific publication or public announcement with respect to any Cellectis Licensed Product Targeting such Cellectis Program
Target under this Agreement; provided, however, that, except as permitted under Section 7.2, Cellectis will not disclose any of Pfizer’s Confidential Information in any such publication or announcement without obtaining Pfizer’s prior
written consent to do so. The Parties agree that they will release the announcement attached hereto as Schedule 7.3.1 regarding the signing of this Agreement following the Effective Date. 

Publications. During the Term, each Party will submit to the other Party (the “Non-Disclosing Party”) for review and
approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, each Party will submit to the other Party for its review and approval any
proposed publication or public presentation relating to the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Intellectual Property, Cellectis CAR-T Developed IP
and Pfizer CAR-T Developed IP and the rights granted to each Party hereunder and determining whether any portion of the proposed publication or presentation containing the Non-Disclosing Party’s Confidential Information should be modified or
deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted to the Non-Disclosing Party no later than thirty (30) days before submission for publication or presentation (the
“Review Period”). The Non-Disclosing Party will provide its comments with respect to such publications and presentations within twenty (20) days after its receipt of such written copy, and the other Party will delete any
Confidential Information of 

  
 45 

 
the Non-Disclosing Party upon request. The Review Period may be extended for an additional sixty (60) days in the event the Non-Disclosing Party can, within fifteen (15) days of receipt
of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. Cellectis and Pfizer will each comply with standard academic practice regarding authorship of scientific
publications and recognition of contribution of other parties in any publication governed by this Section 7.3.2. 
 7.4 Obligations
in Connection with Change of Control. If Cellectis is subject to a Change of Control, Cellectis will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Pfizer is released to (a) any
Affiliate of Cellectis that becomes an Affiliate as a result of the Change of Control or (b) any Representatives of Cellectis (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the Change
of Control, unless such Representatives have signed individual confidentiality agreements which include equivalent obligations to those set out in this Article 7. If any Change of Control of Cellectis occurs, Cellectis will promptly notify Pfizer,
share with Pfizer the policies and procedures it plans to implement in order to protect the confidentiality of Pfizer’s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are
reasonably requested by Pfizer. 
  

	8.	REPRESENTATIONS AND WARRANTIES. 

 8.1 Mutual Representations and Warranties. Each
of Cellectis and Pfizer hereby represents and warrants to the other Party that: 
 8.1.1. it is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization; 
 8.1.2. the execution, delivery and performance of this Agreement by such
Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities
or voting interests; 
 8.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;

 8.1.4. this Agreement has been duly executed and is a legal, valid and Binding Obligation on each Party, enforceable against such Party in
accordance with its terms; and 
 8.1.5. the execution, delivery and performance by such Party of this Agreement and its compliance with the
terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. 

  
 46 

 8.2 Representations and Warranties of Cellectis. Cellectis hereby represents and warrants
to Pfizer that: 
 8.2.1. except as expressly disclosed in Schedule 8.2.1, Cellectis is the sole and exclusive owner of the Cellectis
Technology existing as of the Effective Date, all of which is free and clear of any claims, liens, charges or encumbrances; 
 8.2.2. it has
and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer or Pfizer’s Affiliates under this Agreement; 

8.2.3. as of the Effective Date (a) Schedule 8.2.3 sets forth a true and complete list of all Cellectis Patent Rights, (b) each such
Patent Right is in full force and effect and (c) Cellectis or its Affiliates or their licensors have timely paid all filing and renewal fees payable with respect to such Patent Rights; 

8.2.4. to its knowledge: (i) the Cellectis Patent Rights existing as of the Effective Date, are, or, upon issuance, will be, valid and
enforceable patents and (ii) as of the Effective Date, except as set forth in Schedule 8.2.4, no Third Party (a) is infringing any Cellectis Patent Right for use in CARs in the Field or (b) has challenged or threatened to challenge
the extent, validity or enforceability of any Cellectis Patent Right (including, by way of example, through the institution or threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and
Trademark Office or any analogous foreign Governmental Authority); 
 8.2.5. it and its counsel, and, to its knowledge, [***], have complied
with all Applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Cellectis Patent Rights existing as of the Effective Date; 

8.2.6. except as expressly disclosed in Schedule 8.2.6, Cellectis has independently developed all Cellectis Know-How existing as of the
Effective Date or otherwise has a valid right to use, and to permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, such Cellectis Know-How for all permitted purposes under this Agreement; 

8.2.7. it [***] has obtained from all inventors of Cellectis Technology existing as of the Effective Date, valid and enforceable agreements
assigning to Cellectis [***] each such inventor’s entire right, title and interest in and to all such Cellectis Technology; 
 8.2.8.
except as expressly disclosed in Schedule 8.2.8, no Cellectis Technology existing as of the Effective Date is subject to any funding agreement with any Governmental Authority; 

8.2.9. except as expressly disclosed in Schedule 8.2.9, neither Cellectis nor any of its Affiliates are subject to any agreement or obligation
that limits any 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 47 

 
ownership or license right granted to Pfizer or its Affiliates under this Agreement, including any right granted to Pfizer or its Affiliates to access, practice, grant any licenses or sublicenses
under, or provide Pfizer’s Sublicensees with access to any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or obligation, be included
in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; 
 8.2.10. (a) there are no Cellectis Third
Party Agreements existing as of the Effective Date, other than the Cellectis Third Party Agreements expressly disclosed in Schedule 8.2.10 (each, a “Disclosed Third Party Agreement”), true and complete redacted copies of which have
been provided to Pfizer, (b) except as provided in the Disclosed Third Party Agreements and except for the Servier Agreement, no Third Party has any right, title or interest in or to, or any license under, any Cellectis Technology for use of
CAR-Ts in the Field, (c) no rights granted by or to Cellectis or its Affiliates under any Disclosed Third Party Agreement conflict with any right or license granted to Pfizer or its Affiliates hereunder and (d) Cellectis and its Affiliates
are in compliance in all respects with all Disclosed Third Party Agreements, including all due diligence obligations of Cellectis under the Disclosed Third Party Agreements; 

8.2.11. there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil,
criminal, regulatory or otherwise, pending or, to the knowledge of Cellectis, threatened against Cellectis or any of its Affiliates or (b) judgment or settlement against or owed by Cellectis or any of its Affiliates, in each case in connection
with the Cellectis Technology or relating to the transactions contemplated by this Agreement. 
 8.3 Representations and Warranties of
Pfizer. Pfizer hereby represents and warrants to Cellectis that it has and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Cellectis or
Cellectis’s Affiliates under this Agreement. 
 8.4 Cellectis Covenants. In addition to the covenants made by the Parties
elsewhere in this Agreement, Cellectis hereby covenants to the other that: 
 8.4.1. Cellectis will use its reasonable efforts to obtain,
[***] of the Effective Date or as soon thereafter as practicable, an executed confirmatory letter agreement [***] substantially in the form as provided by Pfizer prior to the Effective Date or as otherwise acceptable to Pfizer. 

8.5 Mutual Covenants. In addition to the covenants made by the Parties elsewhere in this Agreement, each Party hereby covenants to the
other that, from the Effective Date until expiration or termination of this Agreement: 
 8.5.1. it will not (a) take any action that
diminishes the rights under the Licensed Cellectis Intellectual Property or Licensed Pfizer Intellectual Property or 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 48 

 
Developed IP granted or assigned under this Agreement or (b) fail to take any action that is reasonably necessary to avoid diminishing the rights under the Licensed Cellectis Intellectual
Property, Licensed Pfizer Intellectual Property or Developed IP granted or assigned to Pfizer or Pfizer’s Affiliates under this Agreement; 

8.5.2. it will (a) not enter into any Third Party Agreement that adversely affects (i) the rights granted to the other Party
hereunder or (ii) its ability to fully perform its obligations hereunder; (b) not amend, terminate or otherwise modify any Third Party Agreement (including for Cellectis, the Servier Agreement) or consent or waive rights with respect
thereto in any manner that (i) adversely affects the rights granted to the other Party hereunder or (ii) its ability to fully perform its obligations hereunder; (c) fulfill, and cause its Affiliates to fulfill, all of their respective
obligations under all Third Party Agreements (including for Cellectis Servier Agreements) so as not to be in breach of such agreements; (e) inform Pfizer of existence of all notices received by Cellectis or its Affiliates relating to any
alleged breach or default by Cellectis or its Affiliates under any Third Party Agreement (including Servier Agreement), and all other notices received by Cellectis or its Affiliates in connection with any Cellectis Third Party Agreement (including
any Disclosed Third Party Agreement) that pertain to the rights granted to Pfizer or Pfizer’s Affiliates hereunder, within [***] after receipt thereof; and (f) in the event that Cellectis does not resolve any such alleged breach or
default, notify Pfizer within [***] before the expiration of the cure period for such breach of default under such Cellectis Third Party Agreement such that Pfizer is able to cure or otherwise resolve such alleged breach or default, and if Pfizer
makes any payments to any Third Party in connection with the cure or other resolution of such alleged breach or default, then Pfizer may credit the amount of such payments against any royalties or other amounts payable to Cellectis pursuant to this
Agreement. 
 8.5.3. it will not enter into or otherwise allow itself or its Affiliates to be subject to any agreement or arrangement which
limits the ownership rights of the other Party or its Affiliates with respect to, or limits the ability of the other Party or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any
intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to the other Party or its
Affiliates pursuant to this Agreement; and 
 8.5.4. it will maintain valid and enforceable agreements with all Persons acting by or on
behalf of itself or its Affiliates under this Agreement which require such Persons to assign to it their entire right, title and interest in and to all Patent Rights, Know-How or other intellectual property rights that are conceived or generated in
the course of performing Research Plan Services. 
 8.6 Representation by Legal Counsel. Each Party hereto represents that it has been
represented by legal counsel in connection with this Agreement and acknowledges that it 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 49 

 
has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party
which drafted such terms and provisions. 
 8.7 Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF
ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 

 

	9.	GOVERNMENT APPROVALS; TERM AND TERMINATION. 

 9.1 Government Approvals. Each of
Cellectis and Pfizer will cooperate with the other Party and use Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents,
transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 

9.2 Term. The term of this Agreement (the “Term”) will commence on the Effective Date and will extend, unless this
Agreement is terminated earlier in accordance with this Article 9, on a Pfizer Licensed Product-by-Pfizer Licensed Product and country-by-country basis, until such time as the Royalty Term with respect to the sale of such Pfizer Licensed Product in
such country expires. 
 9.3 Termination by Pfizer for Failure of Cellectis to Obtain Shareholder Approval. In the event that
Cellectis is unable to obtain approval of its shareholders by August 15, 2014 for the issuance of 2,786,924 ordinary shares of Cellectis to Pfizer pursuant to the Subscription Agreement by and between Cellectis and Pfizer OTC BV dated as of the
Effective Date, then Pfizer will have the right, at its sole discretion, to terminate this Agreement in its entirety. 
 9.4 Termination
by Either Party for Cause. Either Party may terminate this Agreement, in its entirety or, at the terminating Party’s option, on a Pfizer Target-by-Pfizer Target basis or Cellectis Program Target-by Cellectis Program Target basis, as
applicable, at any time during the Term of this Agreement by giving written notice to the other Party if the other Party commits a material breach of its obligations under this Agreement and such breach remains uncured for ninety (90) days,
measured from the date written notice of such breach is given to the breaching Party. Notwithstanding the foregoing, a Party will have the right to terminate this Agreement pursuant to this Section 9.4 (a) in part with respect to an
individual Pfizer Target or Cellectis Program Target, as applicable, only if the other Party’s material breach giving rise to such termination right relates to such Pfizer Target or Cellectis Program Target, as applicable, or (b) in its
entirety only if such material breach fundamentally frustrates the objectives or transactions contemplated by this Agreement taken as a whole or affects substantially all of the Research Program. 

  
 50 

 9.5 Termination by Pfizer for Convenience. At any time after the one (1) year
anniversary of the Effective Date, Pfizer will have the right to terminate this Agreement for any or no reason, either in its entirety or on a Pfizer Target-by-Pfizer Target basis, by providing sixty (60) days advance written notice of such
termination to Cellectis. 
 9.6 Termination on Insolvency of Cellectis. This Agreement may be terminated upon written notice by
Pfizer at any time in the event of a Cellectis Insolvency Event. 
 9.7 Effects of Termination. 

9.7.1. Effect of Termination by Pfizer for Failure of Cellectis to Obtain Shareholder Approval. If Pfizer terminates this Agreement
pursuant to Section 9.3: 
 (a) all work under all Research Plans will cease; 

(b) all rights and licenses granted by Cellectis to Pfizer pursuant to Sections 4.1 and will terminate; 

(c) all rights and licenses granted by Pfizer to Cellectis pursuant to Sections 4.2 will terminate; and 

(d) Pfizer will be relieved of any and all payment obligations under Section 5, including the upfront payment that would become due and
payable pursuant to Section 5.1; and 
 (e) Any material or Confidential Information provided by a Party to the other Party in the
course of the performance of this Agreement will be returned or destroyed as directed in writing by the providing Party. 
 9.7.2. Effect
of Termination by Pfizer for Cause. If Pfizer terminates this Agreement with respect to any or all Pfizer Targets pursuant to Section 9.4 (each, a “Terminated Target”): 

(a) all work under the applicable Research Plan with respect to each Terminated Target will cease; 

(b) all licenses granted to Pfizer with respect to such Terminated Target and any Pfizer Licensed Product Targeting such Terminated Target
(each, a “Terminated Pfizer Licensed Product”), including under Section 4.1, will continue and become irrevocable and perpetual, and Pfizer will have no further obligations to Cellectis under this Agreement with respect to any
such Terminated Target or Terminated Pfizer Licensed Product (including no further obligation to pay Milestone Payments) other than (i) those obligations that expressly survive termination in accordance with Section 9.9 and (ii) an
obligation to pay royalties 

  
 51 

 
with respect to Net Sales of Terminated Pfizer Licensed Products in accordance with the terms and conditions of this Agreement, in an amount equal to [***] of the amount that would otherwise have
been payable under this Agreement; 
 (c) If Pfizer terminates this Agreement in its entirety pursuant to Section 9.4, or if Pfizer
terminates this Agreement in its entirety pursuant to Section 9.5: (i) all licenses granted by Pfizer to Cellectis under Sections 4.1.1 an 4.2.2 will terminate, (ii) Pfizer will have no further obligations to Cellectis under this
Agreement other than those obligations that expressly survive termination in accordance with Section 9.9, and (iii) any material or Confidential Information provided Pfizer to Cellectis in the course of the performance of this Agreement
will be returned or destroyed as directed in writing by Pfizer; 
 (d) Pfizer will have the right to offset, against any payment owing to
Cellectis under subparagraph (b) above, any damages found or agreed by the Parties to be owed by Cellectis to Pfizer; 
 (e) Cellectis
will remain entitled to receive payments that accrued before the effective date of such termination; 
 (f) nothing in this
Section 9.7.1 will limit any other remedy Pfizer may have for Cellectis’ breach of this Agreement; and 
 (g) the rights and
obligations of the Parties with respect to all Pfizer Targets other than any such Terminated Target will remain in full force and effect. 

9.7.3. Effect of Termination by Pfizer on Insolvency of Cellectis. If Pfizer terminates this Agreement pursuant to Section 9.6: 

(a) Cellectis will have no further obligation to perform any of its obligations under this Agreement (including Cellectis’ obligations
under the Research Program) other than those obligations that expressly survive termination of this Agreement in accordance with Sections 9.7.2(b) and 9.9; 

(b) all licenses granted to Pfizer, including under Section 4.1, will continue and become, subject only to the royalty obligation set
forth below in this Section 9.7.2(b), irrevocable and perpetual, and Pfizer will have no further obligations to Cellectis under this Agreement (including no further obligation to pay Milestone Payments) other than (i) those obligations
that expressly survive termination in accordance with Section 9.9 and (ii) an obligation to pay royalties with respect to Net Sales of Pfizer Licensed Products in accordance with the terms and conditions of this Agreement; 

(c) Cellectis will remain entitled to receive payments that accrued before the effective date of such termination; 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 52 

 (d) Pfizer will have the right to offset, against any payment owing to Cellectis under
subparagraph (b) above, any damages found or agreed by the Parties to be owed by Cellectis to Pfizer; and 
 (e) nothing in this
Section 9.7.2 will limit any other remedy Pfizer may have for Cellectis’ breach of this Agreement. 
 9.7.4. Effect of
Termination by Cellectis for Cause or by Pfizer for Convenience. 
 (a) If Cellectis terminates this Agreement with respect to any Pfizer
Target pursuant to Section 9.4, or if Pfizer terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.5, then (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2 and 4.1.3 with respect
to any such Pfizer Target, (ii) any Pfizer Licensed Product Targeting such Pfizer Target will terminate, and (iii) any material or Confidential Information provided by Cellectis to Pfizer in the course of the performance of this Agreement
will be returned or destroyed as directed in writing by Cellectis. 
 (b) If Cellectis terminates this Agreement in its entirety pursuant to
Section 9.4, or if Pfizer terminates this Agreement in its entirety pursuant to Section 9.5: (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2 and 4.1.3 will terminate, (ii) Cellectis will have no
further obligations to Pfizer under this Agreement other than those obligations that expressly survive termination in accordance with Section 9.9, (iii) all rights and licenses granted by Pfizer to Cellectis pursuant to Section 4.2
will continue, (iv) Pfizer’s right of first refusal set forth in Section 3.9 will continue to the extent that such Cellectis Product is Covered by Licensed Pfizer Intellectual Property and (v) any material or Confidential
Information provided by Cellectis to Pfizer in the course of the performance of this Agreement will be returned or destroyed as directed in writing by Cellectis. 

(c) In the event that Cellectis terminates this Agreement for cause pursuant to Section 9.4 or Pfizer terminates this Agreement without
cause pursuant to Section 9.5 with respect to a Licensed Pfizer Product Targeting a Pfizer Target, on Cellectis’ written notice to Pfizer, which notice may only be delivered within [***] following the effective date of such termination,
unless such termination is related to material concerns regarding the safety of the Compound(s) or Product(s), the Parties will negotiate in good faith for a period not to exceed [***] following the effective date of termination regarding: 

(i) the grant by Pfizer to Cellectis of a royalty-bearing, non-exclusive license under the Applicable Pfizer Technology permitting Cellectis
to continue to Develop, Commercialize and Manufacture any Product under Development or Commercialization by Pfizer under this Agreement at the time of termination, in the form in which such Product then exists (a “Continuation
Product”); and 
 (ii) the related transfer to Cellectis of development data and regulatory filings specifically relating to such
Continuation Product or the granting to Cellectis of rights of reference with respect to such data and filings. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 53 

 (d) Neither Party will be obligated to enter into any transaction described in
Section 9.7.4(c) and neither Party will have any liability to the other for failure to do so. 
 (e) For the avoidance of doubt, if
Cellectis terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.4, or if Pfizer terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.5, in each case including all Pfizer Targets in
the event that this Agreement is terminated in its entirety, any such Pfizer Target will no longer be considered to be a Pfizer Target for the purpose of this Agreement. 

9.7.5. Satisfaction of Obligations During Notice Period. During the period from providing a notice of termination through the
termination of the Agreement, the Parties will continue to perform their obligations under this Agreement. 
 9.7.6. Pending Dispute
Resolution. If a Party gives notice of termination under Section 9.4 and the other Party disputes whether such notice was proper, then the issue of whether this Agreement has been terminated will be resolved in accordance with
Section 11.10 and this Agreement will remain in effect pending the resolution of such dispute. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination will be effective
immediately. If as a result of such dispute resolution process it is determined that the notice of termination was improper, then no termination will have occurred and this Agreement will remain in effect. 

9.8 Disposition of Inventories of Products. Following termination of this Agreement with respect to one or more Pfizer Targets, Pfizer,
its Affiliates and its Sublicensees will have the right to continue to sell their existing inventories of Pfizer Licensed Product(s) Targeting such Pfizer Targets that have received Regulatory Approval prior to such termination for a period not to
exceed [***] after the effective date of such termination or expiration and Pfizer will pay any royalties payable in connection with such sales in accordance with Section 5.5. 

9.9 Survival of Certain Obligations. Expiration or termination of this Agreement will not relieve the Parties of any obligation that
accrued before such expiration or termination. The following provisions will survive expiration or termination of this Agreement: Sections 1 (Definitions); 5.6.2 to 5.6.6 (Reports and Payments); 5.7 (Maintenance and Audit Rights); 7
(Confidentiality); 8 (Representations and Warranties); 9.3 to 9.9 (Effect of Termination); 10 (Limitation on liabilities) and 11 (Miscellaneous). In addition, any Section that is referred to in the above listed Sections shall survive solely for the
interpretation or enforcement of the listed Sections. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 54 

 9.10 Right to Termination of Research Project(s) or Research Program by Pfizer upon Change of
Control of Cellectis. If a Change of Control of Cellectis is consummated during the Research Term, Pfizer will have the right to terminate any Research Project or the Research Program in its entirety, upon written notice to Cellectis within
[***] after consummation of such Change of Control of Cellectis. Such termination of any Research Project or the Research Program (a) will not constitute termination of this Agreement, (b) will not affect the Parties’ rights and
obligations under this Agreement other than those relating to such Research Project or the Research Program and (c) will not relieve either Party of any obligation that arose prior to such termination. Following any such termination of any
Research Project or the Research Program, as applicable, Pfizer will have no further funding obligation under Article 2 or Section 5.3 with respect to such Research Project or the Research Program, as applicable, other than that which may have
accrued prior to such termination. In addition, if, at any time following a Change of Control of Cellectis consummated during the Research Term, Cellectis or its successor fails to perform its obligations under the Research Program in any material
respect, then, effective upon written notice to Cellectis or its successor, Pfizer will have the right to terminate any Research Project or the Research Program in its entirety pursuant to this Section 9.10, and Cellectis will promptly transfer
to Pfizer, at no additional cost to Pfizer, such Cellectis Know-How and Cellectis Improvements, including related materials, as is necessary for Pfizer to complete all activities contemplated under such Research Project or the Research Program, as
applicable. For the avoidance of doubt, in the event that Pfizer terminates a Research Project or the Research Program in accordance with this Section 9.10, such termination will not be deemed to be a termination for cause under
Section 9.4 or a termination for convenience under Section 9.5, and the only effects of such termination are as set forth in this Section 9.10. Notwithstanding any provision of this Agreement to the contrary, nothing in this
Section 9.10 will limit, or preclude Pfizer from seeking, any other remedy Pfizer may have for Cellectis’ breach of this Agreement; provided that Pfizer may not seek remedy under both this Section 9.10 and Section 9.4 with
respect to the same performance failure by Cellectis or its successor. 
 9.11 Bankruptcy. All rights and licenses granted under or
pursuant to this Agreement by Cellectis are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the U.S.
Bankruptcy Code. The Parties agree that Pfizer, as licensee of intellectual property under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that in the event
of a rejection of this Agreement by Cellectis in any bankruptcy proceeding by or against Cellectis under the U.S. Bankruptcy Code, (i) Pfizer will be entitled to a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property, which, if not already in Pfizer’s possession, will be promptly delivered to it upon Pfizer’s written request therefor, and (ii) Cellectis will not interfere with
Pfizer’s rights to intellectual property and all embodiments of intellectual property, and will assist and not interfere with Pfizer in obtaining intellectual 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 55 

 
property and all embodiments of intellectual property from another entity. The term “embodiments” of intellectual property includes all tangible, intangible, electronic or other
embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Pfizer Licensed Products, filings with Regulatory Authorities and related rights, and Cellectis Technology. 

 

	10.	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE. 

 10.1 No Consequential
Damages. Except with respect to liability arising from a breach of Article 7, from any willful misconduct or intentionally wrongful act, or to the extent such Party may be required to provide indemnification under this Article 10, in no event
will either Party, its Affiliates, its Sublicensees or any of its, its Affiliates’ or its Sublicensees’ respective Representatives be liable under this Agreement for any special, indirect, incidental, consequential or punitive damages,
whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates or Representatives. Without limiting the generality of the foregoing,
“consequential damages” will be deemed to include, and neither Party will be liable to the other Party or any of such other Party’s Affiliates, Representatives or stockholders for, any damages based on or measured by loss of projected
or speculative future sales of the Pfizer Licensed Products, any Milestone Payment due upon any unachieved event under Section 5.3, any unearned royalties under Section 5.4 or any other unearned, speculative or otherwise contingent
payments provided for in this Agreement. 
 10.2 Indemnification by Pfizer. Pfizer will indemnify, defend and hold harmless Cellectis,
its Affiliates, their sublicensees, contractors, subcontractors and distributors and each of its and their respective employees, officers, directors and agents (each, a “Cellectis Indemnified Party”) from and against any and all
liability, loss, damage, expense (including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”) that the Cellectis Indemnified Party may be required to pay to one or more Third Parties resulting from
or arising out of: 
 [***] 

10.3 Indemnification by Cellectis. Cellectis will indemnify, defend and hold harmless Pfizer, its Affiliates, Sublicensees, contractors,
distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and against any and all Liabilities that the Pfizer Indemnified Party may be required to pay to
one or more Third Parties resulting from or arising out of: 
 [***] 

10.4 Procedure. 
 10.4.1.
Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any
governmental investigation) with respect to any matter for which a Party (the 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 56 

 
“Indemnified Party”) is entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party will promptly notify the Party obligated to
indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation
hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby. 
 10.4.2. Control. Subject to
Pfizer’s right to control any actions described in Section 6.2 (even where Cellectis is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within ten (10) Business Days
after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including
the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in
the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing
that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are
collectively referred to as the “Litigation Conditions”). Within ten (10) Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the
Indemnified Party will give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the
expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and
control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will
cooperate, and will cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such
conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of
the Indemnifying Party’s intent to defend any Third Party Claim within ten (10) Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of
its choice and at the Indemnifying Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified

  
 57 

 
Party, as the case may be, will have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not
control, at its own expense, the defense of any Third Party Claim that the other Party is defending as provided in this Agreement. 
 10.4.3.
Settlement. The Indemnifying Party will not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified
Party will have the sole and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief’, but will not
have the right to settle such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not make any
admission of liability in respect of any Third Party Claim without the prior written consent of the other Party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

10.5 Insurance. Each Party will obtain and maintain, during the Term, commercial general liability insurance, including products
liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification obligations under Section 10.2 or
Section 10.3, as applicable, in each case with limits of not less than [***] per occurrence and in the aggregate. 
  

	11.	MISCELLANEOUS. 

 11.1 Other Cellectis Targets. For sake of clarity, except as set
forth in Section 2.1.4 (CAR-T Exclusivity), 2.3 (Selection of Other Cellectis Targets), 2.4 (Targets Selection Process), and 2.8 (Right of Negotiation) Other Cellectis Targets are outside the scope of this Agreement. 

11.2 Assignment. Either Party may not assign this Agreement or any interest hereunder without the prior written consent of the other,
which consent will not be unreasonably withheld or delayed., except that this Agreement may be assigned as follows: (a) a Party may assign its rights and obligations under this Agreement by way of sale of itself or the sale of the portion of
its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest and (b) a Party may assign its rights and obligations under this Agreement to any of its Affiliates. This Agreement will be
binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of
this Agreement. Any assignment not in accordance with this Section 11.2 will be void. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 58 

 11.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

11.4 Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and the
nonperforming Party takes Commercially Reasonable Efforts to resume performance. For purposes of this Agreement, “force majeure” will include conditions beyond the control of the Parties, including an act of God, voluntary or involuntary
compliance with any Applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, or destruction of production facilities or materials
by fire, earthquake, storm or like catastrophe. 
 11.5 Notices. Any notice or notification required or permitted to be provided
pursuant to the terms and conditions of this Agreement (including any notice of force majeure, breach, termination, change of address, etc.) will be in writing and will be deemed given upon receipt if delivered personally or by facsimile
transmission (receipt verified), five days after deposited in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by overnight delivery using a nationally recognized
express courier service and specifying next Business Day delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as will be specified by like notice,
provided, however, that notices of a change of address will be effective only upon receipt thereof): 
 All correspondence to Pfizer will be
addressed as follows: 
 Pfizer Inc. 

Notices: R&D Business Development 

235 East 42nd Street 
 New York,
NY 10017 
 Attention: R&DBD Contract Notice 

[***] 
 with a copy to: 

Pfizer Inc. 
 Notices: Pfizer
Legal Division 
 235 East 42nd Street 

New York, NY 10017 
 Attn.: Chief
Counsel, R&D 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 59 

 All correspondence to Cellectis will be addressed as follows: 

Cellectis 
 8, rue de la Croix
Jarry 
 75013 Paris 
 Attn.:
Chief Executive Officer 
 Fax.: +33 1 81 69 16 03 

with a copy to: 
 Cellectis 

8, rue de la Croix Jarry 
 75013
Paris 
 Attn.: General Counsel 

Fax.: +33 1 81 69 16 03 
 11.6
Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

11.7 Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees
except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party will not be construed to
be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 
 11.8 Severability. If any clause or
portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion
as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause or portion thereof had never been contained in this Agreement, and there will be deemed
substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

11.9 Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or effect in
construing or interpreting any of the provisions of this Agreement. 
 11.10 Dispute Resolution. If any dispute or disagreement arises
between Pfizer and Cellectis in respect of this Agreement, they will follow the following procedures in an attempt to resolve the dispute or disagreement: 

11.10.1. The Party claiming that such a dispute exists will give notice in writing (a “Notice of Dispute”) to the other Party
of the nature of the dispute. 

  
 60 

 11.10.2. Within [***] of receipt of a Notice of Dispute, the Pfizer Alliance Manager and the
Cellectis Alliance Manager will meet in person or by teleconference and exchange written summaries reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting they will use their reasonable endeavors to resolve the
dispute. 
 11.10.3. If the Alliance Managers are unable to resolve the dispute during the meeting described in Section 11.10.2 or if
for any reason such meeting does not take place within the period specified in Section 11.10.2, then the dispute will be referred to the JRC which will meet no later [***] following the initial receipt of the Notice of Dispute and use
reasonable endeavors to resolve the dispute. 
 11.10.4. If the JRC is unable to resolve the dispute during the meeting described in
Section 11.10.3 or if for any reason such meeting does not take place within the period specified in Section 11.10.3, then the head of Rinat and the Chief Executive Office of Cellectis will meet at a mutually agreed-upon time and location
for the purpose of resolving such dispute. 
 11.10.5. If, within a further period of [***], or if in any event within [***] of initial
receipt of the Notice of Dispute, the dispute has not been resolved, or if, for any reason, the meeting described in Section 11.10.4 has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that,
subject to Section 11.11 below, either Party may initiate litigation to resolve the dispute. 
 11.11 Election of Resolution
Process. Notwithstanding any provision of Section 11.10 to the contrary, if (i) either Party raises any allegation or claim of Misuse (each, a “Misuse Allegation”) and (ii) the Parties are unable to resolve such Misuse
Allegation pursuant to the dispute escalation process described in Sections 11.10.1 through 11.10.5 (the “Escalation Process”), then, following completion of the Escalation Process, the Parties may mutually agree to have such Misuse
Allegation resolved pursuant to the terms of Section 11.12 (the “Arbitration Process”). If the Parties fail to agree on use of arbitration pursuant to Section 11.12 in a timely manner (not to exceed [***]), then the Parties will
be deemed to have elected to have such Misuse Allegation resolved through litigation. 
 11.12 Arbitration Process. If the Parties
mutually elect to resolve any Misuse Allegation pursuant to the Arbitration Process, then such Misuse Allegation will be referred to and finally resolved by binding arbitration in accordance with the Commercial Rules and Procedures (the
“Rules”) of the International Chamber of Commerce (“ICC”), by an arbitral tribunal composed of three arbitrators, all of whom will have relevant experience in pharmaceutical industry, appointed by agreement of the Parties in
accordance with the Rules. If, at the time of the arbitration, the Parties agree in writing to submit the dispute to a single arbitrator, said single arbitrator will (1) have relevant experience in pharmaceutical industry and (2) be
appointed by agreement of the Parties, or, failing such agreement, by ICC in accordance with the Rules. The foregoing 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 61 

 
arbitration proceedings may be commenced by either Party by written notice to the other Party. Unless otherwise agreed by the Parties hereto, all such arbitration proceedings will be held in
London, England, provided that proceedings may be conducted by telephone conference call with the consent of both Parties and the arbitrator(s). All arbitration proceedings will be conducted in the English language. 

11.12.1. Limited Discovery. Documentary discovery may be conducted at the discretion of the arbitrator(s), provided that any such
discovery will (a) be limited to documents directly relating to the Misuse Allegation, (b) be conducted pursuant to document discovery procedures as set forth under the laws of the State of New York, U.S.A., (c) be conducted subject
to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s), and (d) not require either Party, its Affiliates or their respective employees, officers, directors or agents to be subject
to deposition. Notwithstanding any provision of this Section 11.12.1 to the contrary, all discovery must be completed within sixty (60) days of the notice of commencement of arbitration proceedings. 

11.12.2. Awards and Fees. The arbitrator(s) may only consider awards of direct monetary damages and will not under any circumstances
have the authority to grant (a) injunctive relief, (b) equitable relief, (c) orders for specific performance, (d) punitive damages or (e) consequential damages as described in Section 10.1. The allocation of expenses of
the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such determination, each Party will pay its own expenses. 

11.12.3. Rulings. All arbitration proceedings must be completed within 180 days of the notice of commencement of arbitration
proceedings. The Parties hereby agree that, subject to the provisions of this Section 11.12.3, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrator(s) deem reasonable
and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. Rulings will be issued by written order summarizing the arbitration proceedings no more than 30 days after the final submissions of the
Parties. All rulings by the arbitrator(s) will be final and non-appealable to any court except in circumstances where such rulings do not comply with the terms of Section 11.12. 

11.12.4. Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s) pursuant to
Section 11.12 may be enforced, to the extent that such ruling complies with the provisions of Section 11.12, in any court having jurisdiction over any of the Parties or any of their respective assets. 

11.12.5. Confidentiality. All activities undertaken by the arbitrator(s) or the Parties pursuant to this Section 11.12 will be
conducted subject to obligations of confidentiality no less restrictive than those set forth in Section 7. Further, the Parties acknowledge and agree that their respective conduct during the course of the arbitration and their respective
statements and all information exchanged in connection with the arbitration is Confidential Information under this Agreement and subject to the provisions of Section 7. 

  
 62 

 11.12.6. Unauthorized Disclosure of Confidential Information to Third Parties.
Notwithstanding any provision of this Agreement to the contrary (i) the provisions of this Section 11.12 will not apply to Pfizer’s disclosure of Cellectis Confidential Information to any Third Party in violation of Section 7 and
(ii) Cellectis reserves its rights under Section 11.10 to immediately initiate litigation seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights
under Section 7 with respect to any such unauthorized disclosure. 
 11.13 Governing Law. This Agreement, and all claims arising
under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof 

11.14 Consent to Jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the
exclusive jurisdiction of the United Kingdom for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof, hereby waives to
the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred to any court other than one of the above-named courts, or
should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees
not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other than one of the above-named
courts whether on the grounds of inconvenient forum or otherwise. 
 11.15 Entire Agreement. This Agreement, including its Exhibits
and Schedules, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written,
between the Parties respecting the subject matter hereof and thereof, including the Confidentiality Agreement which is hereby terminated effective as of the Effective Date, provided that such Confidentiality Agreement will continue to govern the
treatment of Confidential Information disclosed by the Parties prior to the Effective Date in accordance with its terms. 
 11.16
Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of
their agents or employees, or any other legal arrangement that would impose liability upon one Party 

  
 63 

 
for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on
behalf of, the other Party, or to bind the other Party in any respect whatsoever. 
 11.17 Pfizer Anti-Bribery and Anti-Corruption
Practices. Throughout the term of this Agreement, Cellectis, its Affiliates and Subcontractors must comply with the Anti-Bribery and Anti-Corruption provisions set forth in Attachment 11.17 hereto. 

11.18 Counterparts. This Agreement may be executed in two counterparts, each of which will be an original and both of which will
constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which will be binding when received by the applicable Party. 

11.19 No Third Party Rights or Obligations. No provision of this Agreement will be deemed or construed in any way to result in the
creation of any rights or obligation in any Person not a Party to this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer will
remain liable hereunder for the performance by any such Affiliates of any such obligations. 
 IN WITNESS WHEREOF, duly authorized
representatives of the Parties have duly executed this Agreement to be effective as of the Effective Date. 
  

									
	PFIZER INC.				CELLECTIS SA
					
	By:		 /s/
				By:		 /s/

	Name:		G. M. DOLSTEN				Name:		André Choulika
	Title:		President of RD				Title:		CEO

  
 64 

 ATTACHMENT 11.17 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRACTICES 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 65 

 EXHIBIT 1 TO ATTACHMENT 11.17 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRINCIPLES 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 66 

 Schedule 1.52: Expected Subcontractors 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 67 

 Schedule 2.6.1: Research Plan 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 68 

 Appendix A: 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 69 

 Appendix B: 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 70 

 Appendix C: 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 71 

 Appendix D: 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 72 

 Schedule 8.2.1: In Licensed Patent Right comprised in the Cellectis Technology 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 73 

 Schedule 8.2.3: Cellectis Patent Rights 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 74 

 Schedule 8.2.4: [Exception to Representation and Warranties of Cellectis 8.2.4] 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 75 

 Schedule 8.2.8: [Exception to Representation and Warranties of Cellectis 8.2.8] 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 76 

 Schedule 8.2.9: [Exception to Representation and Warranties of Cellectis 8.2.9] 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 77 

 Schedule 8.2.10: Disclosed Third Party Agreement 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 
 78EX-10.5

 Exhibit 10.5 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 132965/MG/CP 

RESEARCH, PRODUCT DEVELOPMENT, OPTION, LICENSE 

AND COMMERCIALIZATION AGREEMENT 

BETWEEN 
 LES
LABORATOIRES SERVIER SAS 
 INSTITUT DE RECHERCHES INTERNATIONALES SERVIER SAS 

AND 
 CELLECTIS SA

  
 1/44 

 PRODUCT DEVELOPMENT, OPTION, LICENSE AND COMMERCIALIZATION AGREEMENT 

This Product Development, Option, License and Commercialization Agreement shall become effective as of the 17 day of February, 2014 (the “Effective
Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and lnstitut de Recherches
lnternationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”),
and Cellectis SA, a company incorporated under the laws of France having a principal place of business, at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a
“Party” and collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Cellectis has developed, owns or otherwise Controls (as hereinafter defined) certain intellectual property and know-how regarding the
engineering of primary cells (e.g. T-cells) for therapeutic applications in the field of anti-tumor adoptive immunotherapy. 

WHEREAS, Servier possesses research, development, manufacturing and commercialization expertise for the development and commercialization of
pharmaceutical products in the field of oncology. 
 WHEREAS, Servier wishes Cellectis, and Cellectis accepts, to perform development activities up
to and including Phase I of certain of the Candidate Product(s) selected by Servier. 
 WHEREAS, Servier wishes to have the exclusive option to get
an exclusive worldwide licence over certain Product(s) it may wish to select in order to further develop, promote and commercialize them, as specified in the Agreement. 

Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  

	ARTICLE 1.	DEFINITIONS. 

 The following capitalized terms or derivatives thereof (verbs, nouns, singular, plural),
when used in this Agreement, will have the following meanings: 
 1.1. “Affiliates” means with respect to a Party, any person or entity,
whether de jure or de facto, which directly or indirectly controls, is controlled by, or is under common control with such Party. Solely as used in this definition, the term “control” means (i) the ownership, directly or indirectly,
beneficially or legally, of at least fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a person or entity in a particular jurisdiction) of such Party
or other person or entity, as applicable, or such other comparable ownership interest with respect to any person or entity that is not a corporation; or (ii) the possession, directly or indirectly of the power, whether pursuant to contract,
ownership of securities or otherwise, to direct the management and policies of a Party or such other person or entity, as applicable. 

  
 2/44 

 1.2. “Agreement” means this Product Development, Option, License and Commercialization Agreement
together with the recitals and all exhibits, schedules and attachments hereto. 
 1.3. “Attribute” means a particular genome modification
obtained by nucleases or any other methods, including without limitation knock out, knock in and point mutations. 
 1.4. “Background IP”
means Patents and Know How Controlled by a Party prior to the Effective Date and/or developed or acquired by such Party during, but outside of, this Agreement 

1.5. “Backup Product” [***]. 
 1.6.
“Candidate Product” means an allogenic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR) directed against a particular Target including specific Attributes selected by Servier according to
Section 3.2(c). Except for section 6.3., Candidate Product also applies to a Backup Product and/or a Follow-on Product in case of application of Section 3.4. 

1.7. “Cellectis IP” means any and all Cellectis Patent(s) and Know-How developed and/or Controlled by Cellectis and its Affiliates before the
Effective Date or thereafter during the Term, that is necessary or useful for the Development, Manufacture and Commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. For avoidance of doubt Cellectis IP shall
include Cellectis’ interest in the Joint Intellectual Property. 
 1.8. “Cellectis Know-How” means all Know-How that is developed or
Controlled by Cellectis at the Effective Date and thereafter during the Term and (i) that results from Cellectis’ activities with respect to the Development or (ii) is reasonably necessary or useful for the Development, Manufacture
and/or Commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. 
 1.9. “Cellectis Knowledge” means
the knowledge, at the Effective Date that Cellectis has after due inquiry. 
 1.10. “Cellectis Patent” means all Patents that are
Controlled by Cellectis and its Affiliates at the Effective Date and thereafter during the Term and that Cover, or would be reasonably necessary or useful for, the Development, Manufacture or Commercialization of Pre-Candidate Product(s), Candidate
Product(s), or Product(s), as appropriate,) (including its composition, formulation, combination, product by process, or method of use, manufacture, preparation or administration). Cellectis Patents shall include Cellectis’ interest in Joint
Patent that meet the above requirements, and in any event shall include those Patents set forth on Exhibit 2. 
 1.11. “Change of Control”
means, with respect to Cellectis, the occurrence of any of the following events: (i) any Third Party begins to control (under the meaning of “control” set forth in Section 1.2 (“Affiliate”)) Cellectis, directly or
indirectly, by any means (including acquisition of shares, share exchange or share transfer); or (ii) Cellectis conveys, transfers, divests or leases (including general succession and all types of corporate split) in one or more transactions to
any Third Party either: (x) all or substantially all of the assets of Cellectis or (y) all or substantially all of its assets that are material to the purpose of performance of its obligations under this Agreement. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 3/44 

 1.12. “Claim” means any charge, complaint, action, suit, proceeding, hearing, investigation,
claim or demand, including without limitation any investigation by a Governmental Authority. 
 1.13. “Clinical Development” means any and
all Development activities performed by a Party following the achievement of animal in vivo proof of concept Milestone. 
 1.14.
“Commercialization” means with respect to a Product any and all activities of marketing, promoting, distributing, importing, offering for sale, having sold and/or selling such Product in the Field in the Territory, including without
limitation defining pricing and reimbursement strategy and approval and pre-launch marketing strategy. 
 1.15. “Commercially Reasonable
Efforts” means, [***]. 
 1.16. “Competent Authority” means any court, tribunal, regulatory agency of (a) any
national, federal, state, provincial, county, city or other political subdivision government, including the FDA, (b) any supranational body (including the EMA). 

1.17. “Competent Authority Approval” means any and all approvals, licenses, registrations or authorizations by a Competent Authority and
necessary for the Development activities (including without limitation any applicable pricing, final labeling and reimbursement approvals of such Governmental Authority), and any MAA or equivalent. 

1.18. “Control”, “Controlled” or “Controlling” means, with respect to a subject item, the ability of a Party, whether
arising by ownership, possession or pursuant to a license or sublicense, to grant licenses or sublicenses to another Party with respect to such subject item, as provided in this Agreement, without violating the terms of any agreement or other
arrangement with any Third Party. 
 1.19. “Cover” “Cover”, “Covered” or “Covering” means, with respect to a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate, and a Patent, that, in the absence of a (sub)license under, or ownership of, such Patent, the making, using, offering for sale, selling or
importing of such a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate, with respect to a given country, would infringe a Valid Claim of such Patent. 

“Data” means any and all research, pharmacology, medicinal chemistry, pre-clinical, clinical, commercial, marketing, process development,
manufacturing and other data or information, including investigator brochures and reports (both preliminary and final), statistical analyses, expert opinions and reports, and safety data, in each case generated from clinical Studies or non-clinical
studies, research or testing specifically related or directed to the Pre-Candidate Product(s), the Candidate Product(s) or Product(s). 
 1.20.
“Development” means with respect to a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate and on a Targeted Indication and Targeted Territory basis, the activities, including the Preclinical Development as well as
the Clinical Development, performed by a Party as from the beginning of the work on a Pre-Candidate Product until and including the MAA filing for the relevant Product, including without limitation: activities related to research, process
development and manufacturing, pre- clinical and clinical drug development of such Candidate Product and/or Product in its Targeted Indication in the Field and in its Targeted Territory, including without
limitation, test method development and stability testing, assay development, toxicology, pharmacology, formulation, quality assurance, quality development, technology transfer, statistical analysis, process development, and scale-up,
pharmakocinetic  

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 4/44 

 
studies, data collection and management, clinical studies (including research to design clinical studies), regulatory affairs (including all necessary steps to Develop the Candidate Product
and/or Product as an orphan drug, obtaining scientific advices), project management, drug safety surveillance activities related to clinical studies, validation of methods and tests. “Development Plan” means, for each Candidate
Product or Product, a working document describing the Targeted lndication(s), Targeted Territories, expected timelines, the preclinical, clinical, manufacturing, regulatory, as well as Candidate Product risk assessment planned activities up to the
issuance of the Phase 1 Data Package by Cellectis to Servier. The JRDC may propose from time to time amendment to the Development Plan that shall be submitted to the JSC for validation as the circumstances may require and subject to
Section 3.3. 
 1.21. “Executive Officer” means the Chief Executive Officer of Cellectis and the Chief Executive Officer of Servier,
or their duly authorized respective designees with equivalent decision-making authority with respect to matters under this Agreement. 
 1.22.
“Field” means the anti-tumor adoptive immunotherapy. 
 1.23. “First Commercial Sale” means the first sale in the Territory
to a Third Party of the Product by or under the authority of Servier or its Affiliate or sublicensees after receipt of the applicable regulatory approval from the Competent Authority(ies). 

1.24. “Follow-on Product” [***]. 

1.25. “Servier Foreground IP” means, with respect to a Product, the part of the Foreground IP that is specifically and solely related to a
Product for which an Option to License has been exercised by Servier according to Section 4.1. 
 1.26. “Good Manufacturing Practices
(cGMP)” means (i) EC Directive 2003/94/EEC as amended from time to time and all the relevant associated detailed guidelines; (ii) the current principles and guidelines of Good Manufacturing Practice for medicinal products for
human use as required by, but not limited to, the applicable sections of the US Federal Food, Drug and Cosmetic Act, the US Public Health Service Act, the US Code of Federal Regulations, Title 21, Parts 210 (Current Good Manufacturing Practice in
Manufacturing, Processing, Packing or Holding of Drugs; General), and relevant US Food and Drug Administration Guidance and Points to Consider for drugs and/or biotechnology-derived products, as amended from time to time; and (iii) the
equivalent current law or regulation in any market. 
 1.27. “In Vitro Data Package” [***]. 

1.28. “In-Vivo Milestone” [***]. 

1.29. “Joint Intellectual Property” or “Joint IP” means all intellectual property rights in Joint Inventions (which for the
avoidance of doubt shall include Joint Know-How and Joint Patent). 
 1.30. “Joint lnvention(s)” means an invention arising during the Term
that is jointly created by one or more employees, consultants, or contractors of each Party or of any Affiliate or sublicensee of such Party in the course of performing activities under this Agreement. 

1.31. “Joint Know-How” means all Know-How arising during the Term that is jointly created by one or more employees, consultants, or
contractors of each Party or of any Affiliate of such Party in the course of performing activities under this Agreement. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 5/44 

 1.32. “Joint Patent” means a Patent that claims a Joint Invention. 

1.33. “Know-How” means all technical information, techniques, data, database rights, discoveries, inventions, practices, methods, knowledge,
skill, experience, test data or information necessary for the discovery, development, manufacture use, sale or commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. 

1.34. “MAA” means, in relation to any Product, an application filed or to be filed with the European Medicines Agency (or equivalent national
agency), for authorization to place a medicinal product on the market in the European Union (or any other territory). 
 1.35. “Manufacture”
means with respect to a Pre-Candidate Product, a Candidate Product or a Product, any and all processes and activities conducted to manufacture preclinical, clinical and commercial quantities of such, in particular, the production, the
manufacture, the processing, the filling, the packaging, the labeling, the inspection and the shipping of such Pre-Candidate Product, Candidate Product or Product. Manufacture shall also include the supply of any raw materials or packaging materials
with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process qualification and validation, commercial manufacture, stability and release testing, quality assurance and quality control. For
clarity, “Manufacturing” has a correlative meaning. 
 1.36. “Manufacturing process validation” [***]. 

1.37. “Milestone Data” means any information and results supporting the achievement of a Milestone. 

1.38. “Net Revenues” [***]. 
 1.39.
“Net Sales” [***]. 
 1.40. “Option Date” shall mean the date at which the Option to License over a particular Product
is exercised by Servier pursuant to Section 4.1 (b). 
 1.41. “Patent” means (a) issued patent, including any extension,
registration, confirmation, reissue, continuation, supplementary protection certificate, divisional, continuation-in-part, re-examination or renewal thereof, (b) pending applications for all of the
foregoing, and (c) foreign counterparts of any of the foregoing; in each case to the extent the same has not been held, by a court of competent jurisdiction, to be invalid or unenforceable in a decision from which no appeal can be taken or from
which no appeal was taken within the time permitted for appeal. 
 1.42. “Phase 1” means first time in human clinical trial in the first
indication. 
 1.43. “Phase 1 Data Package” [***]. 

1.44. “Pre-Candidate Product” means an allogenic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR)
directed against a particular Target including specific Attributes. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 6/44 

 1.45. “Preclinical Development” means any and all non-clinical Development activities performed
by a Party until and including animal in vivo Proof of Concept Milestone. 
 1.46. “Product” means a Candidate Product selected by Servier
according to Section 4.1(b). Except for sections 6.2. and 6.3, Product also means a Backup Product and/or a Follow-on Product. 
 1.47.
“Program” means the Development activities performed by Cellectis relating to a particular Pre-Candidate Product and Candidate Product up to and including Phase 1, as described in Exhibit 1 for
the UCART19 Product, and as described in a separate document provided by the JRDC as per Section 3.2(b) for the other Pre-Candidate Product and Candidate Product(s). 

1.48. “Program Term” means the duration of each Program. 

1.49. “Royalty Term” means on a country-by-country basis and Product-by-Product basis, the period commencing on the First Commercial Sale of
a Product in a country and ending on the latest of (a) expiration of the last-to-expire Valid Claim of a Cellectis Patent that Covers such Product in such country or (b) the expiration of the Regulatory Exclusivity Rights with respect to
such Product in such country. 
  1.50. “Servier IP” means any and all Servier Patent(s) and Know-How developed and/or Controlled by
Servier and its Affiliates after the Effective Date that is necessary or useful for the discovery, development, manufacture, use, sale or commercialization of a Pre-Candidate Product, a Candidate Product or a
Product, as appropriate. For avoidance of doubt Servier IP shall include Servier’ interest in the Joint Intellectual Property. 
  1.51.
“Servier Know-How” means all Know-How that is developed or Controlled by Servier after the Effective Date and thereafter during the Term and (i) that results from Servier’s activities with respect to the Development or
(ii) is reasonably necessary or useful for the Development, manufacture, and/or Commercialization of a Pre-Candidate Product, a Candidate Product or a Product, as appropriate. 

1.52. “Servier Patent” means all Patents that are Controlled by Servier and its Affiliates after the Effective Date and thereafter during the
Term and that Cover, or would be reasonably necessary or useful for, the Development, manufacture or Commercialization of the Pre-Candidate Product(s), Candidate Product(s) or the Product(s) (including its composition, formulation, combination,
product by process, or method of use, manufacture, preparation or administration). Servier’s Patents shall include Servier’s interest in Joint Patent that meet the above requirements. 

1.53. “TAL nuclease” means an artificial restriction enzyme consisting of one or more polypeptides that comprise a sequence from a
transcription activator-like effector protein designed to recognize and cleave a recognition site in a target sequence, engineered and sold by Cellectis or its Affiliates in the framework of this Agreement. [***]. 

1.54. “Target” means an antigen expressed on the cell surface of a tumor cell proposed by Cellectis to Servier and/or by Servier to Cellectis
through the JRDC and approved by the JSC, all before the beginning of the implementation of each Program by Cellectis. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 7/44 

 1.55. “Targeted Indication” means with respect to a Pre-Candidate Product, a Candidate Product
or a Product, the therapeutic indication determined in such Product’s Development Plan, and within the Field. 
 1.56. “Targeted
Territory” means with respect to each Pre-Candidate Product, Candidate Product or Product, the following country(ies) or region(s): [***]. 

1.57. “Term” will have the meaning assigned to such term in Section 11.1. 

1.58. “Territory” means any and all countries of the world. 

1.59. “Third Party” means any person or entity other than Cellectis, Servier or an Affiliate of Cellectis or Servier. 

1.60. “UCART19 Product” [***]. 
 1.61.
“Valid Claim” means a claim of an issued and unexpired patent or patent application included in a Patent, which claim has not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction
or has not been held or admitted to be invalid or unenforceable through re-examination or disclaimer, reissue, opposition procedure, nullity suit or otherwise. Notwithstanding the foregoing, if a claim of a pending patent application within a Patent
has not issued as a claim of a patent within [***] after the filing date from which such claim takes priority, such claim shall not be a Valid Claim for the purposes of this Agreement, unless and until such claim issues as a claim of any issued
patent (from and after which time the same would be deemed a Valid Claim subject to the first sentence of the definition above). With respect to a claim of a pending patent application, the phrase to “infringe a Valid Claim” shall mean to
engage in activity that would infringe such claim if it were contained in an issued patent. 
  

	ARTICLE  2.	MANAGEMENT 

 2.1. Overview. Promptly after the Effective Date, the Parties shall establish three
(3) committees which shall manage the collaboration between the Parties until the exercise (or non-exercise) of the Option to License by Servier as indicated in section 4.1 hereafter. 

2.2. Alliance Managers. Each of Servier and Cellectis shall appoint one or two senior representatives who possess a general understanding of
development, regulatory, manufacturing and commercialization matters to act as its respective alliance manager(s) for this relationship (each, an “Alliance Manager”). Each Party may replace its respective Alliance Manager(s) at any time
upon written notice to the other in accordance with this Agreement. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager. Each Alliance Manager shall be charged with creating and maintaining a
collaborative work environment within and among the Committees. Consistent with the Development Plan and Section 2.10, each Alliance Manager, on behalf of the applicable Party’s Co-Chairperson of the applicable Committee, will also be
responsible for: 
  

	 	(a)	providing a primary single point of communication responsible for the flow of communication and for seeking consensus both within the respective Party’s organization and together regarding key strategy and plan
issues; 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 8/44 

	 	(b)	ensuring that the governance procedures and rules set forth herein are complied with 

  

	 	(c)	identifying and raising disputes to the JSC or JEC for discussion in a timely manner; and 

  

	 	(d)	planning and coordinating internal and external communications in accordance with the terms of this Agreement. 

The Alliance Managers shall be entitled to attend all JRDC, JSC and JEC meetings, and shall have the right to attend all Subcommittees meetings. Consistent
with Section 2.10, each Alliance Manager may bring any matter to the attention of the JSC or JEC where such Alliance Manager reasonably believes that such matter requires attention of the JSC or JEC. 

At the latest ten (10) days after the Effective Date, each Party shall appoint and notify the other Party of the identity of their representatives to act
as alliance managers under this Agreement. 
 2.3. Project Directors. Within ten (10) days following the Effective Date each Party shall appoint
and notify the other Party of the identity of a representative to act as its project director (“Project Director”). The Project Director shall be responsible for the follow-up of the Development activities under this Agreement on a regular
basis. The Project Director may attend the meetings of the JSC, as requested by the Co- Chairperson. Each Party may replace its Project Director upon written notice to the other Party. 

2.4. Joint Executive Committee (the “JEC”). 

2.4.1. Composition. The JEC shall be comprised of up to two (2) senior executives from each Party. Promptly following the Effective Date, each
Party shall designate by written notice to the other Party its initial representatives on the JEC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change.
Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to such representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the
same as those set forth in article 8. 
 2.4.2. Function and Powers of the JEC. The JEC shall: (a) manage the overall collaboration between the
Parties and manage resource allocation and major changes to the collaboration requiring amendments to this Agreement, (b) resolve disputed matters that may arise at the JSC, in accordance with Section 2.10, (c) draw up an annual
review of implementation of the Collaboration and performance of the Agreement. 
 2.4.3. Frequency of Meetings. The Joint Executing Committee shall
meet annually, and in no event less than once annually and such meetings may be conducted by telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, provided that not less than two (2) Business Days’
prior written notice has been given to the other Party, and subject to such other Party’s approval (not to be unreasonably withheld, delayed or retained), other employees of the Parties may attend Joint Executive Committee meetings as
observers. Either Party may also call a special meeting of a Joint Executive Committee (in person, by videoconference or teleconference) by at least ten (10) Business Days’ prior written notice to the other Party in the event such Party
reasonably believes that a significant matter 

  
 9/44 

 
must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the Joint Executive Committee no later than ten (10) Business Days prior to the special meeting
with materials reasonably adequate to enable an informed decision. 
 2.5. Joint Steering Committee (the “JSC”). 

2.5.1. Composition. The JSC shall be comprised of three (3) named representatives of each Party (or such other number as the Parties may agree) in
addition to each Party’s Alliance Manager who are members ex-officio. Promptly following the Effective Date, each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or
more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in article 8. 

2.5.2. Function and Powers of the JSC. The JSC shall: (a) review and approve the Development Plan and the associated budget and any annual or
interim updates and proposed amendments thereto; (b) direct and oversee the JRDC on all significant issues; (c) review and approve the recommendations of the JRDC; (d) with respect to each Program, to validate the criteria of success
of each Milestone proposed by the JRDC (the “Criteria of Success”) and the achievement of each Milestone, provided that such validation shall be deemed reached if the corresponding Milestone Data meet the corresponding Criteria of Success;
(e) shall have overall responsibility for the oversight of the performance of the Clinical activities for each Program; (f) direct and oversee any operating subcommittee on all significant issues; (g) validate and back-up the
intellectual property strategy; (h) resolve disputed matters that may arise at the JRDC and the subcommittees, in accordance with Section 2.10, and (i) assume a general role of leadership in the partnership. 

2.5.3. Frequency of Meetings. The Joint Steering Committee shall meet at least two (2) times per year or more or less often as otherwise agreed by
the Parties, but in no event less than once annually and such meetings may be conducted by telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, and provided that not
less than two (2) Business Days’ prior written notice has been given to the other Party, other employees of the Parties may attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting
without the other Party’s prior consent. Each Party may also call for special meetings of the Joint Steering Committee with reasonable prior written notice (it being agreed that at least ten (10) Business Days shall constitute reasonable
notice) to resolve particular matters requested by such Party and within the decision-making responsibility of the Joint Steering Committee. Each Co-Chairperson shall ensure that its Joint Steering Committee members receive adequate notice of such
meetings. 
 2.5.4. Subcommittees. The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee shall
consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute
representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in article 8. Except as expressly provided in this Agreement, no
subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC. 

  
 10/44 

 2.6. Joint Research and Development Committee (the “JRDC”). 

2.6.1. Composition. The JRDC shall be comprised of four (4) named representatives of each Party (or such other number as the Parties may agree) in
addition to each Party’s Alliance Manager who are members ex-officio. Promptly following the Effective Date, each Party shall designate by written notice to the other Party its initial representatives on the JRDC. Each Party may replace one or
more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in article 8. 

2.6.2. Function and Powers of the JRDC. The JRDC responsibilities shall include the following activities: (a) propose for approval by the JSC, the
Development Plan(s), as well as any update, with respect to each Program, and the criteria of success for the Milestones, (b) implement the Preclinical Development activities of the Collaboration; (c) shall take responsibility for the
performance of the Clinical activities for each Program; (d) oversee the implementation of the Development Plan(s) and the Development operational aspects of the Program(s); (e) develop forecasts for Clinical Supply Requirements to enable
the timely preparation of the Manufacturing Plan; (h) oversee clinical and regulatory matters pertaining to Pre-Candidate Product(s), Candidate Product(s) or Products in the Field arising from the Development Plans, and review and approve
protocols, statistical analysis plans, clinical study endpoints, clinical methodology and monitoring requirements for clinical trials of Candidate Product(s) and Product(s) in the Field as contemplated under the Development Plan(s);
(i) evaluate the need and conduct biomarker strategy, (j) establish sub-committees of the JRDC, as appropriate. 
 2.6.3. Frequency of
Meetings. The Joint Research and Development Committee shall meet at least once (1) time per quarter or more or less often as otherwise agreed by the Parties, but in no event less than twice annually and such meetings may be conducted by
telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, and provided that not less than two (2) Business Days’ prior written notice has been given to the other Party, other employees of the Parties may
attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting without the other Party’s prior consent. Each Party may also call for special meetings of the Joint Research and Development Committee
with reasonable prior written notice (it being agreed that at least ten (10) Business Days shall constitute reasonable notice) to resolve particular matters requested by such Party and within the
decision-making responsibility of the Joint Research and Development Committee. Each Co-Chairperson shall ensure that its Joint Research and Development Committee
members receive adequate notice of such meetings. 
 2.6.4. Subcommittees. The JRDC may establish and disband such subcommittees as deemed
necessary by the JRDC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written
notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in article 8.
Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JRDC. 

  
 11/44 

 2.7. Co-Chairpersons. 

Each Party shall appoint one of its members in each Committee to co-chair such Committee’s meetings (each, a “Co-Chairperson”). The
Co-Chairpersons shall (i) ensure the orderly conduct of the Committee’s meetings, (ii) attend each Committee meeting (either in-person, by videoconference or telephonically), and
(iii) ensure the preparation and issuance of written minutes of each meeting within thirty (30) days thereafter accurately reflecting the discussions and decisions of such meeting. Unless otherwise agreed, the Committee shall have at least
one (1) representative with relevant decision- making authority from each Party such that the Committee is able to effectuate all of its decisions within the scope of its responsibilities. In the event
the Co-Chair from either Party is unable to attend or participate in a Committee meeting, the Party who designated such Co-Chairperson may designate a substitute Co-Chairperson for the meeting in its sole
discretion. 
 2.8. Quorum; Location. 
 Except where a
Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittee, respectively, shall be effective
only if at least one (1) representative of each Party is present or participating. The JEC, JSC, JRDC and subcommittee may meet either (a) in person at either Party’s facilities or at such locations as the Parties may otherwise agree
or (b) by audio or video teleconference; provided that no less than one (1) meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittee may also be held with the consent of
each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in connection with participating in all
such meetings. 
 2.9. Cooperation. 
 Each Party shall
provide the JSC such information as required under the Development Plan, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under the Development Plan. 

2.10. Decisions. 
 Other than as set forth herein, in
order to make any decision required of it hereunder, the Joint Steering Committee and the Joint Executive Committee must have present (in person, by videoconference or telephonically) at least the Co-Chairperson of each Party (or his/her designee
for such meeting). The Parties will endeavor to make decisions where required of the JSC and JEC by consensus of the Co-Chairpersons and only following a unanimous vote, with each Party having one
(1) vote. If a dispute arises which cannot be resolved within the Joint Research and Development Committee or within a Subcommittee, the Co-Chairpersons of either Party may cause such dispute to be referred to the Joint Steering Committee for
resolution. If a dispute arises which cannot be resolved within the Joint Steering Committee, the Co-Chairpersons of either Party may cause such dispute to be referred to the Joint Executive Committee for resolution. Within the Joint Executive
Committee, the Co-Chairperson of each Party shall try to reach a decision by mutual consent with respect to all matters during the Program Term, however in the event of disagreement between the Co-Chairperson, Servier
Co-Chairperson shall have the final say. 

  
 12/44 

 2.11. Exceptions. 

Notwithstanding the foregoing, neither Party in exercising its right to finally resolve a dispute pursuant to Section 2.10 shall have any power to amend,
modify, or waive compliance with the terms of this Agreement. 
 2.12. Authority. 

The JEC, JSC, JRDC and any subcommittee shall have only the powers assigned expressly to it in this article 2 and elsewhere in this Agreement, and shall not
have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated
or vested in the JEC, JSC, JRDC or subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. 

2.13. Discontinuation of Participation on a Committee. 

Each Committee shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the Committee or (b) early
termination of the Agreement pursuant to article 11. 
 2.14. Interactions Between the Joint Executive Committee, the Joint Steering Committee, the
Joint Research and Development Committee and the Subcommittees. 
 The Parties recognize that while they will establish the JEC, JSC, JRDC and other
Subcommittees for the purposes hereof, each Party maintains internal structures (including its own committees, teams and review boards) that will be involved in administering such Party’s activities under this Agreement. The Parties shall
establish procedures to facilitate communications between the JEC, JSC, JRDC and Subcommittees hereunder and the relevant internal committees, teams or boards within each Party in order to maximize the efficiency of the Parties’ activities
pursuant to this Agreement. 
  

	ARTICLE  3.	DEVELOPMENT ACTIVITIES 

 3.1. Development of UCART19 Product up to Phase 1. 

Cellectis shall be responsible for conducting the part of Development of the UCART19 Product up to and including the end of Phase I, in accordance with
the corresponding Program description set out in Exhibit 1 and with the corresponding Development Plans. 
 3.2. Development of the five additional
Pre-Candidate Products, Candidate Products and Products. 
 (a) Selection of five Targets. At Effective Date, five Targets as in
Exhibit 3 have been selected and agreed by the Parties. 
 (b) [***] after the Effective Date, the JRDC will, [***], define the
corresponding Programs in the Field (a draft of Program description is enclosed in Exhibit 3) to be approved by the JSC. During [***] or for [***] if agreed by both Parties, for the Target(s) on which Cellectis has not started its Development
activities, the JSC may decide to replace said Target(s) initially 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 13/44 

 
selected by another new Target, provided that Cellectis has the right to refuse any proposed new Target. For the sake of clarity, the initial Target that is replaced by a new Target is outside of
the scope of this Agreement and Cellectis remains free to exploit such initial Target. 
 (c) Selection of the Candidate Products.
Cellectis shall be diligent in the development of an In Vitro Data Package for each Pre-Candidate Product. Such development shall start no later than [***] as of the approval date of the corresponding Program
by the JSC, as stated in Section 3.2. (b) above. Upon reception by Servier of the In Vitro Data Package, Servier shall have the opportunity during [***] to raise questions regarding the In Vitro Data Package and the Pre-Candidate Product.
Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier shall decide within [***] to turn this Pre-Candidate Product into a Candidate
Product (hereinafter the “Candidate Product Selection”).For sake of clarity, Servier has no obligation to turn any Pre-Candidate Product into a Candidate Product and as a consequence has no
obligation to pay the Milestone event “[***]” for a Pre-Candidate Product not turned into a Candidate Product. 

If Servier does not turn a Pre-Candidate Product into a Candidate Product, Servier definitely waives its right under the Candidate Product and its associated
Primary Target and associated Cellectis IP, Servier will have no further right under the Pre-Candidate Product and its associated Primary Target and its associated Cellectis IP. 

(d) Validation of Milestones achievement. For each of the following Milestone events indicated in Section 6.3(a),
““[***]” per Candidated Product” ““[***]” per Candidate Product”, “[***] per Candidate Product” and “[***] per Candidate Product”, Cellectis will develop a corresponding Milestone Data.
Upon reception by Servier of each data package, Servier shall have the opportunity during [***] to raise questions regarding each data package and the Candidate Product(s). Following that period, Cellectis has [***] to answer to Servier’s
questions to Servier’s satisfaction. Then the JSC may decide within [***] to validate or not the achievement of the corresponding Milestone on the basis of the corresponding Milestone Data. 

(e) Right of First Refusal on a Candidate Product. Should Cellectis wish to transfer (whether by way of a license or an assignment or
the like) to a Third Party Candidate Product(s) for which Servier has exercised its Opt-Out Option as per section 3.6(a), Cellectis shall first propose such transfer to Servier who shall have the right to substitute itself to said Third Party and to
execute corresponding agreement with Cellectis, within a period of [***] after having had the opportunity to review the latest data available, at the same terms and conditions than those proposed by Cellectis to said Third Party. 

3.3. Development of the Pre-Candidate Product(s) and Candidate Products up to Phase 1. 

Following identification and selection of each Pre-Candidate Product and Candidate Product, Cellectis shall be responsible for conducting the Development
activities of the corresponding Pre-Candidate Product and Candidate Product up to and including the end of Phase I, in accordance with the corresponding Program description set out in Exhibit 1 for UCART19 Product and as defined by JRDC and
validated by the JSC for the other Pre-Candidate Product and Candidate Product(s) and with the corresponding Development Plan. Cellectis shall prepare the Development Plan for each Pre-Candidate Product and Candidate Product. Cellectis shall
prepare, file and prosecute all regulatory applications useful or necessary to obtain approvals at Cellectis name to develop the Pre-Candidate Product and Candidate Product up to Phase 1 (e.g. Clinical Trial
Application or equivalent), based on the Development Plan as previously 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 14/44 

 
agreed by the JSC. For sake of clarity, for any Development of a Pre-Candidate Product and Candidate Product not initially planned in the Development Plan, the Parties shall meet in order to
define the technical and financial conditions for such additional Development. 
 3.4. Development of Back-up Products and Follow-on Products. 

The JSC may decide, at any time during the Program Term to add a Back-up Product or, at any time during the Term of the Agreement to add a Follow-on Product
in the corresponding Program. Upon such decision of the JSC, the Back-up Product or the Follow-on Product will be considered as a Pre-Candidate Product or Candidate Product and any and all terms and conditions (except the financial ones as stated in
sections 6.2 and 6.3 below) related to a Pre-Candidate Product or Candidate Product provided in the present Agreement will apply to the Back-up Product or the Follow-on Product. 

3.5. Failure to Develop a Product by Servier. 
 Servier
should use Commercially Reasonable Efforts for the Development of any Product after having exercised its Option to License in relation to such Product. However, should Servier decide to discontinue the Development of any Product after having
exercised the Option to License in relation to such Product, then Servier shall promptly inform Cellectis of such situation and Servier shall terminate the Agreement in accordance with section 11.2.4. 

3.6. Opt-Out Option. 
 (a) Servier has a
right to opt-out from any Program in case Servier decides not to pursue such Program (the “Opt-Out Option”) as follows. Servier may exercise its Opt-Out Option within a period of [***] following the presentation by Cellectis to the JRDC of
the corresponding Milestone Data (“Opt-Out Period”), by sending a written notification. In case the Opt-Out Option is exercised despite achievement of the Milestone by Cellectis as reviewed by the JRDC and validated by the JSC, all sums
due for the achievement of such Milestone shall be paid by Servier to Cellectis. 
 (b) Subject to Section 3.2 (e) “Right of
First Refusal on a Candidate Product”, if Servier has exercised its right under the Opt-Out Option, the corresponding Candidate Product is considered as terminated under this Agreement. Consequently, such
Program is considered as terminated and the rights granted by Cellectis to Servier under the corresponding Program shall automatically terminates and Cellectis shall have no further obligations towards Servier with respect to such Candidate Product.
For sake of clarity, dispositions of Section 11.3 shall to apply. 
 (c) At the end of the Opt-Out Period, if Servier has not exercised
its Opt-Out Option, the payment corresponding to the Milestone validated by the JSC is due to Cellectis for the corresponding Candidate Product, and Cellectis shall continue further Development of the Candidate Product in accordance with this
Section 3. 
 3.7. Subcontracting. 
 Cellectis may
engage its Affiliates, and/or Third Party subcontractors (including contract manufacturing organizations or contract research organizations) to perform certain of its obligations under this Agreement. Any Third Party subcontractor to be engaged by
Cellectis to perform Cellectis’ obligations set forth in this Agreement will meet the qualifications typically 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 15/44 

 
required by Cellectis for the performance of work similar in scope and complexity to the subcontracted activity. The activities of any such Third Party subcontractors will be considered
activities of Cellectis under this Agreement. Cellectis will be responsible for ensuring compliance by any such Third Party subcontractors with the terms of this Agreement. In any case in which Cellectis engaged a Third Party subcontractor,
Cellectis will contractually agree to obtain sole ownership or secure a license (with the right to grant sublicenses) of all inventions, data, information developed by such Third Party subcontractor necessary for the Development of Pre-Candidate Product, Candidate Product or Product(s). Cellectis will remain responsible for any breach by a subcontractor of the terms of this Agreement or the applicable subcontractor agreement. 

Cellectis will, and will contractually require that its sub-licensees, subcontractors and Affiliates, if any, use Commercially Reasonable Efforts to conduct
the relevant Development activities in an effort to meet Cellectis’ commitments with respect to such Programs and any development activities. 

3.8. Clinical Trial Activities after Phase 1. 
 After
exercising its Option to License according to Section 4.1, Servier will be sole responsible for further Developing and Commercializing the Product(s). However, Servier may request Cellectis to perform certain Development activities after Phase
1, on behalf of Servier and subject to a separate written agreement that will be negotiated by the Parties in good faith. 
 3.9. Data. 

During the Program Term, Cellectis shall promptly make available to Servier all Data generated by Cellectis and its Affiliates or on their behalf. 

3.10. Non-Compete. 
 During the Term, Cellectis
undertakes not to perform (or have a Third Party performing on Cellectis’s behalf) research on, development on, and/or commercialization of a product directed against a Target that is used for the same purpose than for its use with a Pre-Candidate Product, Candidate Product or Product (“Primary Target”). However, for sake of clarity and based on current knowledge, Cellectis may use the Target if it is not intended to directly
trigger the destruction of tumors or tumor cells by the product but intended to provide specificity or additional functionalities to the product directed against another primary target. In this case, the Target is used necessarily in combination
with another primary target to develop the product. 
 3.11. Right of First Negotiation. 

During the Term, Cellectis has the right to perform internal research activities on the selected Targets for other uses than as Primary Target(s). In the
event Cellectis wishes to grant a license or transfer the outcome of such research activities to a Third Party, Servier will have a right of first negotiation. After Cellectis written notification of the existence of such outcome, Servier shall have
the opportunity, during [***] from the receipt of said notification, to raise questions regarding the outcome. Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier shall
decide, within [***] from the Cellectis’s answer, if it wishes to exercise its right of first negotiation to obtain a license on such outcome. The Parties will then have [***], from the notification by Servier to exercise its right of first
negotiation, to reach an agreement as to the licensing terms and conditions pertaining to such outcome. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 16/44 

	ARTICLE  4.	GRANT OF RIGHTS TO SERVIER 

 4.1. Exclusive Option to License. 

(a) Cellectis hereby grants to Servier, and Servier accepts, an exclusive option, exercisable according to the conditions set forth in
Section 4.1(b), to obtain, on a Product-by-Product basis, an exclusive license under each Product (the “Option to License”) 

(b) Exercise of the exclusive Option to License. Upon reception by Servier of each Phase 1 Data Package, Servier shall have the
opportunity during [***] to raise questions regarding the Phase 1 Data Package and the Candidate Product. Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier may, during the
following [***], exercise the Option to License for the corresponding Candidate Product, by sending a written notification to Cellectis. 
 For the
avoidance of doubt, the Parties understand and agree that Option to License will be exclusive, and unless and until Servier exercises its right to the Option to License with respect to any relevant Candidate Product, neither Cellectis nor any of its
Affiliates will have the right to offer or negotiate with any Third Party regarding the grant to such Third Party of any right or license in or to Candidate Product. However, Cellectis shall remain free to use said Candidate Product for its internal
research. 
 (c) Non-exercise of Option to License. In the event Servier fails to notify Cellectis of its election, or elects not to
exercise its Option to License, Servier’s rights to such Candidate Product shall terminate and Cellectis shall have no further obligations towards Servier with respect to such Candidate Product, and Cellectis may independently pursue all
activities related to such Candidate Product and/or license-out the Candidate Product and the associated Cellectis IP , Joint IP and Servier IP to a Third Party. To that end, Servier grants to Cellectis a non-exclusive, sublicensable,
royalty-bearing license on Servier’s IP (the “License to Cellectis”). 
 Notwithstanding the foregoing, in consideration for the License to
Cellectis and for Servier’s financial contribution to the Development of the Candidate Product, Cellectis will pay to Servier the following payments, to the extent that the said Candidate Product is Covered by a Valid Claim of Servier Patents:

  

	 	(i)	If Servier terminates the license with respect to a Candidate Product up to the first Phase I, Cellectis shall pay to Servier [***] of the Net Revenues it receives from a Third Party; 

 

	 	(ii)	If Servier terminates the license between the beginning of first Phase I and Phase Ill of a Candidate Product or Product, Cellectis shall pay to Servier [***] of the Net Revenues it received from a Third Party;

  

	 	(iii)	If Servier terminates the license with respect to a Product from MAA filing of a Product, Cellectis shall pay [***] of Net Revenues for such Product. 

4.2. Servier Rights and Obligations Upon Exercise of Option. 

(a) Exclusive License. Upon Servier’s exercise of its Option to License for a given Product, Cellectis shall grant to Servier, during the
Term, an exclusive worldwide license, with the right to grant sublicenses, under Cellectis IP to Develop, have developed, manufacture, have manufactured and Commercialize said Product in the Field. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 17/44 

 (b) With respect to each Product elected by Servier, through its Option to License, Servier will
assume full responsibility, at its expenses, for the further Development, manufacture and Commercialization of such Product in the Field. 

(c) Servier Diligence. Upon Servier’s exercise of the Option to License for a given Product, Servier will use, and will ensure that its
Affiliates, Sublicensees and subcontractors use Commercially Reasonable Efforts in Developing and Commercializing the corresponding Product in the Targeted Indications and the Targeted Territory, and are in compliance with the Agreement. 

 

	ARTICLE  5.	TRANSFER AND SUPPLY 

 5.1. Cellectis Transfer Cooperation. 

Upon Servier’s exercise of the Option to License, Cellectis will provide Servier with any information, materials and data, Competent Authorities’
approval available to it and reasonably necessary for Servier to continue the Development, Manufacturing and/or Commercialization of the Product, and Cellectis will cooperate with Servier to provide transfer of such information, materials and data
as soon as reasonably practicable after the Option to License is exercised. 
 5.2. Supply of Product. 

Upon exercise of the Option to License with respect to a given Program, and upon Servier’s request, Cellectis shall Manufacture or have Manufactured in
compliance with cGMP the corresponding Products for Servier’s benefit until the end of the Phase II studies to be conducted by Servier, its Affiliates or its Sublicensees, subject to a written supply and quality agreements whose terms and
conditions shall be negotiated in good faith between the Parties within [***] upon exercise of each Option to License. The supply price of the Product (in finished form) shall be at manufacturing costs, incurred by Cellectis, plus [***]. 

Servier may elect at any time before entering into the first Phase II studies (or during the performance of the Phase II studies) to have the manufacture of
the Products transferred by Cellectis or its designee, at Servier’s costs, to a Contract Manufacturing Organization selected by Servier and reasonably acceptable to Cellectis. The Parties will execute a
tri- partite technology transfer agreement between Servier, the Contract Manufacturing Organization and Cellectis, provided that Cellectis will transfer (or will have transferred) to the Contract Manufacturing
Organization the know-how, material and data necessary for the proper manufacturing of the Products. 
  

	ARTICLE  6.	PAYMENTS AND MILESTONES 

 6.1. Upfront Fee. In consideration for the signature of the Agreement,
Servier shall pay Cellectis the non-refundable and non-deductible lump sum payment of two millions and five hundred thousand euros (2,500,000 €), excluding taxes, within [***] of the Effective Date and
receipt of the corresponding invoice. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 18/44 

 6.2. License Fees. Upon exercise of each Option to License for Products pursuant to Section 4.1
herein (except for Backup Products), Servier will pay Cellectis the non- refundable and non-deductible lump sum payment of [***], excluding taxes. 

Upon exercise of each Option to License for Follow-on Products pursuant to Section 4.1 herein, Servier will pay Cellectis the non-refundable and non-deductible lump sum payment of [***], excluding taxes. 
 6.3. Milestone event Payments to
Cellectis. 
 (a) In consideration for the rights granted to Servier under this Agreement Servier will pay to Cellectis for each
Candidate Product, Product, Backup Product or Follow-on Product the following non-refundable milestone payments upon the occurrence of each event as set forth below. No milestone payment will be owed by Servier to Cellectis if the corresponding
event to which such milestone payment relates is not deemed as achieved by the JSC pursuant to Section 3.5. 
  

			
	 Milestone event
	  	Milestone payment (in €)
	 [***]
	  	

 (b) The non-refundable milestones set forth below shall be paid in full for the Candidate Product or the
Product (as applicable). 
 (c) Those milestones set forth below, when already paid for the Candidate Product or the Product, shall not be
paid a second time for the Backup Product. For sake of clarity, the milestones that have not been paid for the Candidate Product or Product shall be paid in full for the Backup Product. 

(d) For Follow-on Products, those milestones shall only be paid at [***] (i.e. the “[***]” milestone shall only be [***]). 

(e) No milestone payment will be owed by Servier to Cellectis if the corresponding event to which such milestone payment relates is not deemed
as achieved by the JSC pursuant to Section 3.5. 
  

			
	 Milestone event
	  	Milestone payment (in €)
	 [***]
	  	

 (f) Milestones already achieved at the Effective Date. 

 

	 	(i)	With respect to UCART19 Product, the Parties hereby acknowledge that the following Milestones have been achieved by Cellectis at the Effective Date: 

 

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 19/44 

 Consequently Servier shall pay to Cellectis the sum of [***] excluding taxes, within [***] of
the Effective Date. 
  

	 	(ii)	With respect to the other five additional Programs, the Parties hereby acknowledge that Cellectis has already committed to reserve for Servier 5 additional Targets in the Field. Consequently, Servier shall pay to
Cellectis the sum of [***], excluding taxes, within [***] of the Effective Date. 

 For sake of clarity, within [***] of the
Effective Date, Servier shall pay to Cellectis a total amount not exceeding seven million and five hundred fifty thousand euros (7,550,000€). 

(g) In the event that Servier grants rights relating to Cellectis IP for the Development and/or Commercialization of a Candidate-Product or
Product (including but not limited to a right of first refusal, or a right of first negotiation, or an option) to a Third Party for the territory of the United States of America before the date of exercise of each Option to License pursuant to
section 4.1, on a Candidate Product-by-Candidate Product or Product-by-Product basis, Servier undertakes to pay to Cellectis an amount equal to [***] of all sums received by Servier from such Third Party, for such right, before the date of exercise
of each Option to License and [***] thereafter. 
 6.4. Sales Milestones to Cellectis. 

Servier shall pay the following sales milestones the first time that annual Net Sales of a Product reach the following thresholds: 

 

			
	 First time annual Net sales of a Product reaches
	  	Milestone payment (in €M)
	 [***]
	  	

 6.5. Royalties to Cellectis. 

During the Royalty Term(s), Servier shall pay royalties to Cellectis on annual Net Sales of the Products: 

 

			
	 Aggregate annual Net Sales of the Products
	  	Royalty
	 [***]
	  	

 6.6. Royalty Reductions. 

6.6.1. Joint Patent(s). Notwithstanding the foregoing, should a Product, at any time, be solely Covered by Joint Patent in a given country within the
Territory, then the royalties payable by Servier to Cellectis for such Product in such country shall be reduced by [***] of the amount otherwise payable hereunder (e.g., from [***]) as of the date such situation occurs. 

6.6.2. Competition on the Target. Notwithstanding the foregoing, if there are and as soon as there are, in a given country within the Territory, sales of an
allogeneic CART cell therapy 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 20/44 

 
targeting the same Target as a Product occurring before the First Commercial Sale of a Product, the royalties payable to Cellectis hereunder for the Product in such country shall be reduced by
[***] of the amount otherwise payable hereunder (e.g., from [***]) as of the date of such first sales. 
 6.6.3. Third Party Royalty Payments. If Servier or
any of its Affiliates or sublicensee (i) determines in its good faith judgment with advice from a external legal attorney that it is necessary or advisable to obtain a license from any Third Party in order to make, have made, use, sell, offer
for sale or import any Product and pursuant to such license is required to pay any consideration, in the form of a royalty based on sales of such Product, or (ii) is required by any court of competent jurisdiction to pay damages and/or such
license fees to such a Third Party in order to make, have made, use, sell, offer for sale or import any Product, then Servier shall use commercially reasonable efforts to negotiate a favorable economic license and Servier will be entitled to deduct
up to [***] of such payments (until full reimbursement by Cellectis) from the royalties associated to such Product otherwise payable under Section 6.5 (Royalties to Cellectis), provided however that in a given year, Royalties of Cellectis shall
not be reduced of more than [***] than the initial value stated in 6.5. 
 The foregoing shall be without prejudice to any payment Cellectis has to make to
Third Parties on the basis of intellectual property that: (i) is licensed by Cellectis prior to or as of the Effective Date; (ii) is intellectual property that Cellectis had knowledge of potential infringement from a Third Party prior to
the exercise by Servier of the exclusive Option to License and that Cellectis did not disclose same to Servier in writing at that time at the latest; or (iii) is licensed or acquired by Cellectis after the Effective Date without Servier’s
prior written consent and related to the Product or uses or methods of manufacture thereof (or of its components). 
 6.7. Payment Terms. 

6.7.1. All sums due hereunder to either Servier or Cellectis will be payable in Euros, by bank wire transfer in immediately available funds to such bank
account(s) as the Parties will designate. Each Party will notify the other as to the date and amount of any such wire transfer at least seven (7) days prior to such transfer. 

6.7.2. Except as otherwise set forth herein, all other payments due hereunder will be paid within [***] following receipt of an invoice requesting such
payment. 
 6.7.3. Invoices. All invoices provided to a Party hereunder should include the receiving Party’s bank details, the contact name for
issue resolution and will be marked for the attention of the alliance manager assigned to this Agreement, whose name will be provided by the Parties to each other. 

6.7.4. Late Payment Penalties. Interest shall accrue on any late payment of fees owed to the receiving Party not made on the date such payment is due,
at an annual interest rate equal to the lesser of the Euribor 1 month fixed by the European Central Bank plus three percent (3%) or the highest rate permissible by law, with such interest accruing from the date the payment was originally due to
the receiving Party, and any late payment pursuant to this Section shall be credited first to interest and then to any outstanding fees. This Section shall in no way limit any other rights and remedies available to the Party to whom payment is owed,
whether arising under this Agreement or at law or in equity. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 21/44 

 6.8. Reports and Audits. 

(a) Milestone Payment Reports. After each Option Date, and on a Product-by-Product basis,
Servier shall report each event that triggers a payment to Cellectis pursuant to Section 6.3, within ten (10) business days of the occurrence of such event. Cellectis will then prepare an invoice to Servier for the same, such payment shall
be due within [***] from the invoice date. If no event has been reached, this shall be reported once a year [***] following the 151 of January of each contractual year. 

(b) Sales Payment Reports. After the First Commercial Sale by Servier, its Affiliates or its Subcontractor of a Product requiring the
payments due to Cellectis pursuant to Sections 6.4 and/or 6.5, Servier shall send to Cellectis an annual written reports within [***] following the 1st of January of each contractual year. Such report shall state, for the previous contractual year,
the number and description of each Product sold, by country, the corresponding Net Sales and the calculation of Milestone and royalties due. Concurrently with the sending of such reports, Servier shall pay to Cellectis royalties and/or milestones
due at the rates specified in Sections 6.4 and 6.5. 
 (c) Records; Inspection. Servier shall keep complete, true and accurate books
of account and records for the purpose of determining the royalty amounts or Milestone payment amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such Party, as the case may be, for at
least [***] following the end of the [***] to which they pertain. Servier shall make such account and records available, on reasonable notice sent by Cellectis, for inspection during business hours by an independent auditor nominated by Cellectis
and reasonably acceptable for Servier, for the purpose of verifying the accuracy of any statement or report given by Servier pursuant to Section 6.8 (a) and (b). The auditor shall be required to keep confidential all information learnt
during any such inspection, and to disclose to Cellectis only such details as may be necessary to report the accuracy of Servier’s statement and/or report. Cellectis shall be responsible for the auditor’s costs, unless the auditor
certifies that there a variation or error producing an increase exceeding five percent (5%) of the royalty amount stated for any period covered by the inspection, then all reasonable costs relating to the inspection for such period and any
unpaid amounts that are discovered shall be paid promptly by Servier, together with interest thereon from the date such were due at the lesser of the legal rate fixed by the European Central Bank plus two percent (2%) or the highest rate
permissible by law, and any pursuant to this Section shall be credited first to interest and then to any outstanding royalties. 
  

	ARTICLE 7.	INTELLECTUAL PROPERTY AND PATENT RIGHTS 

 7.1. Inventions and Intellectual Property Ownership.

 (a) Inventions. Ownership of inventions shall be determined according to the rules in effect at the time of invention in the country
where the invention is made. 
 (b) Sole Inventions. Each Party shall own all inventions, Know-How and other intellectual property, whether
or not patentable, conceived and made solely by its or its Affiliates’ own employees, agents, or independent contractors in the course of conducting its or its Affiliates’ activities under this Agreement, together with all intellectual
property rights therein (“Sole Inventions”). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 22/44 

 (c) Joint IP shall be co-owned equally by the Parties. Each Party shall have a right of first
refusal to any assignment of its interest into a Joint Patent by a Party (the “Assigning Party”) to any Third Party. Should the Assigning Party wish to assign such Joint Patent to a Third Party, the Assigning Party shall first propose such
assignment to the other Party who shall have the right to substitute itself to said Third Party within a period of [***]. 
 Parties agree to share the
exploitation of the Joint IP as follow: 
  

	 	(i)	Servier shall have the sole right to exploit, directly or indirectly, the Joint IP that covers specifically and solely a Pre-Candidate Product, Candidate Product or Product (the “Product Joint IP”) without any
financial compensation to Cellectis, and Cellectis shall have the right to use such Product Joint IP solely to perform its rights and obligation as contemplated in the Agreement. 

 

	 	(ii)	Cellectis shall have the sole right to exploit and sublicense Joint IP that does not cover specifically and solely a Pre-Candidate Product, Candidate Product or Product (the “Platform Joint IP”) without any
financial compensation to Servier, and Servier shall have the right to use such Platform Joint IP to perform its rights and obligation as contemplated in the Agreement. 

(d) Background IP. Each Party will own all right, title and interest in its Background IP. 

7.2. Patent Prosecution. 
 Cellectis Patent(s). Cellectis
will be responsible, at its own cost for preparing, filing, prosecuting and maintaining all Cellectis Patents and conducting any interferences, re-examinations, reissues and oppositions relating to such Patents. Cellectis shall seek patent
protection on all Cellectis Patents. Cellectis and its Affiliates have the right to cease all activities relating to the preparation, filing, prosecution and/or maintenance of any Patents as provided in this Section 7.2(a) if Cellectis or its
Affiliates question the patentability of such Patents and/or such Patents do not cover Pre-Candidate Product, Candidate Product or Product, in which case Cellectis will promptly inform Servier of such planned cessation and Servier may, upon
providing written notice to Cellectis, at its own choice, either assume responsibility, at Cellectis’ costs for the preparation, filing, prosecution and/or maintenance of such Patents, or rescind this Agreement. 

(a) Servier Patent(s). Servier will be responsible, at its own cost for preparing, filing, prosecuting and maintaining all Patents covering
the Servier Patents and conducting any interferences, re-examinations, reissues and oppositions relating to such Patents. 
 (b) Joint
Patent(s). So long as Servier has not exercised the Option to License as indicated in section 4.1 above (Exercise of the exclusive Option to License), the provision of section 7.2(a) above shall apply. As soon as Servier has exercised the Option to
License as indicated in section 4.1 above (Exercise of the exclusive Option to License), the provision of section 7.2 (b) above shall apply. Should a Party (the “Abandoning Party”), in charge of the prosecution of the Joint IP, decide
not to protect, prosecute or maintain the protection of Joint Patent, such Abandoning Party shall inform the other Party (the “Non-Abandoning Party”) reasonably in advance so that such Non-Abandoning Party may elect to pursue said
protection and/or maintenance of said protection in its own name. In such case, the Non-Abandoning Party shall have full ownership of and title to said Joint Patent. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 23/44 

 7.3. Patent Term Extensions. 

The Parties will cooperate with each other in gaining Patent term extension where applicable to Candidate Product or Products. 

7.4. Defense and Settlement of Third Party Claims. 
 From
the Effective Date and until Servier’s exercise of its Option to License for a given Pre-Candidate Product or Candidate Product, if a Third Party asserts that a patent right or other right owned by it is infringed by the manufacture, use, sale
or importation of the given Pre-Candidate Product or Candidate Product in the Territory by Cellectis, Cellectis shall have the sole right to defend against any such assertions at its sole cost and shall immediately inform Servier of such assertion.

 After Servier has exercised its Option to License for a given Product, if a Third Party asserts that a patent right or other right owned by it is
infringed by the manufacture, use, sale or importation of the given Product in the Territory by Servier, Servier shall have the sole right to defend against any such assertions at its sole cost. Cellectis shall reasonably assist Servier and
cooperate in any such litigation at Servier’s request, and Servier shall reimburse Cellectis any reasonable, documented, out-of-pocket costs incurred in connection therewith. Subject to such control, Cellectis may join any defense and
settlement pursuant to this Section 7.4 (Defense and Settlement of Third Party Claims), with its own counsel at its sole cost. Servier shall seek and reasonably consider Cellectis’ comments before determining the strategy for such matter.
Without limiting the foregoing, Servier shall keep Cellectis advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Cellectis copies of and an opportunity to review and comment
on any such communications, filings and submissions. Servier shall not settle or consent to the entry of any judgment in any such action without Cellectis’s prior written consent, not to be unreasonably withheld or delayed. Servier shall keep
Cellectis fully informed of all claims and actions governed by this Section 7.4 (Defense and Settlement of Third Party Claims). In the event Servier becomes engaged in: (i) settlement discussions with a Third Party that has specifically
asserted that a patent right of such Third Party would be infringed by the use, sale or importation of the Pre-Candidate Product or Candidate Product or Product; (ii) settlement discussions of an interference involving a patent corresponding to
a Cellectis Patent; Servier shall keep Cellectis reasonably informed of the status of such discussions; and (b) Servier shall consider in good faith any comments or suggestions of Cellectis. 

7.5. Enforcement. 
 Each Party shall promptly notify the
other Party in writing if it reasonably believes that any Cellectis IP or Joint IP are infringed or misappropriated by a Third Party in the Territory. 

Prior to Servier’s exercise of its Option to License. 

Cellectis shall have the sole right, but not the obligation, to enforce Cellectis IP and Joint IP against any actual, alleged or threatened infringement or
misappropriation by Third Parties in the Territory, at Cellectis’ sole cost. 
 From and after Servier’s exercise of its Option
to License. 
 If a Party has knowledge that a Third Party is making, using, selling a product in the Field in the Territory that infringes or may
infringe a Cellectis IP or a Joint IP, such Party shall promptly notify the other Party in writing of the possible infringement and such notice shall describe in detail the information suggesting the infringement of the Cellectis IP or the Joint IP.

  
 24/44 

 Prior to commencing any action to enforce a Cellectis IP or a Joint IP, the Parties shall diligently enter into
good faith negotiations on the desirability to bring a suit, the Parties to the action and the selection of counsel, and any such matters as the Parties need to discuss. 

If Servier is the Party designated by the Parties to initiate the action (such decision shall be subject, without limitation, to the rights of the Third
Parties owners of Cellectis Patents at the Effective Date), Servier shall have the right, but not the obligation, to enforce Cellectis IP and Joint IP against any actual, alleged or threatened infringement or misappropriation by Third Parties in the
Territory, in the Field and related to a Product, at Servier’s sole costs. In the event Servier elects to bring and prosecute such an action, Cellectis shall reasonably assist Servier and cooperate in any such action at Servier’s request
(and Servier shall reimburse all reasonable, documented, out-of-pocket expenses incurred by Cellectis in connection therewith), and Servier shall seek and reasonably consider Cellectis’s comments before determining the strategy. Without
limiting the foregoing, Servier shall keep Cellectis advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Cellectis with copies of and an opportunity to review and comment on
any such material communications, filings and submissions. Servier shall not settle, or consent to any judgment in, any action under this Section 7.5, without Cellectis’s prior written consent, not to be unreasonably withheld or delayed.

 If Cellectis is the Party designated by the Parties to initiate the action Cellectis shall be entitled to bring and prosecute such an action at
Cellectis’ sole cost and Servier will cooperate with Cellectis. If Cellectis elects to bring and prosecute such an action, then Cellectis shall seek and reasonably consider Servier’s comments on strategy. Without limiting the foregoing,
Cellectis shall keep Servier advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Servier copies of and an opportunity to review and comment on any such material
communications, filings and submissions. Cellectis shall not settle, or consent to any judgment in, any action under this 7.5, without Servier’s prior written consent, not to be unreasonably withheld or delayed. 

For sake of clarity, nothing in the Agreement shall be understood as affecting or reducing the Cellectis’s right to enforce Cellectis Patents in the
Field and in the Territory. 
 In any case, Servier shall not take any actions which can affect the scope, the validity, the enforceability or otherwise the
Cellectis Patents without the Cellectis’s prior written approval. 
  

	ARTICLE 8.	CONFIDENTIAL INFORMATION 

 8.1. During the term of this Agreement and for a period of [***] after
its termination or expiration, each Party and/or its Affiliates (the “Receiving Party”) undertakes to keep strictly confidential and not to publish or disclose to a Third Party, all the information which is transmitted visually, orally, in
writing, in electronically, or in any and all other manner by the other Party and/or its Affiliates (the “Disclosing Party”) pursuant to and in accordance with this Agreement, and/or relating to this Agreement, each Program, each
Pre-Candidate Product or Candidate Product or Product and intellectual property (the “Confidential Information”) without the prior written consent of Disclosing Party. The Joint IP shall be deemed Confidential Information of both Parties.

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 25/44 

 8.2. The Receiving Party shall only be entitled to disclose, on a need to know basis for the purpose of
the performance of the Agreement, Confidential Information to its directors, employees, Affiliates, consultants, sublicensees, licensors, subcontractors, or to a potential investor in the Receiving Party or to a potential acquirer of all or
substantially all of the assets of the business to which this Agreement pertains (collectively, the “Authorized Recipients”); 
 provided that
(i) the Receiving Party has previously informed the Disclosing Party of its intent to communicate Confidential Information and keep available upon the Disclosing Party’s request the content of such communication, and (ii) the
Receiving Party has taken into good faith consideration the comments made by the Disclosing Party, and (iii) the Receiving Party considers in good faith the Disclosing Party’s request to be communicated the name of the potential
investor(s) or potential acquirer(s), and (iv) the Receiving Party has bound such Authorized Recipients by confidentiality and restricted use obligations at least as stringent than those set forth in this Agreement. The Receiving Party shall be
responsible towards the Disclosing Party for any breach by its Authorized Recipients of any such confidentiality and restricted use obligations. 
 8.3.
Notwithstanding Article 8.1, the Receiving Party may use or disclose those information to the extend it can demonstrate, by clear and convincing evidence, that such information: 

(a) at the time of disclosure or acquisition is generally available to the public, or after the time of disclosure or acquisition is generally
available to the public through no wrongful act or omission of the Receiving Party and its Authorized Recipients, or 
 (b) was in the
lawful possession and at the free disposal of the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by written records then in the possession of the Receiving Party, or 

(c) is rightfully made available to the Receiving Party by third parties not bound by confidentiality or restricted use obligations, or 

(d) is independently developed by the Receiving Party without use of the Material and information imparted by the Disclosing Party, or 

(e) is disclosed by the Receiving Party in order to comply with the requirements of applicable law, governmental regulation or definitive
court order, provided that the Receiving Party shall first notify the Disclosing Party of such required disclosure and of each Confidential Information concerned and shall limit such disclosure as far as possible under applicable law. Such
disclosure shall, however, not relieve the Receiving Party of its other obligations contained herein. 
 8.4. Upon termination of this Agreement, the
Receiving Party will return or destroy all documents or other media containing Confidential Information of the Disclosing Party, provided however that the Receiving Party may retain one copy in its confidential files for the sole purpose of
verifying its obligations hereunder. 
 8.5. Remedies. Money damages will not be an adequate remedy if this Article 8 is breached and, therefore,
either Party may, in addition to any other legal or equitable remedies, seek an injunction or other equitable relief against such breach or threatened breach without the necessity of posting any bond or surety. 

  
 26/44 

 8.6. Publications. Prior to any publication in relation to the performance of the Programs, the publishing
Party agrees to provide the other Party with a copy of the paper or proposal for publication or for any other public disclosure at least thirty (30) days prior to its submission for publication or public disclosure. The other Party may review
the manuscript solely in order to: 
  

	 	•	 	ascertain whether its Confidential Information would be disclosed by the publication; and 

  

	 	•	 	identify results that are potentially patentable technology so that appropriate steps may be taken to protect such technology, pursuant to Section 7. 

The non-publishing Party agrees to hold such advance copies of any papers or proposals for publication in confidence. The non-publishing Party will provide
comments, if any, within fifteen (15) days of receipt of paper or abstract. If the non-publishing Party decides, according to Section 7, that a patent application should be filed, the publication or presentation may, at the non-publishing
Party’s request, be delayed an additional sixty (60) days or until a patent application is filed, whichever is sooner. 
 Authorships of any
publications will accurately reflect respective contributions made by the Parties. 
  

	ARTICLE 9.	REPRESENTATIONS; WARRANTIES AND COVENANTS 

 9.1. Representations and Warranties of both Parties.
Each Party represents and warrants to the other Party, at the Effective Date, that: 
  

	 	(i)	such Party is duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the
provisions hereof; 

  

	 	(ii)	this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation, enforceable against it in accordance with the terms hereof, subject to (a) the
effect of applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the rights of creditors and (b) the effect or availability of rules of law governing specific performance, injunctive relief or other
equitable remedies (regardless of whether any such remedy is considered in a proceeding at law or in equity); 

  

	 	(iii)	the execution and delivery of this Agreement by such Party do not, and the performance of this Agreement by such Party, including the grant of rights to the other Party pursuant to this Agreement, will not:
(a) conflict with, or result in any violation of or default under, any agreement, instrument or understanding, oral or written, to which it or any Affiliate is a party or by which it or any Affiliate is bound; (b) conflict with any rights
granted by such Party to any other Third Party or breach any obligation that such Party has to any Third Party; or (c) violate any provision of any applicable law; and 

  
 27/44 

 9.2. Representations and Warranties of Cellectis. 

Cellectis hereby represents that, at the Effective Date: 

9.2.1. Cellectis has the right to grant the rights granted to Servier under this Agreement, and no rights granted to Servier pursuant to this Agreement are in
violation of any agreement between Cellectis or any of its Affiliates and any Third Party; 
 9.2.2. As of the Effective Date, it has sufficient legal
and/or beneficial title and ownership under the Cellectis Patents and Licensed Cellectis Know-How to grant the licenses to the other Party as purported to be granted pursuant to this Agreement; 

9.2.3. None of Cellectis or its Affiliates, or, to the knowledge of Cellectis, any Third Party acting by or on behalf of Cellectis or any of its Affiliates in
connection with the research, development or manufacture of the Pre-Candidate Product, Candidate Product or Product has been debarred or is subject to debarment; 

9.2.4. Cellectis Controls the Cellectis Patents listed on the Cellectis Patents, free of any liens. The Cellectis Patents in the Territory listed on the
Exhibit 2 constitute a true and complete list of all Patents Controlled by Cellectis or its Affiliates in the Territory relating to the Pre-Candidate Product, Candidate Product or Product in the Territory; 

9.2.5. [***] 
 9.2.6. [***] 

9.2.7. [***] 
 9.2.8. [***] 

9.2.9. [***] 
 9.2.10. [***] 

9.2.11. [***] 
 Cellectis undertakes to reiterate the above
representations and warranties at the time of exercise by Servier of each Option to License for a given Candidate Product. 
 9.3. Cellectis Covenants.

 Cellectis shall [***] to maintain any existing agreement with Third Party(ies), to the extent the rights and licenses granted to Cellectis thereunder
are sublicensed to Servier hereunder, and shall not modify, amend, terminate or breach those Third Party(ies) agreement, if such modification, amendment, termination or breach would adversely affect Servier’s rights under this Agreement (after
taking into account any period(s) permitted to cure alleged breaches). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 28/44 

 9.4. Mutual Disclaimer of Warranties. 

Except as expressly provided in this Agreement, neither Party makes any warranty of any kind either express or implied relating to the Patents, Know-How,
Products, Pre-Candidate Products, Candidate Products, processes used in the Development of the Pre-Candidate Product, Candidate Product or Products, including without limitation any warranty regarding their use, safety, efficacy, or performance, any
warranty of merchantability or any warranty for fitness for any particular purpose or a warranty or representation that anything made, used, sold, or otherwise disposed of under the license granted in this Agreement is or will be free from
infringement of patents, copyrights, and other rights of Third Parties or any other express or implied legal or contractual warranty. 
  

	ARTICLE 10.	INDEMNIFICATION; INSURANCE 

 10.1. Indemnification by Servier. 

Servier will indemnify, defend and hold harmless Cellectis, and its Affiliates, and their respective directors, officers, employees, licensees, and agents,
from and against any and all liabilities, damages, losses, claims, costs and expenses including, but not limited to, the reasonable fees of attorneys and other professionals (collectively “Losses”), arising out of or resulting from any and
all Third Party Claims based upon: 
  

	 	(i)	[***] 

  

	 	(ii)	[***] 

 [***] 

10.2. Indemnification by Cellectis. 
 Cellectis will
indemnify, defend and hold harmless Servier and its Affiliates, and their respective directors, officers, employees and agents, from and against any and all Losses, arising out of or resulting from any and all Third Party Claims based upon: 

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

 [***] 

10.3. Procedure. 
 In the event that any person or entity
(an “Indemnitee”) entitled to indemnification under this Agreement is seeking such indemnification, such Indemnitee will: (a) inform, in writing, the indemnifying Party of the Claim as soon as reasonably practicable after such
Indemnitee receives notice of such Claim; (b) permit the indemnifying Party to assume direction and control of the defense of the Claim (including the sole right to settle it at the sole discretion of the indemnifying Party; provided that such
settlement does not impose any obligation on, or otherwise adversely affect, the Indemnitee or other Party); (c) cooperate as requested (at the expense of the indemnifying Party) in the defense of the Claim; and (d) undertake all
reasonable steps to mitigate any loss, damage or expense with respect to the Claim(s). Notwithstanding the 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 29/44 

 
foregoing, the Indemnitee may retain separate co-counsel reasonably acceptable to the indemnifying Party at its sole cost and expense and participate in the defense of the applicable Claim for
which the indemnifying Party has assumed control. 
 10.4. In no event shall either Party be liable to the other Party for loss of profits, special,
indirect, incidental, punitive or consequential damages arising out of this Agreement or the transactions contemplated by this Agreement. 
 10.5.
Insurance. 
 Each Party will maintain, at its cost, as of the Effective Date and during the Term thereafter, adequate insurance against liability and
other risks associated with its activities contemplated by this Agreement, including but not limited to its clinical trials and its indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices in the
pharmaceutical industry for the activities to be conducted by it under this Agreement. 
  

	ARTICLE 11.	TERM AND TERMINATION 

 11.1. Term. 

This Agreement will become effective as of the Effective Date and, unless earlier terminated pursuant to the provisions of the Sections 11.2, or 12.2.3s, will
expire upon the last sales of Product. Upon expiration of the Royalty Term with respect to a Licensed Product, the licenses granted by Cellectis to Servier under this Agreement with respect to such Product shall remain in effect as granted in
accordance with this Agreement but become fully paid-up, royalty-free licenses until term or termination of this Agreement. 
 11.2. Termination.

 Notwithstanding anything in this Agreement or elsewhere to the contrary, this Agreement may be terminated as follows: 

11.2.1. Material Breach. Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies available to it at law,
terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) will have committed a material breach and such material breach will have continued and/or remained uncured for ninety (90) days (except in
the case of a failure to make any payment due under the terms of this Agreement, in which case such failure to pay must be cured within thirty (30) days), after written notice thereof was provided to the Breaching Party by the Non-Breaching
Party. Any such termination will become effective at the end of such ninety (90) day period (or, in the case of a failure to make a payment, at the end of such thirty (30) day period), unless the Breaching Party has cured any such material
breach prior to the expiration of such ninety (90) day period or thirty (30) day period, as the case may be or (ii) unless the Breaching Party notifies the other Party within such sixty (60) day period that it disagrees in good
faith with such asserted basis for termination, this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 12.2 (Dispute Resolution) and the arbitration award rendered specifies that the
non-breaching Party shall have the right to terminate this Agreement based on such asserted breach. The right of either Party to terminate this Agreement as provided in this Section 11.2.1 will not be affected in any way by such Party’s
waiver or failure to take action with respect to any previous default. 

  
 30/44 

 11.2.2. Mutual Consent. This Agreement may be terminated by the mutual written consent of the Parties.

 11.2.3. Termination if Option to License is not exercised by Servier. This Agreement shall immediately and automatically terminate in its entirety
upon expiration of the last Option to License period in the event Servier has not exercised any of the Option to License in accordance with Section 4.1 (Exclusive Option to License) prior to such expiration. 

11.2.4. Termination for convenience by Servier 
 Servier
shall have the right at its sole discretion and without any liability of any kind on the basis of such termination, to terminate this Agreement only with respect to a given Pre-Candidate Product, Candidate
Product or Product or totally at any time upon three (3) month’s prior written notice to Cellectis. 
 11.2.5. Termination for Safety Reasons
by Servier 
 Servier may terminate this Agreement any time for safety reasons relating to the Pre-Candidate
Product, Candidate Product or Products. 
 11.2.6. Termination for Insolvency. 

Either Party may terminate this Agreement if, at any time, the other Party will file in any court or agency pursuant to any statute or regulation of any state
or country, a petition in bankruptcy or insolvency or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or if the other Party proposes a written agreement of composition or extension of substantially
all of its debts, or if the other Party will be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition will not be dismissed within ninety (90) days after the filing thereof, or if the other Party
will propose or be a party to any dissolution or liquidation, or if the other Party will make an assignment of substantially all of its assets for the benefit of creditors. 

Upon the bankruptcy of any Party, the non-bankrupt Party will further be entitled to a complete duplicate of, or complete access to, any such intellectual
property, and such, if not already in its possession, will be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 

11.3. Effects of Expiration or Termination. 
 In the
event of any termination of this Agreement by Cellectis on the basis of either a Material Breach by Servier (section 11.2.1) or insolvency of Servier (section 11.2.6) or by Servier on the basis of non-exercise of the Option to License (section
11.2.3), or for convenience (section 11.2.4), or for safety reasons (section 11.2.5) or by the Parties upon mutual consent (section 11.2.2), or in case of exercise of the Opt-Out Option (Section 3.7): 

 

	 	(i)	Servier will return to Cellectis or destroy (and certify such destruction to Cellectis) all Cellectis Confidential Information (provided that Servier shall be entitled to retain one (1) copy for archival and
compliance purposes, and as required by applicable Law or regulatory requirement); 

  
 31/44 

	 	(ii)	Servier will use reasonable efforts to, to the extent permitted by applicable law and requested by Cellectis, assign any contracts related to the Pre-Candidate Products, Candidate Products or Products in the Territory
to Cellectis or its designee (including by requesting and using good-faith efforts to obtain any required consents); 

  

	 	(iii)	the Parties shall transition responsibility for Commercialization, Development and, if applicable, Manufacture of the Pre-Candidate Product(s), Candidate Product(s) or Product(s) to Cellectis in accordance with
Section 11.6 (Transition Period); 

  

	 	(iv)	the Parties shall cooperate to promptly transition sole responsibility for the prosecution, maintenance and enforcement in the Territory of Servier IP to Cellectis; 

 

	 	(v)	Cellectis shall have the right to reacquire some or all of the inventory of the Pre-Candidate Product(s), Candidate Product(s) or Product(s), as requested by Cellectis, in possession of Servier and its Affiliates and,
if 

 Cellectis so reacquires inventory, shall reimburse Servier the price paid by it for such inventory; 

 

	 	(vi)	the Parties shall cooperate to promptly transfer ownership of all regulatory filings and regulatory approvals (including any such filings and approvals related to manufacturing), and responsibility for regulatory
communication held by Servier in the Territory to Cellectis; 

  

	 	(vii)	all sublicenses granted by Servier shall terminate; 

  

	 	(viii)	Servier will assign to Cellectis the Servier’s interest in the Product Joint IP under terms and conditions to be agreed upon by the Parties. Servier will assign to Cellectis, without any financial compensation, the
Servier’s interest in the Platform Joint IP. 

  

	 	(ix)	Subject to section 11.3(viii) above, Servier will grant Cellectis a royalty-bearing, non-exclusive, sublicensable license under Servier IP that is necessary to further Develop,
Manufacture and Commercialize the Pre-Candidate Product, Candidate Product or Product(s) in the Territory in the Field. 

  

	 	(x)	Cellectis shall have the right to control all recalls of the Product in the Territory, and in each case Servier shall provide any reasonable assistance requested by Cellectis in connection therewith; and

  

	 	(xi)	at Cellectis’s request, the Parties will discuss in good faith the wind-down or transfer to Cellectis of any ongoing clinical trials for the Candidate Products or Products conducted by or on behalf of Servier or
its Affiliates; provided that Cellectis shall bear any expenses incurred in connection with any such transfer except in the event of termination by Cellectis pursuant to Section 11.2.1 (Termination for Material Breach).

  
 32/44 

 In the event that the Parties are not permitted to transfer regulatory filings or regulatory approvals under
clause (vi) above pursuant to applicable laws, the Parties shall cooperate to establish a right of access and reference to such filings and approvals for Cellectis, and Servier shall maintain such filings and approvals, and take any actions
reasonably requested by Cellectis with respect thereto, and thereafter Servier shall transfer ownership of all such regulatory filings and regulatory approvals to Cellectis or its designee as and when it becomes permissible to do so. Cellectis shall
reimburse Servier its reasonable, documented, out-of-pocket costs incurred as necessary for such maintenance and to perform such requested actions. 

11.4. Consequences of a breach of the Non-Compete obligation by Cellectis 

In the event of a breach by Cellectis of the non-compete provision mentioned in section 3.9 above, then as of the date of the breach by Cellectis,
Servier’s obligations as per the Agreement shall be modified as follows: 
  

	 	(i)	Servier shall be relieved from the payment of the Milestones mentioned in sections 6.3 and 6.4 not already paid by Servier; and 

  

	 	(ii)	the level of royalties due to Cellectis mentioned in section 6.5 above shall be reduced by [***]; and 

  

	 	(iii)	the level of the Net Revenues to be paid by Cellectis to Servier on the basis of section 4.1 (c) (i), (ii) and/or (iii) shall be [***] and shall also apply mutadis mutandis to the sales by Cellectis of
the competing product; and 

  

	 	(iv)	notwithstanding any section to the contrary in this Agreement, Servier shall no longer have any obligation to provide information to Cellectis in relation to the Products (except as provided by applicable laws and in
relation to safety issues); and 

  

	 	(v)	notwithstanding any section to the contrary in this Agreement, Servier shall no longer have any obligation to use Commercially Reasonable Efforts to Develop and/or commercialize the Product(s). 

11.5. Accrued Rights and Obligations; Survival. 

Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to
such termination, relinquishment or expiration. Such termination, relinquishment or expiration will not relieve any Party from obligations which are expressly indicated under this Section 11.6 to survive termination or expiration of this
Agreement. 
 Survival. The provisions of Sections 8, 10, 11.3 and 11.6 will survive the expiration or any termination of this Agreement for any reason, in
accordance with their respective terms and conditions, and for the respective duration stated therein, and where no duration is stated, will survive indefinitely. In addition, any Section that is referred to in the above listed Sections shall
survive solely for the interpretation or enforcement of the latters. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 33/44 

 11.6. Transition Period. 

In the event of any termination of this Agreement by Cellectis on the basis of either a Material Breach by Servier (section 11.2.1) or insolvency of Servier
(section 11.2.7) or by Servier on the basis of nonexercise of the Option to License (section 11.2.3), or for convenience (section 11.2.4), or for safety reasons (section 11.2.5) or by the Parties upon mutual consent (section 11.2.2), or in case of
exercise of the Opt-Out Option (Section 3.7), upon Cellectis’s reasonable request, during the three (3) month period following provision of notice of termination (or, in each case, for such shorter period as Cellectis shall reasonably
request) (the “Transition Period”), the Parties shall cooperate to transition the Development (including any ongoing trials, to the extent permitted by law) and Commercialization of, regulatory responsibility for, and, if
applicable, manufacture of, the Product in the Field in the Territory from Servier to Cellectis. Servier shall take all actions reasonably requested by Cellectis to facilitate such transition, and the Parties shall conduct such transition
expeditiously and as reasonably necessary to minimize disruption in the Development and Commercialization of the Product(s) in the Territory. The Parties shall each be responsible for their own costs incurred in accordance with this Section. 

 

	ARTICLE 12.	CHANGE OF CONTROL 

 12.1. Change of Control. Cellectis shall give Servier written notice within
five (5) days after the public announcement or disclosure of any proposed Change of Control of Cellectis. Upon such notice, Servier shall have the right to buy-out Cellectis’s interest in the Pre-Candidate Products, Candidate Products or
Product(s) hereunder pursuant to the section 12.2 below (Buy-Out). 
 12.2. Buy-Out. Cellectis will notify Servier with [***] after the occurrence of
a Change of Control. If Servier exercises its right to buy-out Cellectis’s interest, Servier will provide written notice to Cellectis (a “Buyout Notice”) within [***] following the Change of Control. Within [***] following
Servier’s provision of the Buyout Notice, the Parties will meet and negotiate the amount of the payment from Servier to Cellectis for the buy-out of Cellectis’s interest in the Pre-Candidate Products, Candidate Products or Product(s) (the
“Buyout Payment”). 
 12.2.1. If the Parties agree on the amount of the Buyout Payment within such [***], then Servier will have [***] to
determine whether to proceed with the buy-out at such price. If Servier elects to proceed with the buy-out at the agreed Buyout Payment, then it will provide written notice thereof to Cellectis (or its successor) and, this Agreement will terminate
[***] after delivery of such written notice, Servier will pay the applicable Buyout Payment to Cellectis (or its successor) within such [***]. 
 12.2.2. If
the Parties fail to agree on an amount of a Buyout Payment within [***] following the provision of the Buyout Notice, then within [***] thereafter each Party will select and pay at its costs one (1) Third Party valuator (such valuators shall be
from top-tier, internationally-recognized investment banks or accounting firms) with relevant expertise to determine the appropriate amount for the Buyout Payment. Each of the Parties will provide to such valuators such information as it deems
pertinent and any information requested by such valuators. Such selected valuators will promptly (and in any event within [***] after the selection of such valuators) determine their respective valuation of the Buyout Payment amount and provide
notice of such amount (and underlying assumptions and methodology) to each of the Parties. If the amount of the Buyout Payment estimated by one valuator is equal to or less than one hundred twenty percent (120%) of the amount of the Buyout
Payment estimated by the other valuator, then the Buyout Payment shall be equal to the average of the amount proposed by the valuators. If the amount of the Buyout Payment estimated by one valuator is greater than one hundred twenty percent
(120%) of the amount of the Buyout Payment estimated by the other 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 34/44 

 
valuator, then the Parties will mutually agree upon a third valuator. In such event, the Buyout Payment determined by the third valuator shall be the Buyout Payment (provided, that the Buyout
Payment shall be capped at the amount of the higher of the Buyout Payments determined by the prior two valuators). 
 12.2.3. After determination of the
Buyout Payment pursuant to Section 12.2.1 or 12.2.2 above, as applicable, Servier will have [***] to determine whether to proceed with the buy-out at such price. If Servier elects to proceed with the buy-out at the agreed Buyout Payment, then
it will provide written notice thereof to Cellectis (or its successor) and this Agreement will terminate [***] after delivery of such written notice, Servier will pay the applicable Buyout Payment to Cellectis (or its successor) within such [***].

  

	ARTICLE 13.	MISCELLANEOUS 

 13.1. Public Announcements 

Except as required by applicable laws or the rules of any stock exchange, neither Party will make any public announcement of any information regarding this
Agreement or any activities under this Agreement without the prior written approval of the other Party, which approval will not be unreasonably withheld or delayed. Each Party will submit to the other Party any proposed announcements at least thirty
(30) days prior to the intended date of publication of such announcement to permit review and approval. Once any statement is approved for disclosure by the Parties or information is otherwise made public in accordance with the preceding
sentence, either Party may make a subsequent public disclosure of the specific contents of such statement without further approval of the other Party. 

13.2. Dispute Resolution. 
 Any dispute, controversy,
difference or claim which may arise between the Parties out of or in relation to or in connection with this Agreement (including arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance,
application or termination of this Agreement) shall be settled by binding arbitration in accordance with the provisions of this Section 13.2 (Arbitration): 
  

	 	•	 	The arbitration shall be conducted in Paris, France. 

  

	 	•	 	The arbitration shall be conducted in accordance with the Rules of Arbitration promulgated by the ‘Centre de Mediation et d’Arbitrage de Paris -CMAP’ then in effect (the “Arbitration
Rules”). 

  

	 	•	 	There shall be three (3) arbitrators, of whom one (1) shall be appointed by each of the Parties and the third shall be appointed by the first two (2) arbitrators and shall serve as chair arbitrator. If
either Party fails to appoint its arbitrator or the arbitrators appointed by the Parties fail to appoint the chair arbitrator within the time period set forth in the Arbitration Rules, such arbitrators will be appointed in accordance with the
Arbitration Rules. 

  

	 	•	 	The proceedings shall be conducted in French, and the arbitrators shall be conversant with and have a thorough command of the French language. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 35/44 

 13.3. Governing Law. 

This Agreement and any dispute arising from the performance or breach hereof will be governed by and construed and enforced in accordance with the laws of
France. 
 13.4. Assignment. 
 This Agreement will not
be assignable by either Party to any Third Party without the written consent of the other Party hereto. Notwithstanding the foregoing, Cellectis may assign this Agreement, without the consent of the other Party, to an Affiliate or to an entity that
acquires all or substantially all of the business or assets of Cellectis to which this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise). Any assignment in violation of this provision is void and without effect.

 13.5. Binding Agreement. 
 This Agreement, and the
terms and conditions hereof, will be binding upon and will inure to the benefit of the Parties and their respective successors, heirs, administrators and permitted assigns. 

13.6. Force Majeure. 
 No Party will be held liable or
responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this Agreement when such failure or delay is due to force
majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, “force majeure” is defined as causes beyond the control of the Party, including, without limitation, acts of God; laws of any
government; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or common carriers. In the event of force majeure,
Cellectis or Servier, as the case may be, will immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice will thereupon be excused from such of its
obligations under this Agreement as it is thereby disabled from performing for so long as such Party is so disabled, up to a maximum of ninety (90) days, after which time the Party not affected by the force majeure may terminate this Agreement.
To the extent possible, each Party will use reasonable efforts to minimize the duration of any force majeure. 
 13.7. Notices. 

Any notice or request required or permitted to be given under or in connection with this Agreement will be deemed to have been sufficiently given if in
writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at
the address set forth for such Party below: 
 If to Cellectis: 

8, rue de Ia Croix Jarry 
 75013 Paris Cedex 

France 
 Attention: Chief Executive Officer 

With a copy to: 
 Attention: VP Business Development 

  
 36/44 

 If to Servier: 
 Les
Laboratoires Servier 
 50 rue Carnot 
 92284 Suresnes Cedex

 France 
 Attention: Alliance Management Director &
US Licenses 
 [***] 
 With a copy to: 

Attention: Director Contract Department 
 Les Laboratoires Servier

 50 rue Carnot 
 92284 Suresnes Cedex 

France 
 or to such other address for such Party as it will have
specified by like notice to the other Parties, provided that notices of a change of address will be effective only upon receipt thereof. If delivered personally or by facsimile transmission, the date of delivery will be deemed to be the date on
which such notice or request was given. If sent by overnight express courier service, the date of delivery will be deemed to be the next business day after such notice or request was deposited with such service. If sent by certified mail, the date
of delivery will be deemed to be the third (3rd) day after such notice or request was deposited with the postal se13.8 Waiver. Neither Party may waive or release any of its rights or
interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances will be construed as a continuing waiver of such condition or term or of another condition or term. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 37/44 

 13.8. Severability. 

If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties will negotiate in good faith a valid, legal and
enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the
intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction. 

13.9. Entire Agreement. 
 This Agreement, including the
schedules and exhibits hereto, sets forth all the covenants, promises, agreements, appendices, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and
understandings between the Parties relating to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject
matter hereof other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of
the Parties. 
 13.10. Independent Contractors. 

Nothing herein will be construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties.
Each Party is an independent contractor. Neither Party will assume, either directly or indirectly, any liability of or for the other Party. Neither Party will have the authority to bind or obligate the other Party and neither Party will represent
that it has such authority. 
 13.11. Headings. 

Headings used herein are for convenience only and will not in any way affect the construction of or be taken into consideration in interpreting this
Agreement. 
 13.12. Construction of Agreement. 
 The
terms and provisions of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion,
whether legal, economic or otherwise. Accordingly, the terms and provisions of this Agreement will be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in
connection with the interpretation and construction of this Agreement of any rule of law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement will be interpreted or construed against the Party whose attorney
prepared the executed draft or any earlier draft of this Agreement. 
 13.13. Counterparts. 

This Agreement may be signed in counterparts, each and every one of which will be deemed an original, notwithstanding variations in format or file designation
which may result from the electronic transmission, storage and printing of copies of this Agreement from separate computers or printers. Facsimile signatures will be treated as original signatures. 

  
 38/44 

 IN WITNESS WHEREOF, the Parties have caused this Product Development, Option, License and
Commercialization Agreement to be executed by their duly authorized representatives. 
 Made in Suresnes, on February 17, 2014 

 

									
	For Cellectis SA,				For Les Laboratoires Servier,
					
	By:		  
				By:		  

	Name:		Andre CHOULIKA				Name:		Christian BAZANTAY
	Title:		Chief Executive Officer				Title:		Proxy
					
							By:		  

							Name:		Pascal TOUCHON
							Title:		Proxy
				
	For Institut de Recherche Internationales Servier						
					
	By:		  
						
	Name:		Dr Emmanuel CANET						
	Title:		President of R&D						

  
 39/44 

 Exhibit 1 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 40/44 

 132965/MG/CP 

EXHIBIT 1A 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 41/44 

 132965/MG/CP 

EXHIBIT 1B 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 42/44 

 132965/MG/CP 

Exhibit 2 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 43/44 

 132965/MG/CP 

Exhibit 3 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 

  
 44/44

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]